US20170306030A1 - Chimeric activators: quantitatively designed protein therapeutics and uses thereof - Google Patents
Chimeric activators: quantitatively designed protein therapeutics and uses thereof Download PDFInfo
- Publication number
- US20170306030A1 US20170306030A1 US15/626,439 US201715626439A US2017306030A1 US 20170306030 A1 US20170306030 A1 US 20170306030A1 US 201715626439 A US201715626439 A US 201715626439A US 2017306030 A1 US2017306030 A1 US 2017306030A1
- Authority
- US
- United States
- Prior art keywords
- activity
- targeting
- binding
- receptor
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 141
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 136
- 239000012190 activator Substances 0.000 title claims description 162
- 239000003814 drug Substances 0.000 title abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 273
- 230000008685 targeting Effects 0.000 claims abstract description 219
- 238000000034 method Methods 0.000 claims abstract description 52
- 210000004027 cell Anatomy 0.000 claims description 410
- 102000005962 receptors Human genes 0.000 claims description 229
- 238000009739 binding Methods 0.000 claims description 205
- 230000027455 binding Effects 0.000 claims description 203
- 206010028980 Neoplasm Diseases 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 77
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 70
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 69
- 229940116977 epidermal growth factor Drugs 0.000 claims description 69
- 239000003446 ligand Substances 0.000 claims description 67
- 201000011510 cancer Diseases 0.000 claims description 64
- 230000035772 mutation Effects 0.000 claims description 53
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 150000001413 amino acids Chemical group 0.000 claims description 22
- 230000019491 signal transduction Effects 0.000 claims description 20
- 102220473592 Cytochrome b5_R149A_mutation Human genes 0.000 claims description 19
- 102220472787 Ras-related protein Rab-10_R144A_mutation Human genes 0.000 claims description 15
- 108091006088 activator proteins Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 102000006240 membrane receptors Human genes 0.000 claims description 15
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 14
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 13
- 102000014150 Interferons Human genes 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 12
- 108091005250 Glycophorins Proteins 0.000 claims description 11
- 229940079322 interferon Drugs 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 102000028180 Glycophorins Human genes 0.000 claims description 9
- 239000000178 monomer Substances 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 230000006916 protein interaction Effects 0.000 claims description 3
- 230000009134 cell regulation Effects 0.000 claims description 2
- 239000003145 cytotoxic factor Substances 0.000 claims description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 abstract description 52
- 102000037865 fusion proteins Human genes 0.000 abstract description 52
- 238000013461 design Methods 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 11
- 230000002588 toxic effect Effects 0.000 abstract description 11
- 238000013459 approach Methods 0.000 abstract description 8
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 230000006882 induction of apoptosis Effects 0.000 abstract description 3
- 108020003175 receptors Proteins 0.000 description 220
- 235000018102 proteins Nutrition 0.000 description 128
- 102000001301 EGF receptor Human genes 0.000 description 79
- 108060006698 EGF receptor Proteins 0.000 description 79
- 102400001368 Epidermal growth factor Human genes 0.000 description 67
- 230000011664 signaling Effects 0.000 description 44
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 40
- 108090000765 processed proteins & peptides Proteins 0.000 description 35
- 238000011282 treatment Methods 0.000 description 32
- -1 RNAse Proteins 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 31
- 102000003390 tumor necrosis factor Human genes 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 25
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 24
- 230000004913 activation Effects 0.000 description 24
- 108700012411 TNFSF10 Proteins 0.000 description 23
- 230000003993 interaction Effects 0.000 description 23
- 230000000875 corresponding effect Effects 0.000 description 21
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 20
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 19
- 229940039781 leptin Drugs 0.000 description 18
- 230000003213 activating effect Effects 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 230000026731 phosphorylation Effects 0.000 description 16
- 238000009792 diffusion process Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000006366 phosphorylation reaction Methods 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 102220608138 Cingulin_K133A_mutation Human genes 0.000 description 13
- 102100031939 Erythropoietin Human genes 0.000 description 13
- 108010002350 Interleukin-2 Proteins 0.000 description 13
- 102000000588 Interleukin-2 Human genes 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229940105423 erythropoietin Drugs 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 108090000394 Erythropoietin Proteins 0.000 description 10
- 102000003951 Erythropoietin Human genes 0.000 description 10
- 241000235058 Komagataella pastoris Species 0.000 description 10
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 231100001274 therapeutic index Toxicity 0.000 description 7
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 108010021466 Mutant Proteins Proteins 0.000 description 6
- 102000008300 Mutant Proteins Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000007781 signaling event Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000235648 Pichia Species 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 108010019813 leptin receptors Proteins 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 102100025221 CD70 antigen Human genes 0.000 description 4
- 208000006332 Choriocarcinoma Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
- 108090000177 Interleukin-11 Proteins 0.000 description 4
- 102000003815 Interleukin-11 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000172 Interleukin-15 Proteins 0.000 description 4
- 102000003812 Interleukin-15 Human genes 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102100031775 Leptin receptor Human genes 0.000 description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 4
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 4
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 201000010208 Seminoma Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000003013 erythroid precursor cell Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 229960005267 tositumomab Drugs 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102100035793 CD83 antigen Human genes 0.000 description 3
- 102100032145 Carbohydrate sulfotransferase 10 Human genes 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 208000009458 Carcinoma in Situ Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 108010008177 Fd immunoglobulins Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 3
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
- 101000775595 Homo sapiens Carbohydrate sulfotransferase 10 Proteins 0.000 description 3
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 102000006823 Mutant Chimeric Proteins Human genes 0.000 description 3
- 108010086789 Mutant Chimeric Proteins Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 3
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 3
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 210000002960 bfu-e Anatomy 0.000 description 3
- 230000008275 binding mechanism Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 2
- 208000013165 Bowen disease Diseases 0.000 description 2
- 208000019337 Bowen disease of the skin Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102000007499 CD27 Ligand Human genes 0.000 description 2
- 108010046080 CD27 Ligand Proteins 0.000 description 2
- 108010017987 CD30 Ligand Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 2
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101100275686 Homo sapiens CR2 gene Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 2
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 description 2
- 101001003142 Homo sapiens Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 2
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 2
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 2
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100275687 Mus musculus Cr2 gene Proteins 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 101710146873 Receptor-binding protein Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108091007178 TNFRSF10A Proteins 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 2
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 2
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 201000009036 biliary tract cancer Diseases 0.000 description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 108091005763 multidomain proteins Proteins 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 102000035025 signaling receptors Human genes 0.000 description 2
- 108091005475 signaling receptors Proteins 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical group C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical class C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100024263 CD160 antigen Human genes 0.000 description 1
- 108010009992 CD163 antigen Proteins 0.000 description 1
- 102100021992 CD209 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000018803 Calgranulin A Human genes 0.000 description 1
- 108010052500 Calgranulin A Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 102100037328 Chitotriosidase-1 Human genes 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102100024539 Chymase Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 1
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100036089 Fascin Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 1
- 101000897416 Homo sapiens CD209 antigen Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000879661 Homo sapiens Chitotriosidase-1 Proteins 0.000 description 1
- 101000909983 Homo sapiens Chymase Proteins 0.000 description 1
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001021925 Homo sapiens Fascin Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000878611 Homo sapiens High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 101000614627 Homo sapiens Keratin, type I cytoskeletal 13 Proteins 0.000 description 1
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101001056466 Homo sapiens Keratin, type II cytoskeletal 4 Proteins 0.000 description 1
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 1
- 101000934758 Homo sapiens Keratin, type II cytoskeletal 72 Proteins 0.000 description 1
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101000586000 Homo sapiens Myocardin Proteins 0.000 description 1
- 101001000109 Homo sapiens Myosin-10 Proteins 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 101001030232 Homo sapiens Myosin-9 Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000686909 Homo sapiens Resistin Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000614354 Homo sapiens Transmembrane prolyl 4-hydroxylase Proteins 0.000 description 1
- 101000795074 Homo sapiens Tryptase alpha/beta-1 Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 238000012450 HuMAb Mouse Methods 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100020990 Interferon lambda-1 Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102100039898 Interleukin-18 Human genes 0.000 description 1
- 102100039879 Interleukin-19 Human genes 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 102100036679 Interleukin-26 Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 102100033501 Interleukin-32 Human genes 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 101710181549 Interleukin-34 Proteins 0.000 description 1
- 108091007973 Interleukin-36 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100025758 Keratin, type II cytoskeletal 4 Human genes 0.000 description 1
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 1
- 102100025380 Keratin, type II cytoskeletal 72 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 101710150912 Myc protein Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100030217 Myocardin Human genes 0.000 description 1
- 102100036640 Myosin-10 Human genes 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 102100038938 Myosin-9 Human genes 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000018779 Replication Protein C Human genes 0.000 description 1
- 108010027647 Replication Protein C Proteins 0.000 description 1
- 102100024735 Resistin Human genes 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 101000873420 Simian virus 40 SV40 early leader protein Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 101100164962 Stachybotrys chlorohalonata (strain IBT 40285) ATR14 gene Proteins 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100036014 T-cell surface glycoprotein CD1c Human genes 0.000 description 1
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 1
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100040472 Transmembrane prolyl 4-hydroxylase Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100029639 Tryptase alpha/beta-1 Human genes 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000021096 adenomatous colon polyp Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 201000004365 colon carcinoma in situ Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- GEHOVXPJMDPCSX-UHFFFAOYSA-N ethyl acetate;ethyl hydrogen carbonate Chemical compound CCOC(C)=O.CCOC(O)=O GEHOVXPJMDPCSX-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000023837 negative regulation of proteolysis Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220024619 rs267607627 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- the invention relates to chimeric proteins, fusion proteins, and therapeutic proteins.
- IFN ⁇ interferon alpha
- TNF TNF
- IL-2 IL-2
- systemic administration of these proteins results in side effects that limit the dose levels that can be used therapeutically.
- IFN ⁇ is useful in treating hepatitis and certain cancers, but causes side effects such as flu-like symptoms and suicidal thoughts.
- targeting mechanisms to permit therapeutic proteins to be delivered locally and to minimize the side effects of systemic administration of therapeutic proteins.
- MylotargTM is a monoclonal antibody chemically conjugated to the toxin calicheamycin (Giles et al. (2003) Cancer 98: 2095). Calicheamycin causes double-stranded breaks in DNA and is highly toxic. However, when covalently bonded to an antibody, this chemical is not toxic because it has no access to DNA.
- MylotargTM binds to the CD33 receptor protein on a tumor cell, the antibody-receptor complex is internalized and the antibody is degraded. The calicheamycin is then liberated to bind to the DNA of the tumor cell.
- MylotargTM received accelerated approval by the FDA for treatment of acute myelogenous leukemia (AML) in 2000.
- AML acute myelogenous leukemia
- ZevalinTM and BexxarTM consist of radioisotopes chemically conjugated to monoclonal antibodies against the B cell marker CD20. These proteins are use to treat B cell lymphoma.
- the radioisotopes used, yttrium-90 and iodine-131 respectively, have short decay path-lengths, so that when the antibody binds to the surface of a tumor cell, there is local irradiation of the tumor.
- ZevalinTM was approved by the FDA in 2002.
- BexxarTM was approved in 2003.
- aspects of the invention relate to methods and compositions for specifically targeting the activity of naturally-occurring proteins to certain cells or tissues where their activity can be therapeutically useful.
- the invention provides therapeutic applications for naturally-occurring proteins that otherwise have serious but finite toxicity.
- Methods and compositions of the invention can be used to target the cell-activating properties of a protein to a subset of target cells without activating non-target cells.
- aspects of the invention relate to chimeric proteins that include a variant of a cell-activating element (also referred to herein as an Activity element) that has reduced cell-activating properties relative to its wild-type counterpart.
- the chimeric proteins also include a cell-targeting element (also referred to herein as a targeting element) that preferentially binds to target cells of interest.
- a cell-targeting element also referred to herein as a targeting element
- the cell-activating variant and the cell-targeting element are connected via a linker.
- the activating and targeting elements are selected so that the resulting chimeric protein only activates cells that are bound by the targeting element.
- the activating element variant is selected such that it can only activate a cell when present in a sufficiently high amount (e.g., concentration) on or near a cell-surface.
- the targeting element is selected such that it can target a sufficient amount of the activating element to the surface of a target cell in order to activate it.
- the linker is selected so that it allows simultaneous binding of the activating and targeting elements to different receptors on the target cell. Accordingly, chimeric proteins of the invention can be used to avoid or reduce unwanted side effects caused by the activating element activating non-target cells.
- aspects of the invention are particularly useful for targeting the activity of toxic activating elements to target cells (e.g., to target cytotoxic elements to cancer cells) without killing surrounding non-target cells.
- aspects of the invention can be useful to harness certain functions of natural proteins that otherwise may be toxic (or have serious toxic side effects) when administered therapeutically.
- IFN ⁇ is normally secreted by virus-infected cells and promotes the death of cells in the immediate vicinity.
- TNF is secreted in response to the presence of bacterial molecules such as lipopolysaccharide and is thought to play an important role in wound-healing.
- Other similar molecules include, but are not limited to, IFN ⁇ , IL-2, IFN ⁇ , and IL-1.
- a recombinant protein of the invention includes a first element that binds to a first receptor on a target cell; a second element that binds to a second receptor on the target cell; and, optionally, a linker that connects the first and second elements, wherein the linker allows the first and second elements to bind simultaneously to the first and second receptors on the target cell, wherein the first element comprises a mutation that reduces its binding affinity for its receptors, and wherein the first element transmits a signal to the host cell when it is bound to the first receptor.
- the first element is an enzyme, a substrate, a receptor, a ligand, or other peptide that can interact (e.g., bind to and/or catalyze a reaction and/or transduce a signal) to the receptor on the cell surface.
- the receptor may be any cell-surface protein that can receive a signal (e.g., resulting in a molecular and/or cellular change) upon interaction with the first element.
- the first element is a variant of an activity element that binds to and/or interacts with more than one receptor (e.g., 2, 3, 4, 5 or more different receptors) in nature.
- the variant activity element (e.g., a natural or engineered mutant element) has reduced affinity for one or more of its natural receptors (e.g., for about 10%-20%, about 20%-40%, about 50%, about 40%-60%, about 60%-80%, about 80%-100% or for all of the different natural receptors).
- a variant activity element may have reduced binding affinity for the receptor (e.g., a signal transduction receptor, enzyme, or other cell surface molecule that can mediate a signal or other desired biochemical or cellular change) or receptors that are being targeted for activation in the target cells.
- a variant activity element may have reduced signaling (e.g., more than about 10%, more than about 25%, more than about 50%, more than about 75%, more than about 80%, more than about 90%, or more than about 95% loss of signaling activity, or complete loss of detectable signaling activity) via the receptor(s) of interest in the absence of the targeting element when compared to the wild-type activity element.
- reduced signaling e.g., more than about 10%, more than about 25%, more than about 50%, more than about 75%, more than about 80%, more than about 90%, or more than about 95% loss of signaling activity, or complete loss of detectable signaling activity
- recombinant proteins of the invention may bind to their target cells as monomers.
- the targeting element binds to its target molecule as a monomer (e.g., as a single copy of the targeting element such as a single copy of an antibody).
- the activity element interacts with its receptor or target as a monomer.
- both the targeting and activity elements interact with their receptors or targets as monomers.
- the cell-surface receptors themselves are monomers. However, they may be multimers as the invention is not limited in this respect.
- the first and second elements are connected via a linker.
- a linker may be any suitable length as described herein (e.g., about 5-10, about 10-20, about 25, about 20-50, about 50, about 50-70 amino acids long, or longer or shorter). In some embodiments, the linker may be flexible.
- aspects of the invention relate to chimeric activators including an activity element and a targeting element, optionally joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- the first binding site is a ligand binding site, a receptor, or an epitope on a cell surface.
- the second binding site is a signal-transduction receptor on a cell surface.
- the targeting element is an antibody, an antibody fragment, an Fc region, a natural or synthetic ligand, or a protein interaction motif.
- the activity element is a cytokine, a cytotoxic protein, a regulatory protein, or an active fragment of any one thereof.
- the linker length is at least equal to the minimum distance between the first and second binding sites on the cell surface. In some embodiments the linker length is at least twice the minimum distance between the first and second binding sites on the cell surface. In some embodiments the linker length is at most five-six times the minimum distance between the first and second binding sites on the cell surface. In some embodiments the activity element is mutated such that the binding affinity of the activity element for the second binding site is lower than the binding affinity of the targeting element for the first binding site.
- aspects of the invention relate to methods for manufacturing a chimeric activator including an activity element and a targeting element joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- methods include: i) optimizing the linker length as a function of the concentration of the first and second binding sites, the size of the activity element and targeting element, the minimum distance between the binding sites of the targeting element and the activity element, and the affinities of the activity element and the targeting element for the first and second binding sites; and ii) preparing a chimeric activator having an optimal linker length.
- methods include: i) mutating the activity element such that the binding affinity of the activity element for the second binding site is lower than the binding affinity of the targeting element for the first binding site; i) optimizing the linker length as a function of the concentration of the first and second binding sites, the size of the activity element and targeting element, the minimum distance between the binding sites of the targeting element and the activity element, and the affinities of the activity element and the targeting element for the first and second binding sites; and iii) preparing a chimeric activator.
- aspects of the invention relate to methods for targeted cellular regulation, the method including: administering to a subject a therapeutically effective amount of a chimeric activator including an activity element and a targeting element joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- a method for treating cancer including: administering to a subject having a cancer a therapeutically effective amount of a composition including a chimeric activator including an activity element and a targeting element joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- aspects of the invention may be used to selectively target any activity (e.g., any activity mediated by a cell surface receptor) to target cells that selectively express a cell surface marker that is different (or expressed at different, for example higher, levels) than on non-target cells.
- aspects of the invention may be used to target cytotoxic or cytostatic activity to any cells associated with a disease or disorder (e.g., cancer cells, immune system cells associated with allergic or chronic inflammatory disorders or reactions, infected cells, pathogen cells, cells that are degenerating, or any other target cells of interest).
- aspects of the invention also may be used to selectively deliver other activating signals to target cells (e.g., other than cytotoxic or cytostatic).
- other activating signals may include on or more proliferation, differentiation, stimulation, or other signals that may be useful in different applications.
- FIG. 1 illustrates a non-limiting embodiment of a general structure of a Chimeric Activator (“mut” indicates that the activity element has a mutation);
- FIG. 2 shows, without wishing to be bound by theory, a proposed mechanism of specific binding of “Chimeric Activators” to target cells
- FIG. 3 shows a molecular model of an IFN ⁇ -EGF Chimeric Activator
- FIG. 4 illustrates an example of activation of IFN ⁇ signaling by chimeric activators
- FIG. 5 illustrates an example of the targeting effect in a Daudi cell line constructed to express EGFR
- FIG. 6 illustrates an example of the dependence of Chimeric Activator function on the receptor for the targeting element
- FIG. 7 illustrates an example of a Chimeric Activator function blocked by antibodies against the receptor for the targeting element
- FIG. 8 shows an example of a TNF-EGF Chimeric Activator
- FIG. 9 illustrates the use of antibody V regions instead of EGF as a targeting element
- FIG. 10 illustrates non-limiting aspects of chimeric activation
- 10 A) illustrates a general structure of a chimeric activator
- 10 B) shows a molecular model of an IFN ⁇ 2a-EGF chimeric activator (space-filling structure)
- 10 C)- 10 D) illustrate a mechanism of specific binding of chimeric activators to target cells
- 10 C) the chimeric activator binds poorly to non-target cells because the intrinsic binding affinity of the mutant activity element to its receptor is low
- the targeting element binds to receptors on a target cell at a high rate (after the targeting element complexes with its receptor, the activity element is in a high local concentration relative to its receptor, so that the activity element can then bind and stimulate signal transduction);
- FIG. 11 illustrates an embodiment of EGFR activation upon treatment with IFN ⁇ 2a-EGF chimeric activators
- FIG. 12 illustrates an example of STAT1 activation upon treatment with IFN ⁇ 2a-EGF chimeric activators
- FIG. 13 illustrates an example of EGFR neutralization
- FIG. 14 illustrates an example of EGFR-dependent anti-proliferative activity of IFN ⁇ 2a-EGF chimeric proteins
- FIG. 15 shows a schematic of an embodiment of the chimera-receptor binding and receptor endocytosis where all model parameters are represented (the average distance between two receptors is shown as b i;j );
- FIG. 16 shows a schematic of an embodiment of the binding mechanism between a receptor and a free ligand or a chimeric ligand
- FIG. 17 shows a plot of the C 1 concentration in time, for different initial values of total R 1 ;
- FIG. 18 shows plots of C 2 over time for different IF mutants (lower darker colored dots correspond to IF, and upper lighter colored dots correspond to chimeric protein);
- FIG. 19 shows a plot of C 2 at 30 min versus linker length for different IFN mutants
- FIG. 20 shows a time plot of an embodiment of the collision rate
- FIG. 21 shows a plot of an embodiment of collision rate versus linker size.
- aspects of the invention relate to chimeric proteins that include a targeting element connected to an activity element.
- the targeting element binds to molecules that are selectively present on target cells.
- the activity element is a variant of a naturally occurring protein that activates cells by binding to one or more cell surface receptors. The variant is selected such that it has reduced or no cell activating properties in the absence of the targeting element.
- the targeting element is selected such that it selectively binds to target cells thereby increasing the local concentration of the variant activity element on the target cells to a level that results in activation of those cells.
- cell activation results in cell death or a reduction or absence of cell proliferation.
- other forms of cell activation may be targeted to specific cells using methods and compositions described herein.
- An activity element may be a receptor binding protein (or functional portion or domain thereof) that binds to one or more naturally-occurring receptors on a cell surface, thereby mediating signaling to the cell (e.g., via signal transduction).
- a variant activity element may include one or more naturally occurring and/or engineered mutations that result in reduced binding to one or more (e.g., all) natural receptors that are bound by the wild-type activity element.
- the binding affinity of the variant activity element for one or more of its receptors may be at least 2 fold lower and preferably at least 5 fold lower or 8 fold lower (e.g., at least 10 fold lower, about 10-50 fold lower, about 50-100 fold lower, about 100-150 fold lower, about 150-200 fold lower, or more than 200 fold lower) than the binding affinity of the wild-type activity element for its natural receptor(s).
- the activity element by itself is significantly less active (e.g., substantially inactive) because it cannot bind to its receptor(s).
- chimeric proteins of the invention are useful to avoid unwanted side effects caused by the activity element binding to its natural receptor on non-target cells.
- the activity element is active on target cells because the targeting element provides the missing binding affinity required for activation.
- a targeting element may be a receptor binding protein, an antibody, or any other natural or engineered protein that binds to a molecule that is preferentially present on target cells of interest relative to non-target cells.
- the affinity of the targeting element for its target molecule e.g., receptor
- the affinity of the targeting element for its target molecule is typically higher (e.g., at least 2 fold, at least 5 fold, about 5-10 fold, about 10-50 fold, about 50-100 fold, about 100-500 fold, about 500-1,000 fold, at least 1,000 fold, at least 10,000 fold, or at least 100,000 fold higher) than the binding affinity of the variant activity element for its receptor(s).
- the activity and targeting elements are connected via a linker.
- the linker may be a natural or artificial peptide that provides sufficient flexibility to allow both the targeting element and the activity element of a chimeric activator to bind simultaneously to their targets and/or receptors on a target cell.
- the linker length may be optimized for the sizes of the target molecules and/or receptors being bound by targeting and activity elements, the sizes of the targeting and activity elements themselves, and other factors described herein in more detail.
- a linker may not be required (or only a short linker may be required) if one or both of the targeting and activity elements are flexible or are connected to each other by flexible domains.
- aspects of the invention relate to Chimeric Activators—proteins that include a targeting element and an activity element that are capable of simultaneously binding to multiple (two or more) unrelated receptors on the same target cell.
- a Chimeric Activator has an activity element, a linker, and a targeting element. See, for example, FIG. 1 .
- the linker if present, is located between the targeting and activity elements.
- aspects of the invention are not limited by the relative positions of the targeting and activity elements.
- the targeting element may be N-terminal to the activity element (regardless of whether a linker separates the two elements).
- the activity element may be N-terminal to the targeting element (regardless of whether a linker separates the two elements).
- proteins of the invention may include one or more additional peptide elements (at the N-terminus, the C-terminus, or within the protein) for purification and/or detection (e.g., peptide tags), stability, function (e.g., secretion and or other function), etc., or any combination thereof.
- targeting and activity elements may bind to overlapping types of molecules (e.g., receptors, substrates, enzymes, or other molecules) that are present on a cell surface.
- the element that is being used as a targeting element has sufficient affinity to target a chimeric protein to a cell-surface molecule that is preferentially (e.g., uniquely or selectively or specifically) present or exposed on a target cell of interest.
- an element that is being used as an activity element may have relatively low affinity for a cell surface molecule.
- the element that is being used as an activity element may interact equally with a molecule that is present on all cell types, but only activates the target cell types due to its linkage to the targeting element.
- both the targeting and activity elements interact with different cell surface molecules that all are preferentially present or exposed on the target cells.
- aspects of the invention may be useful to increase the therapeutic index (e.g., by about 2 fold, about 5 fold, about 10 fold, about 50 fold, about 100 fold, about 200 fold, or more) of any protein therapeutic (e.g., based on a naturally occurring or engineered protein or fragment thereof) by reducing the general toxicity of the protein and maintaining or increasing the selective effect of the protein on target cells or tissue.
- any protein therapeutic e.g., based on a naturally occurring or engineered protein or fragment thereof
- aspects of the invention may be used to treat any disease where selective cell activation is beneficial as described herein.
- the targeting element may be selected on the basis that it target certain diseased cells (e.g., due to the presence of disease-specific antigens on the target cells).
- specific cell types or tissue types may be targeted (e.g., via cell or tissue specific cell surface antigens).
- pathogen-specific molecules may be targeted (e.g., on the cells of a pathogen or on host cells infected with a pathogen).
- compositions described herein have broad application to treating disorders, including infections, cancer, anemia, allergy, and many other disorders where it is beneficial to activate (e.g., kill, stimulate or otherwise activate) one or more particular cell types.
- the invention is useful to treat cancer. Cancer is disease characterized by uncontrolled cell proliferation and other malignant cellular properties.
- cancer includes, but is not limited to, the following types of cancer: breast cancer; biliary tract cancer; bladder cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia; T-cell acute lymphoblastic leukemia/lymphoma; hairy cell leukemia; chronic myelogenous leukemia, multiple myeloma; AIDS-associated leukemias and adult T-cell leukemia/lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer including those arising from epit
- a targeting element comprises a protein component that selectively directs the binding of the chimeric protein to the surface of a desired cell or cells. Accordingly, a targeting element binds specifically to a cell-surface moiety (e.g., an antigen, epitope, protein, glycoprotein, lipid, carbohydrate, or other molecule or portion thereof) that is either only present or exposed on the target cell or is present or exposed in higher amounts on the target cell relative to non-target cells (e.g., about 2 fold, about 5 fold, about 10 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, about 1,000 fold, about 10,000 fold, or more on the target cell).
- the targeting element can be any protein that binds to a cell-surface molecule.
- Targeting elements typically target to a subset of cells, such as tumor cells.
- a targeting element is an antibody or a portion of an antibody.
- a targeting element is a ligand (e.g., a naturally occurring ligand or portion thereof that retains binding properties, or a synthetic ligand that binds, for example, to a receptor on a target cell).
- the targeting element binds to cancers cells (e.g., is a cancer targeting element).
- the targeting element is an antibody, a growth factor, a hormone, a peptide, an aptamer, a cytokine, interferon, vitamin, or a mixture thereof, for example.
- the antibody may be further defined as a full-length antibody, chimeric antibody, Fab′, Fab, F(ab′)2, single domain antibody (DAB), Fv, single chain Fv (scFv), minibody, diabody, triabody, or a mixture thereof, for example.
- the antibody is an anti-HER-2/neu antibody, such as scFv23, for example.
- the antibody is an anti-gp240 antigen antibody, such as one that comprises scFvMEL, for example.
- an antibody from which the pFc′ region has been enzymatically cleaved, or which has been produced without the pFc′ region designated an F(ab′)2 fragment, retains both of the antigen binding sites of an intact antibody.
- an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule.
- Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd.
- the Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.
- CDRs complementarity determining regions
- FRs framework regions
- CDR1 through CDR3 complementarity determining regions
- non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody.
- Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci.
- monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies will have human immunoglobulin amino acid sequences and therefore will not provoke human anti-mouse antibody (HAMA) responses when administered to humans.
- HAMA human anti-mouse antibody
- the present invention also provides for F(ab′)2, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab′)2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences.
- the targeting element of a chimeric protein is an antibody moiety that has been expressed from a single linear nucleic acid as a single peptide and that can fold into a fully functional antibody.
- the chimeric protein is expressed from a nucleic acid that encodes a portion of an antibody (e.g., a heavy chain, a light chain, or a portion thereof as described herein) fused to the activity element (via the optional linker).
- the remainder of the antibody required for specific binding can be provided in trans (e.g., expressed from a different coding sequence in the same cell or expressed in a different cells and mixed in vitro, etc., or any combination thereof).
- a chimeric protein of the invention may be a single linear polypeptide chain or it may include additional polypeptide chains of an antibody or other binding protein required for specific binding to a target molecule.
- the targeting element comprises one or more growth factors, such as, for example, transforming growth factor, epidermal growth factor, insulin-like growth factor, fibroblast growth factor, heregulin, platelet-derived growth factor, vascular endothelial growth factor, or hypoxia inducible factor.
- growth factors such as, for example, transforming growth factor, epidermal growth factor, insulin-like growth factor, fibroblast growth factor, heregulin, platelet-derived growth factor, vascular endothelial growth factor, or hypoxia inducible factor.
- the cancer cell-targeting moiety comprises one or more hormones, such as human chorionic gonadotropin, gonadotropin releasing hormone, an androgen, an estrogen, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, prolactin, growth hormone, adrenocorticotropic hormone, antidiuretic hormone, oxytocin, thyrotropin-releasing hormone, growth hormone releasing hormone, corticotropin-releasing hormone, somatostatin, dopamine, melatonin, thyroxine, calcitonin, parathyroid hormone, glucocorticoids, mineralocorticoids, adrenaline, noradrenaline, progesterone, insulin, glucagon, amylin, erythropoitin, calcitriol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin, neuropeptide Y,
- hormones such as
- the targeting element comprises one or more cytokines, such as IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12, IL13, IL14, IL15, IL-16, IL-17, IL-18, granulocyte-colony stimulating factor, macrophage-colony stimulating factor, granulocyte-macrophage colony stimulating factor, leukemia inhibitory factor, erythropoietin, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , LT- ⁇ , CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, TGF- ⁇ , IL 1 ⁇ , IL-1 ⁇ , IL-1 RA, MIF, IGIF, and/or a combination thereof.
- cytokines such as IL1,
- a targeting element binds to one or more tissue-specific cell surface markers.
- a targeting element is based on the natural ligand of tissue-specific cell surface marker (e.g., a targeting element is a recombinant version of a natural ligand or fragment thereof).
- a targeting element is binding agent, such as a peptide, antibody, or aptamer, that binds to one or more tissue-specific cell surface markers. Appropriate cell surface markers are known by the skilled artisan.
- a non-limiting list of exemplary tissue-specific markers includes: B cell surface markers: (Activated B Cells) CD28, CD38, CD69, CD80, CD83, CD86, DPP4, FCER2, IL2RA, TNFRSF8, TNFSF7; (Mature B Cells) CD19, CD22, CD24, CD37, CD40, CD72, CD74, CD79A, CD79B, CR2, IL1R2, ITGA2, ITGA3, MS4A1, ST6GAL1; (Other B cell surface markers) CD1C, CHST10, HLA-A, HLA-DRA, NTSE.
- B cell surface markers Activated B Cells
- Mature B Cells CD19, CD22, CD24, CD37, CD40, CD72, CD74, CD79A, CD79B, CR2, IL1R2,
- T cell surface markers (Cytotoxic T Cells) CD8A, CD8B1; Helper T Cells: CD4; (Activated T Cells) ALCAM, CD2, CD38, CD40LG, CD69, CD83, CD96, CTLA4, DPP4, HLA-DRA, IL12RB1, IL2RA, ITGA1, TNFRSF4, TNFRSF8, TNFSF7; (Other T cell surface markers) CD160, CD28, CD37, CD3D, CD3G, CD3Z, CD5, CD6, CD7, FAS, KLRB1, KLRD1, NT5E, ST6GAL1; (Natural Killer (NK) cell surface markers) CD2, CD244, CD3Z, CD7, CD96, CHST10, FCGR3B, IL12RB1, KLRB1, KLRC1, KLRD1, LAG3, NCAM1; Monocyte/macrophage surface markers: (Activated Macrophages) CD69, ENG, FCER2, IL2RA; (O
- an activity element comprises a protein component that has the desired signaling activity. This component normally binds to a receptor on the surface of the desired target cell.
- the activity element can be any protein that binds to a cell-surface receptor and stimulates signal transduction.
- the activity element is a variant form (e.g., it is mutated) that has an intrinsic binding to its receptor that is weak as compared to the wild-type protein, to the point that binding of the chimeric protein to a cell is driven by the binding of the targeting element to its receptor.
- the Chimeric Activator first binds to a cell through the targeting element, and after this initial binding step, the mutated activity element is in a high local concentration relative to its own receptor, so binding takes place in spite of the mutation.
- the chimeric protein may not significantly bind to cells that have only the activity element receptor and not the targeting element receptor, because the inherent binding of the activity element is simply too weak.
- the presence of one or more weakening mutations can be essential to reduce side effects from activation of non-target cells.
- FIG. 2 illustrates a non-limiting example of these processes.
- a target cell expresses the Receptors for both the targeting element (R T ) and Receptors for the Activating Element (R A ).
- the Chimeric Activator first binds to the target cell surface via the targeting element (T).
- the resulting complex then undergoes two-dimensional diffusion in the cell membrane, and when the Activating Element (A) is near its receptor, binding will be driven by the high local concentration, in spite of the mutation in the Activating Element that reduces binding. Signal transduction results (lightning).
- the chimeric activator does not bind to non-target cells because the intrinsic binding of the mutant Activator Element to its receptor is simply too low.
- aspects of the invention relate to creating mutations in the activity element, such that the mutated form of the activity element binds to its receptor with a reduced affinity relative to a wild-type form of the activity element.
- chimeric activators differ from fusion proteins in which an element with signaling activity may bind to more than one receptor type, and a mutation is introduced into this element to modulate the receptor type that is used (e.g., certain TNF chimeras, see also for example US20060263368).
- Chimeric Activators of the invention differ from such distinct fusion proteins in that the signaling by a Chimeric Activator is directed through the receptor for which affinity has been reduced by the mutation in the activity element.
- a “mutation” refers to a change in the nucleotide sequence encoding the activity element, relative to a wild-type form of the gene.
- a change in the nucleotide sequence may or may not lead to a change in the amino acid sequence, the three-dimensional structure of the protein, and/or the activity of the protein, relative to the wild-type form of the protein.
- a mutation may be a naturally occurring variant of the gene.
- a mutation may be a single amino acid substitution, two or more amino acid substitutions, one or more deletions, one or more insertions, or any combination of two or more thereof, in the protein sequence of the activity element. It will be understood that the selection of a suitable mutation in an activity element for the creation of a chimeric molecule will depend on multiple factors and in some embodiments will need to be determined empirically for different proteins.
- variant activity elements of the invention may have a reduced binding affinity for their receptor(s) without a loss (or without a significant loss) of signal function (e.g., they substantially or completely retain their ability to promote signal transduction when bound to their receptor(s) even though their affinity for the receptor(s) may be significantly reduced).
- the reduced binding affinity of the variant activity element preferably does not result in a protein element that will not bind to its natural receptor(s), for example, due to steric hindrance or charge repulsion or other negative interaction between the variant activity element and its natural receptor(s), even when the targeting element binds to a target molecule on the same cell (thereby increasing the local concentration of the variant activity element in the vicinity of its natural receptor(s)).
- appropriate levels of reduced binding affinity can be obtained by introducing one or more mutations in charged or hydrophilic amino acids (or amino acids thought to be pointing outward) that have the effect of shortening the side chain of the amino acid(s).
- the charged or hydrophilic side chains are likely to be pointing outward and not into the middle of the protein. Reducing the size of the amino acid side chain(s) removes a contact, but does not create steric hindrance that would completely block binding or signaling.
- mutants may be created in an activity element, and those that reduce but do not abolish binding may be selected (e.g., using one or more binding and/or activity assays known to one of skill in the art) and used to construct a Chimeric Activator.
- variant activity elements of the invention can be identified or selected for any appropriate cell-surface receptor that is involved in a signaling activity that is useful for a particular application of interest.
- tumor necrosis factor receptors e.g., CD120
- death receptors are a family of cytokine receptors that bind to various tumor necrosis factors (TNF) (e.g., TNF-alpha).
- TNF tumor necrosis factor receptors
- Exemplary tumor necrosis factor receptor family members include: CD120a (TNFRSF1A), CD120b (TNFRSF1B), Lymphotoxin beta receptor (LTBR, TNFRSF3), CD134 (TNFRSF4), CD40 (CD40, TNFRSF5), FAS (FAS, TNFRSF6), TNFRSF6B (TNFRSF6B), CD27 (CD27, TNFRSF7), CD30 (TNFRSF8), CD137 (TNFRSF9), TNFRSF10A (TNFRSF10A), TNFRSF10B, (TNFRSF10B), TNFRSF10C (TNFRSF10C), TNFRSF10D (TNFRSF10D), RANK (TNFRSF11A), Osteoprotegerin (TNFRSF11B), TNFRSF12A (TNFRSF12A), TNFRSF13B (TNFRSF13B), TNFRSF13C (TNFRSF13C), TNFRSF14 (TNFRSF14), Nerve growth factor receptor
- TNFRs represent an attractive target for inhibiting cancer cell growth and/or survival.
- the activity elements of the invention are ligands (agonists or antagonists) that bind to one or more tumor necrosis factor receptors known in the art or disclosed herein.
- the activity elements of the invention are tumor necrosis factors or fragments thereof, such as TNF-alpha or TNF-beta (lymphotoxin).
- the activity elements are selected from the TNF Ligand Family: LTA (TNF- ⁇ ), TNF (TNF- ⁇ ), TNFSF5 (CD40 Ligand), TNFSF6 (FasL), TNFSF7 (CD27 Ligand), TNFSF8 (CD30 Ligand), TNFSF9 (4-1BB Ligand), TNFSF10 (TRAIL), TNFSF14 (HVEM-L), TNFSF18, or fragments thereof.
- the activity elements of the invention are tumor necrosis factors or fragments thereof, such as TNF-alpha or TNF-beta (lymphotoxin).
- the activity elements of the invention are tumor necrosis factors with attenuated function.
- the attenuated function is a reduced binding affinity for target receptors.
- certain peptide elements may be used as targeting elements in some embodiments (e.g., a cytokine that can be used to target cells that express the cytokine receptor) and activity elements in different embodiments (e.g., the same cytokine could be used to activate cells that are targeted using a different targeting element in other embodiments).
- a peptide When a peptide is used as a targeting element, its natural affinity for the target molecule may be retained in the chimeric molecule.
- the affinity of a natural peptide for a target molecule may be increased (e.g., by mutation) in order to improve its use as a targeting element.
- the binding affinity may be retained and/or increased but the function activity (e.g., signal transduction or enzymatic activity) may be decreased or removed (e.g., by mutation) if that particular function is not required or is undesirable.
- a variant form e.g., a naturally occurring or engineered mutated form
- one or more of the growth factors and/or cytokines described or listed herein as candidates for targeting elements also may be used as activity elements in other embodiments where they may be mutated to reduce their binding affinity for their receptor or substrate or target molecule.
- One criterion that may be evaluated in selecting activity elements and targeting elements is the affinity of the activity element for its receptor, and the ratio of the affinity of the activity element for its receptor relative to the affinity of the targeting element for its receptor.
- mutated activity elements will be selected such that the activity element has a lower affinity for its receptor than the affinity of the targeting element for its receptor, thus allowing the targeting element to control which cells are bound by the chimeric molecule.
- the affinity ratio may be 1/2, 1/5, 1/10, 1/25, 1/50, 1/75, 1/100, 1/500, 1/1000, or an intermediate value, or a smaller value.
- mutated activity elements will be selected wherein one or both of the following conditions are met: the on-rate of the activity element is lower than that of the targeting element, or if the off-rates are faster than the internalization rate, then the equilibrium constant (K on /K off ) of the targeting element is higher than that of the activity element.
- mutated activity elements Another criterion that may be involved in selecting mutated activity elements is an evaluation of the activity level of the activity element alone, and the activity level of the activity element when it is linked to the targeting element.
- mutated activity elements may be selected that have reduced activity or are inactive alone, relative to a wildtype form of the protein, due to their reduced binding efficiency, but are active when linked to a targeting element, because the binding of a targeting element to its receptor at the cell surface increases the local concentration of the activity element in the vicinity of its receptor at the cell surface. It should be appreciated that appropriate activity levels for a given protein and a given mutation will need to be determined empirically.
- a mutated activity element will be selected such that the mutated activity element will not have sufficient activity to kill a cell when the activity element is alone, due to its reduced binding capacity for its receptor.
- the activity element is linked to a targeting element, the increased local concentration of the activity element at the cell surface allows it to be active and bind to its receptor and kill the cell.
- targeting and activity elements are attached by a linker.
- the linker can be any amino acid sequence that allows the simultaneous binding of the activity element and the targeting element to their receptors on a given cell surface.
- the linker is a non-folding, protease-resistant polypeptide segment that permits the targeting element and the activity element to bind to their cell-surface receptors, typically on the same cell surface, at the same time.
- Linkers may be of varied length (e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 amino acids long or intermediate or longer lengths) and/or amino acid composition. Linkers may be flexible or rigid.
- linker length will be optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- Optimal linker length for a given chimeric activator can be determined at least in part using models disclosed herein. In optimizing linker length, multiple factors will be considered including, but not limited to: the concentration of the first and second binding sites, the sizes of the activity element and targeting element, the minimum distance between the binding sites of the targeting element and the activity element, and the affinities of the activity element and the targeting element for the first and second binding sites.
- a linker length will be chosen that is at least equal to the minimum distance between the first and second binding sites on the cell surface.
- a linker length will be chosen that is at least twice the minimum distance between the first and second binding sites on the cell surface. In some embodiments a linker length will be chosen that is at most five-six times the minimum distance between the first and second binding sites on the cell surface. It will be understood that optimal linker length will vary depending on the specific proteins selected as activity elements and targeting elements. In some embodiments a protein which is blocked at the N- or C-terminus may be selected as an activity element or a targeting element. In these embodiments a linker may be added elsewhere on the protein.
- the linker length is chosen based in part on the known or surmised heights from the cell surface of the targeting element and activity element when each is bound to its receptor. For example, when EGF is bound to EGFR, its N- and C-termini are about 90 Angstroms from the cell surface, and when interferon alpha is bound to its receptor, its N- and C-termini are about 75 Angstroms from the cell surface, so that a linker of at least 15 Angstroms must be used.
- the invention also provides methods for calculating an optimal linker length for a chimeric protein with two elements that simultaneously bind to a cell surface, based on the density of the receptors for each of the two elements on a cell surface and the difference in height from the cell surface of the termini of the two elements when bound to their receptors.
- the method optionally involves knowledge of the on-rates and off-rates of each element for its receptor.
- the method optionally involves calculating, as linker length is increased, the trade-off on the one hand between the increasing volume that can be occupied by one element when the other is bound to its receptor on a cell surface (which negatively impacts on a second binding event), and the increasing portion of cell surface area that may be sampled by one element when the other is bound to its receptor on that cell surface (which positively impacts on a second binding event).
- the density of a targeting element receptor is more than 10,000 per cell and the difference in height from the cell membrane of the bound elements is less than about 50 Angstroms, and in such situations a linker of about 25 to 70 amino acids is found to be optimal, with a linker length of about 30 to 40 amino acids often being more optimal.
- the linker should be flexible.
- both a targeting element and an activity element that engage their receptors through monomeric interactions.
- both the interferon alpha element and the EGF element are monomeric.
- the activity elements TNF and TRAIL which are trimeric
- targeting elements consisting of antibodies which are generally dimeric or have higher-order multivalent binding properties.
- One advantage of using targeting elements and activity elements that function as monomers is that it is easier to quantitatively predict their properties and thus to design specific molecules with desired features. It is also generally easier to predict the structure of the complex on the cell surface in which the targeting element and activity element are simultaneously bound.
- Examples of functionally monomeric activity elements include interferon alpha, interferon beta, IL-1, IL-2, IL-3, IL-4, IL-6, IL-11, IL-12, IL-13, IL-15, IL-18, erythropoietin, insulin, insulin-like growth factor, thrombopoietin, EGF, and CNTF.
- Examples of functionally monomeric targeting elements include single-chain Fv proteins and Fabs, as well as CD4, IL-1, IL-2, IL-3, IL-4, IL-6, IL-11, IL-12, IL-13, IL-15, IL-18, erythropoietin, insulin, insulin-like growth factor, thrombopoietin, EGF, and CNTF. Therefore, the invention provides Chimeric Activators that contain a monomerically functioning activity element and a monomerically functioning targeting element.
- the invention provides proteins comprising two monomerically binding peptide moieties, optionally connected by a linker, such that both moieties can simultaneously bind to their receptors and/or target molecules on a single cell surface, in which at least one moiety signals through its receptor, and for which the signaling moiety contains a mutation relative to its naturally occurring form that reduces the binding to the receptor through which the signaling moiety signals.
- a monomeric portion of a naturally multimeric targeting element and/or activity element may be used (e.g., by removing a multimerization domain).
- the activity element also may include an additional mutation to reduce its affinity for its receptor as described herein.
- a chimeric protein of the invention may include a recombinant binding protein such as recombinant antibody instead of the activity element.
- the binding protein may be engineered to have very low affinity (relative to specific antibody binding affinity) for a target molecule that can transduce a signal (or result in another biological or cellular response) upon binding by the binding protein (e.g., low affinity antibody).
- aspects of the invention described in the context of a chimeric protein including a variant activity element also may be used in connection with an chimeric protein that includes a low affinity engineered binding protein instead.
- the same considerations for the targeting element and the optional linker apply.
- binding refers to a non-covalent or a covalent interaction, preferably non-covalent, that holds two molecules together.
- two such molecules could be an enzyme and an inhibitor of that enzyme.
- Another example would be an enzyme and its substrate.
- a third example would be an antibody and an antigen.
- Non-covalent interactions include, but are not limited to, hydrogen bonding, ionic interactions among charged groups, van der Waals interactions, and hydrophobic interactions among non-polar groups. One or more of these interactions can mediate the binding of two molecules to each other.
- Binding may exhibit discriminatory properties such as specificity or selectivity. Binding affinities may range from mM to pM (e.g., micromolar or nanomolar binding affinities) depending on the concentration of the receptors and the activity of the activator elements.
- HIS-tag refers to an affinity tag consisting of multiple consecutive histidine amino acids. Generally six (hexa-HIS) residues are used, or multiples thereof. His-tagged proteins have a high selective affinity for Ni + and a variety of other immobilized metal ions. Consequently a protein containing a His-tag generally can be selectively bound to a metal ion charged medium while other cellular proteins bind weakly or are washed out with binding or wash buffers. His-tags are small and therefore, tend to be less disruptive to the properties of the proteins on which they are attached.
- myc tag refers to an epitope tag derived from myc protein, generally comprising the sequence amino acid SEQ ID NO: 17: EQKLISEEDL.
- a number of different antibodies are known to recognize the myc epitope tag, for example 9B11 and 9E10.
- RNA equivalent refers to an RNA sequence corresponding to a DNA or amino acid sequence. Such equivalents may correspond directly to the original sequence (in the case of a protein the “coding sequence”), or may include additional sequence, such as untranslated regions and introns. In the case of an RNA equivalent for DNA the correspondence may be complementary to the DNA strand or anti-sense, allowing for the fact that in RNA “U” replaces “T” in the genetic code. DNA/RNA sequences of the sequence listing may be considered to follow this guidance.
- Nucleic acids of the invention include isolated or recombinant nucleic acids comprising coding sequences for Chimeric Activators or components thereof described herein.
- the nucleic acids may be on vectors.
- the nucleic acids may be in host cells. It should be appreciated that the nucleic acids also may include regulatory sequences for transcription (e.g., promoters, activators, terminators, etc.) and translation (e.g., ribosome binding sequences, IRES elements, terminators, etc.) of the chimeric proteins in addition to sequences required for vector replication and/or selection and/or packaging in host cells (e.g., prokaryotic or eukaryotic host cells, including, but not limited to bacterial, mammalian, yeast, insect, and/or other host cells).
- host cells e.g., prokaryotic or eukaryotic host cells, including, but not limited to bacterial, mammalian, yeast, insect, and/or other host cells.
- aspects of the invention relate to recombinant vectors which include one or more nucleic acids of the invention (e.g., SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, and 15), as well as host cells containing the vectors or which are otherwise engineered to contain or express nucleic acids or polypeptides of the invention, and methods of making such vectors and host cells and their use in production of polypeptides of the invention by recombinant or synthetic techniques.
- Targeting and activity elements may be isolated (e.g. expressed and purified) independently and linked via a synthetic linker.
- the polynucleotides of the invention are joined to a vector (e.g., a cloning or expression vector).
- the vector may be, for example, a phage, plasmid, or viral vector.
- Viral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.
- the polynucleotides may be joined to a vector containing a selectable marker for propagation in a host.
- Introduction of the vector construct into the host cell can be effected by techniques known in the art which include, but are not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. (1986) Basic Methods In Molecular Biology.
- polypeptides of the invention or fragments thereof may be provided in substantially pure form, that is to say free, to a substantial extent, from other proteins.
- a polypeptide may be provided in a composition in which it is the predominant component present (i.e., it is present at a level of at least 50%; preferably at least 75%, at least 90%, or at least 95%; when determined on a weight/weight basis excluding solvents, carriers, or coupling agents).
- Polypeptides of the invention can be recovered and purified from recombinant cell cultures or organisms by well-known methods including, ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, affinity chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography, molecular sieving chromatography, centrifugation methods, electrophoresis methods and lectin chromatography.
- Chimeric Activator proteins are expressed in and secreted from the yeast Pichia pastoris . In one embodiment, a combination of these methods is used. In another embodiment, high performance liquid chromatography is used.
- an antibody which specifically binds to a polypeptide of the invention can be used to deplete a sample comprising a polypeptide of the invention of the polypeptide or to purify the polypeptide.
- Techniques well-known in the art may be used for refolding to regenerate native or active conformations of the polypeptides of the invention when the polypeptides have been denatured during isolation and or purification, should such be desired.
- Polypeptides of the invention may comprise sequences, for example, epitope or affinity tags, that may aid in isolation or purification of the protein. However, they need not do so.
- proteins of the invention e.g., SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16
- proteins of the invention may be purified through use of reagents that bind myc and/or HIS tags, but the invention also contemplates embodiments in which the proteins lack the myc and/or HIS tags, or which utilize different epitope or affinity tags.
- Chimeric Activator nucleic acids and/or polypeptides may be screened, such as in high-throughput screening of a library of Chimeric Activators to select for a Chimeric Activator of the desired characteristics, or may be screened individually. For example, measurement of signal transduction in mammalian cells using Western blots that detect phosphorylation at specific sites may be used to screen for Chimeric Activators of a desired signal transduction activity.
- Chimeric activators may be of various functions, e.g., having activity working against cancer, viral infection, and obesity. Diverse proteins can be used as activity elements and targeting elements. These proteins can be structurally varied, including monomers, trimers, and heterodimers of alpha helices and beta sheets. Some design considerations are illustrated in the Examples. Activity elements may be a non-toxic pro-drug that is activated in the target locale, for example, by cancer cells. It should be appreciated that many functions are compatible with the chimeric activators of the claimed invention. In some embodiments, the targeting element targets the activity element to a specific cell or cell type in order to kill a specific cell or cell type.
- the targeting element targets the activity element to a specific cell or cell type, for a purpose other than to kill the specific cell or cell type (e.g. to upregulate or downregulate one or more proteins or cellular properties such as cell growth, or proliferation).
- Chimeric Activator nucleic acids and/or polypeptides may be used in gene therapy or in pharmaceutical compositions. Chimeric Activator nucleic acids and/or polypeptides may be used in treatment of a subject or patient, and may be used in combination with other therapies. Use of Chimeric Activator nucleic acids and/or polypeptides may be indicated by a diagnostic or theranostic, for example, a biopsy, for the appropriate presence of receptors for the Targeting and/or activity element.
- chimeric activator proteins are used to treat subjects who have cancer.
- the term “subject” refers to a human or non-human mammal or animal.
- Non-human mammals include livestock animals, companion animals, laboratory animals, and non-human primates.
- Non-human subjects also specifically include, without limitation, chickens, horses, cows, pigs, goats, dogs, cats, guinea pigs, hamsters, mink, and rabbits.
- a subject is a patient.
- a “patient” refers to a subject who is under the care of a physician or other health care worker, including someone who has consulted with, received advice from or received a prescription or other recommendation from a physician or other health care worker.
- a patient is typically a subject having or at risk of having cancer.
- treatment or “treating” is intended to refer to prophylaxis, amelioration, prevention and/or cure of a condition (e.g., cancer).
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment after a condition e.g., cancer
- Treatment of subjects before a condition e.g., cancer
- prophylactic treatment aims to reduce the risk of developing the condition and/or lessen its severity if the condition does develop.
- the term “prevent” refers to the prophylactic treatment of a subject who is at risk of developing a condition (e.g., cancer) resulting in a decrease in the probability that the subject will develop the disorder, and to the inhibition of further development of an already established disorder.
- cancer refers to an uncontrolled growth of cells that may interfere with the normal functioning of the bodily organs and systems, and includes both primary and metastatic tumors.
- Primary tumors or cancers that migrate from their original location and seed vital organs can eventually lead to the death of the subject through the functional deterioration of the affected organs.
- a metastasis is a cancer cell or group of cancer cells, distinct from the primary tumor location, resulting from the dissemination of cancer cells from the primary tumor to other parts of the body. Metastases may eventually result in death of a subject.
- cancer includes, but is not limited to, the following types of cancer: breast cancer (including carcinoma in situ), biliary tract cancer; bladder cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia; T-cell acute lymphoblastic leukemia/lymphoma; hairy cell leukemia; chromic myelogenous leukemia, multiple myeloma; AIDS-associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; mesothelioma, neuroblastomas; oral cancer including
- Non-limiting examples of precancerous conditions include dysplasia, premalignant lesions, adenomatous colon polyp, and carcinoma in-situ such as Ductal carcinoma in-situ (DCIS), etc.
- Other cancers that can be treated with methods of the invention will be known to those of ordinary skill in the art.
- the cancer is melanoma.
- the cancer is adenocarcinoma.
- the cancer is a solid tumor cancer.
- compositions of the invention may be administered in effective amounts.
- An effective amount is a dosage of the composition of the invention sufficient to provide a medically desirable result.
- An effective amount means that amount necessary to delay the onset of, inhibit the progression of or halt altogether the onset or progression of the particular condition (e.g., cancer) being treated.
- An effective amount may be an amount that reduces one or more signs or symptoms of the condition (e.g., cancer).
- effective amounts will depend, of course, on the particular condition being treated (e.g., the cancer), the severity of the condition, individual subject parameters including age, physical condition, size and weight, concurrent treatment, frequency of treatment, and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
- compositions of the invention can be varied to obtain an amount of the composition of the invention that is effective to achieve the desired therapeutic response for a particular subject, compositions, and mode of administration.
- the selected dosage level depends upon the activity of the particular composition, the route of administration, the severity of the condition being treated, the condition, and prior medical history of the subject being treated. However, it is within the skill of the art to start doses of the composition at levels lower than required to achieve the desired therapeutic effort and to gradually increase the dosage until the desired effect is achieved. In some embodiments, lower dosages would be required for combinations of multiple compositions than for single compositions.
- an optimized dosage may be based, at least in part, on the residual non-specific toxicity of the activity element in a chimeric activator, the concentration of target molecules on the target cells, the binding affinity of the targeting element of the chimeric activator for the target molecules, and the length and flexibility of the linker.
- the amount of compound added should be sufficient to obtain a concentration of chimeric activator on the target cells that is sufficient to promote the desired response in the target cells. However, the amount should not be higher than necessary to avoid exposing non-target cells with levels of variant activity element that would be sufficient to activate the non-target cells. It should be appreciated that the optimal amount may be different for different chimeric activators (e.g., with different relative binding of targeting and activity elements, etc.).
- compositions of the invention can be administered to a subject by any suitable route.
- the compositions can be administered orally, including sublingually, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically and transdermally (as by powders, ointments, or drops), bucally, or nasally.
- parenteral administration refers to modes of administration other than through the gastrointestinal tract, which include intravenous, intramuscular, intraperitoneal, intrasternal, intramammary, intraocular, retrobulbar, intrapulmonary, intrathecal, subcutaneous and intraarticular injection and infusion.
- Surgical implantation also is contemplated, including, for example, embedding a composition of the invention in the body such as, for example, in the brain, in the abdominal cavity, under the splenic capsule, or in the cornea.
- Dosage forms for topical administration of a composition of this invention include powders, sprays, ointments, and inhalants as described herein.
- the composition is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants that may be required.
- compositions of the invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions also can contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It also may be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents that delay absorption, such as aluminum monostearate or gelatin.
- the absorption of the composition in order to prolong the effect of the composition, it is desirable to slow the absorption of the composition from subcutaneous or intramuscular injection. This result can be accomplished by the use of a liquid suspension of crystalline or amorphous materials with poor water solubility. The rate of absorption of the composition then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered composition from is accomplished by dissolving or suspending the composition in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the composition in biodegradable polymers such a polylactide-polyglycolide. Depending upon the ratio of composition to polymer, and the nature of the particular polymer employed, the rate of composition release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial- or viral-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- the invention provides methods for oral administration of a pharmaceutical composition of the invention.
- Oral solid dosage forms are described generally in Remington's Pharmaceutical Sciences, 18th Ed., 1990 (Mack Publishing Co. Easton Pa. 18042) at Chapter 89.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, troches or lozenges, cachets, pellets, and granules.
- liposomal or proteinoid encapsulation can be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673).
- liposomes generally are derived from phospholipids or other lipid substances.
- Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any nontoxic, physiologically acceptable, and metabolizable lipid capable of forming liposomes can be used.
- the present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like.
- the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y.
- Liposomal encapsulation may include liposomes that are derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556).
- the formulation includes a composition of the invention and inert ingredients which protect against degradation in the stomach and which permit release of the biologically active material in the intestine.
- the composition is mixed with, or chemically modified to include, a least one inert, pharmaceutically acceptable excipient or carrier.
- the excipient or carrier preferably permits (a) inhibition of proteolysis, and (b) uptake into the blood stream from the stomach or intestine.
- the excipient or carrier increases uptake of the composition of the invention, overall stability of the composition, and/or circulation time of the composition in the body.
- Excipients and carriers include, for example, sodium citrate, or dicalcium phosphate, and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, cellulose, modified dextrans, mannitol, and silicic acid, as well as inorganic salts such as calcium triphosphate, magnesium carbonate and sodium chloride, and commercially available diluents such as FAST-FLO®, EMIDEX®, STA-RX 1500®, EMCOMPRESS® and AVICEL®, (b) binders such as, for example, methylcellulose ethylcellulose, hydroxypropyhnethyl cellulose, carboxymethylcellulose, gums (e.g., alginates, acacia), gelatin, polyvinylpyrrolidone, and sucrose, (c) humectants, such as glycerol, (d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca
- compositions of a similar type also can be employed as fillers in soft and hard-filled gelatin capsules, using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They optionally can contain opacifying agents and also can be of a composition that they release the active ingredients(s) only, or preferentially, in a part of the intestinal tract, optionally, in a delayed manner.
- exemplary materials include polymers having pH sensitive solubility, such as the materials available as EUDRAGIT® Examples of embedding compositions that can be used include polymeric substances and waxes.
- composition of the invention also can be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms can contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol ethyl carbonate ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydroflirfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emul
- the oral compositions also can include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, coloring, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, coloring, flavoring, and perfuming agents.
- Oral compositions can be formulated and further contain an edible product, such as a beverage.
- Suspensions in addition to the composition of the invention, can contain suspending agents such as, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- suspending agents such as, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- composition of the invention is delivered to the lungs of a mammal while inhaling, thereby promoting the traversal of the lung epithelial lining to the blood stream.
- Adjei et al. Pharmaceutical Research 7:565-569 (1990); Adjei et al., International Journal of Pharmaceutics 63:135-144 (1990) (leuprolide acetate); Braquet et al., Journal of Cardiovascular Pharmacology 13 (suppl.5): s.
- Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including, but not limited to, nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
- Some specific examples of commercially available devices suitable for the practice of the invention are the ULTRAVENT® nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the ACORN II® nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the VENTOL® metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, N.C.; and the SPINHALER® powder inhaler, manufactured by Fisons Corp., Bedford, Mass.
- each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants, and/or carriers useful in therapy.
- the composition may be prepared in particulate form, preferably with an average particle size of less than 10 ⁇ m, and most preferably 0.5 to 5 ⁇ m, for most effective delivery to the distal lung.
- Carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol.
- Other ingredients for use in formulations may include lipids, such as DPPC, DOPE, DSPC and DOPC, natural or synthetic surfactants, polyethylene glycol (even apart from its use in derivatizing the inhibitor itself), dextrans, such as cyclodextran, bile salts, and other related enhancers, cellulose and cellulose derivatives, and amino acids.
- liposomes In addition, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
- Formulations suitable for use with a nebulizer typically comprise a composition of the invention dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution.
- the formulation also can include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure).
- the nebulizer formulation also can contain a surfactant to reduce or prevent surface-induced aggregation of the inhibitor composition caused by atomization of the solution in forming the aerosol.
- Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the composition of the invention suspended in a propellant with the aid of a surfactant.
- the propellant can be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof.
- Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid also can be useful as a surfactant.
- Formulations for dispensing from a powder inhaler device comprise a finely divided dry powder containing the composition of the invention and also can include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol, in amounts that facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
- a bulking agent such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol
- Nasal delivery of the composition of the invention also is contemplated.
- Nasal delivery allows the passage of the composition to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung.
- Formulations for nasal delivery include those with dextran or cyclodextran. Delivery via transport across other mucous membranes also is contemplated.
- compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the composition of the invention with suitable nonirritating excipients or carriers, such as cocoa butter, polyethylene glycol, or suppository wax, which are solid at room temperature, but liquid at body temperature, and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers such as cocoa butter, polyethylene glycol, or suppository wax, which are solid at room temperature, but liquid at body temperature, and therefore melt in the rectum or vaginal cavity and release the active compound.
- Example 1 An IFN ⁇ EGF Chimeric Activator
- a Chimeric Activator protein was constructed with the following protein components: a mutated version of interferon alpha (IFN ⁇ ) as the Activating Element, a linker, and epidermal growth factor (EGF) as the targeting element.
- IFN ⁇ interferon alpha
- EGF epidermal growth factor
- FIG. 3 An embodiment of this chimeric protein is illustrated in FIG. 3 .
- the IFN ⁇ activity element is shown in region (1)
- the (Gly 4 Ser) 7 linker is shown in region (2)
- the EGF targeting element is shown in region (3).
- the Chimeric Activator is bound to both IFN ⁇ R2 (shown as region (4)) and an active EGFR dimer (shown as region (5)).
- the figure shows only the extracellular domains of the receptors. The membrane-spanning domains would be at the bottom of the figure.
- IFN ⁇ and its PEGylated derivatives are used as drugs in the treatment of hepatitis B, hepatitis C, and certain forms of cancer.
- Side effects of IFN ⁇ treatment include flu-like symptoms, depression, and myelosuppression, which limit the dose and limit the therapeutic index.
- An engineered form of IFN ⁇ with reduced side effects may have the potential to replace IFN ⁇ for many diseases, and open up new treatments.
- compositions of the invention can be performed in the absence of such information as described herein.
- Table 1 shows the binding characteristics of EGF and IFN ⁇ , and compares them with an anti-EGFR antibody that has been used in targeting studies.
- the chimeric activators and the corresponding IFN ⁇ mutant proteins were compared for their ability to activate the IFN ⁇ receptor in HeLa cells, which naturally express EGFR and IFN ⁇ R.
- STAT1 phosphorylation was detected by Western blotting; STAT1 tyrosine 701 is directly phosphorylated upon activation of IFN ⁇ receptor.
- the results shown in FIG. 4 indicate that an IFN ⁇ -EGF chimeric protein (without a mutation) and IFN ⁇ alone induce IFN signaling with about equal efficiency.
- the IFN ⁇ mutant proteins K133A, R144A, and R149A which respectively are reduced by 10 ⁇ , 40 ⁇ , and 200 ⁇ for IFN ⁇ R binding, show corresponding low levels of IFN ⁇ signaling.
- IFN ⁇ proteins showed reduced signaling in a manner correlated with their reduced binding to IFN ⁇ receptor, while the IFN ⁇ -EGF mutant chimeric proteins showed much higher levels of signaling through STAT1. All lanes were loaded with an essentially equal amount of total cell protein.
- Daudi cells are a human Burkitt's lymphoma cell line whose proliferation and survival are inhibited by IFN ⁇ , but does not express EGFR.
- FIG. 5 illustrate the experiments with the EGFR-expressing Daudi cell line.
- Cells were transfected with a plasmid that constitutively expresses EGFR.
- Parental cells, cells transfected with an empty plasmid vector, and EGFR-transfected cells were treated with EGF, and then phosphorylation of EGFR was detected by Western blotting.
- Daudi cells engineered to express EGFR FIG. 5
- parental Daudi cells were treated with Chimeric Activators and mutant IFN ⁇ proteins, and STAT1 phosphorylation was measured by Western blot.
- the IFN ⁇ (R149A)-EGF protein specifically induced signal transduction in cells expressing EGFR.
- the EGFR-expressing cells correspond to therapeutic target cells, while the cells lacking EGFR correspond to ‘side-effect’ cells.
- activation with the mutant IFN ⁇ Chimeric Activator protein was poor or undetectable.
- the IFN ⁇ (R149A)-EGF protein stimulated STAT1 phosphorylation only in Daudi-EGFR cells, while the IFN ⁇ -EGF protein and IFN ⁇ alone were active in both cell lines and the IFN ⁇ mutant did not work in either cell line.
- Chimeric activators with the intermediate-strength mutations K133A and R144A showed intermediate reductions in signaling in Daudi cells, consistent with their predicted quantitative properties (data not shown).
- this experiment was useful to compare cells with and without EGFR, the Daudi-EGFR cells correspond to tumor cells expressing EGFR or another target receptor, and the parental Daudi cells are analogous to “side-effect cells”—other cells in the body with little or no target receptor. It was estimated that the addition of the EGF targeting element enhances the specificity of IFN ⁇ signaling by at least 20-fold in this system.
- Chimeric Activators of Example 1 can be tested/screened for activity in animal tumor models.
- Pharmaceutical Product Development, Inc. (New York, N.Y.) can be used as a contract testing service to perform these tests.
- This type of experiment is standard in the development of anti-cancer drugs, and involves injection of human tumor cells into mice that have immune-suppressing mutations so that the tumor cells will not be rejected.
- tumor cells are injected subcutaneously and then grow into a lump that can be measured with calipers. Once a tumor has reached a measurable size, treatment is started and the extent of tumor growth inhibition or shrinkage can be charted with time.
- mice which are immunodeficient and therefore do not reject the tumor cells as foreign; use of Nude mice also means that the mice will not generate antibodies against the injected proteins.
- PPD, Inc. offers testing for the Daudi models. They can also pre-test the engineered cell lines to verify that Daudi-EGFR cells can be used to generate tumors. PPD, Inc. can also perform mycoplasma testing on the tumor cell lines before they are used.
- the treatment groups can be:
- mice 8 to 10 mice may be used per group, for a total of about 80 mice for four dose groups in mice with the two different cell lines.
- the amount of protein needed for these experiments may be less than 2 mgs for the entire experiment.
- the productivity of these Pichia pastoris lines is such that the culture supernatant contains about 1 mg/ml of the desired chimeric protein, and only small amounts of other proteins.
- the proteins, which contain a histidine tag, will be purified using a nickel column by standard techniques.
- the protein can be administered by injection directly into subcutaneous tumors three times a week for three weeks. Tumor growth/shrinkage can be measured over a period of about a month. It can be tested whether appropriate signal transduction is activated in the tumor cells in vivo. Tumor biopsies can be frozen in liquid nitrogen, stored, and transferred back for Western blot analysis. The methods of Starostik et al. ((1998) Cancer Res. 58: 4552-4557) and Menon et al. ((2003) Am J Physiol Heart Circ Physiol. 284: H317-329) can be used to analyze the tissue for STAT1 phosphorylation.
- TNF ⁇ Tumor Necrosis Factor ⁇
- each element (activity element, a linker, and a targeting element) of the constructs of Example 1 can be replaced with an alternative component that is structurally different and/or has a different biological function. This is illustrated in this example and those that follow. These experiments may provide a molecule for testing in animals.
- TNF ⁇ Tumor Necrosis Factor
- TNF is a trimer with a completely different structure from IFN ⁇ .
- the structure of the TNF/TNF receptor complex has been solved.
- the N-terminus and C-terminus are not part of the interface with the receptor, so they are free for linker attachment.
- a chimeric protein with the TNF at the N-terminus followed by the linker and the EGF can be made.
- IFN ⁇ -EGF chimeric proteins described in Example 1 above a series of proteins with various mutations, as well as control wild-type and mutant TNF proteins lacking EGF, can be made.
- the proteins can have a histidine tag to aid in purification.
- TNF-linker-EGF Chimeric Activator by itself and in a complex with TNF receptor (see FIG. 8 ) illustrate how the TNF portion can still bind to its receptor when attached to the linker at EGF.
- TNF has a trimeric structure, such that the chimeric protein is also a trimer in embodiments that include the trimerization domains.
- TNF receptors are expressed on HeLa cells (Baglioni et al. (1985) J Biol Chem. 260: 13395-13397). TNF signaling will be measured using the same type of phosphorylation/Western blot analysis as described above for IFN ⁇ . TNF signaling by a molecule such as TNF(S147Y)-EGF may depend on the EGF-EGF receptor interaction, which can be tested by showing that TNF signaling can be inhibited by an anti-EGF antibody, and that signaling by the corresponding TNF(S147Y) mutant protein without EGF is much weaker or undetectable.
- EGFRde(2-7) is a mutant form of the EGF receptor with a deletion in the extracellular domain that creates a novel junction. (Exons 2 through 7 are deleted, creating a novel protein joint from exon 1 and exon 8.) This mutant form of the receptor is oncogenic and is naturally found on many tumor types, glioblastoma in particular. Since EGFRde(2-7) comes about by a mutation in cancer cells, it is not present at all in normal cells and thus it is an absolutely cancer-specific surface protein. The Pastan and Bigner groups have generated and characterized an antibody that recognizes the novel peptide junction.
- the antibody termed MR1-1, has been affinity-optimized and has an on-rate that is only about 4-fold lower than the on-rate of EGF (Kuan et al. (2000) Int J Cancer. 88: 962-969; see Table 1 above).
- EGFRvIII is a deleted form of EGF receptor that is only expressed on tumor cells.
- the deletion junction creates a novel amino acid sequence (*).
- MR1-1 is an antibody that recognizes this deletion junction, and does not recognize normal EGF receptor.
- a Chimeric Activator based on MR1-1 should be completely tumor-specific.
- U87MG nude mouse model is sensitive to IFN ⁇ (Iqbal Ahmed et al. (2001) Cancer Gene Ther. 8: 788-795).
- U87MG is derived from a human glioblastoma cell line.
- Glioblastoma is one of the most difficult types of human cancer to treat, and many patients die within a year of diagnosis. Most glioblastoma tumor cells have the EGFRde(2-7) deletion, so an IFN ⁇ -MR1-1 Chimeric Activator should work in this type of patient. Because glioblastoma patients rarely respond to treatment and progress so quickly, it may be possible to detect responses to an IFN ⁇ -MR1-1 Chimeric Activator during the Phase I stage of clinical trials.
- IFN ⁇ -MR1-1 Chimeric Activators can be constructed with wild-type IFN ⁇ and the same three mutants used above (K133A, R144A, and R149A).
- the MR1-1 antibody V regions can be formatted as a “single-chain Fv” (scFv) to make molecules with IFN ⁇ at the N-terminus, a 35 amino acid glycine/serine linker, the heavy chain V region of MR1-1, a 15 amino acid glycine/serine linker, the light chain V region of MR1-1, and a histidine tag for purification.
- scFv single-chain Fv
- These chimeric proteins will be expressed in Pichia pastoris and purified as for the IFN ⁇ -EGF Chimeric Activators.
- Pichia is known to be a good system for expression of antibody V regions formatted as single-chain Fv molecules.
- IFN ⁇ signaling can be measured using the STAT1 phosphorylation/Western blot assay described above.
- signaling can be measured using different linker lengths (e.g., the 35 amino acid glycine/serine linker can be doubled or tripled to create linkers of 70 and 105 amino acids between the IFN ⁇ and MR1-1 parts of the protein). It may also be necessary to introduce other amino acids besides glycine and serine, simply because the DNA sequences encoding the repeating peptide units may undergo genetic recombination because of the corresponding repeats in the DNA.
- Example 5 A TNF-Leptin Chimeric Activator for Treatment of Obesity
- Leptin is a hormone that is produced by adipocytes (fat cells) and also binds to receptors on adipocytes.
- leptin was thought to be a potential treatment for obesity, but further research indicated that in the vast majority of obese people, leptin is produced at high levels.
- leptin serves as a targeting element and its biological activity is not important to the function of the TNF-leptin Chimeric Activator.
- TNF TNF-leptin receptors are present on only a few other cell types in the body, such as cells in the hypothalamus that are thought to influence feeding and hunger. The action of TNF-leptin on these cells may be to inhibit feeding.
- TNF-leptin Chimeric Activators can be constructed using the same TNF mutations described above to bind to adipocytes (fat cells) and stimulate fat-burning for obesity treatment.
- Leptin would be the targeting element and a mutant form of TNF would be the activity element.
- the Chimeric Activators will have leptin at the C-terminus, since leptin has a disulfide bond that involves a cysteine at its very C-terminus, and a construct with the other orientation might have defective disulfide bond formation.
- the configuration of the leptin/leptin receptor complex is thought to be similar to the IFN ⁇ /IFN ⁇ receptor complex, and is favorable for the construction of a Chimeric Activator, as the C-terminus of TNF and the N-terminus of leptin are expected to be about the same distance away from the cell membrane.
- a stably transfected cell line that already expresses TNF receptor with an expression plasmid expressing a leptin receptor can be used.
- the activity of the TNF-leptin chimeric activators in the pair of cell lines with and without leptin receptor can be compared to demonstrate a specific requirement for the leptin receptor.
- mice The biological activity of the TNF-leptin molecule can be tested in overweight mice. These would be normal mice that are fed a high-fat diet, which are a good representation of human obesity.
- CD4 is a surface protein on T cells that is the receptor for the HIV envelope protein, gp120. During later stages of HIV infection, the envelope protein appears on the cell surface and could be targeted by a Chimeric Activator with CD4 as a targeting element.
- the structures of the gp120/CD4 complex has been solved (Zhou et al. Nature 445: 732-737), and it indicates that the N-terminus of CD4 could be used as a junction for a protein fusion.
- the same IFN ⁇ mutations described above can be used.
- only the N-terminal domain of CD4 is used, as depicted in the crystal structure, and IFN ⁇ -CD4 Chimeric Activators are constructed with a CD4 targeting element, targeting to the HIV envelope protein on HIV-infected cells.
- a stably transfected Daudi cell line that already expresses IFN ⁇ receptor with an expression plasmid expressing gp120 can be used.
- the activity of the Chimeric Activators can be compared in the pair of cell lines with and without gp120, to demonstrate a specific requirement for the gp120.
- the standard animal test system for HIV drugs is the SCID-hu mouse.
- an immunodeficient SCID mouse is populated with human immune cells, then infected with HIV.
- Evolution modulates the quantitative characteristics of protein interactions, and often uses combinations of weak interactions to achieve a particular specificity. How quantitative optimization might be used in the design of multidomain proteins was evaluated using a chimera containing epidermal growth factor (EGF) as a cell targeting element and interferon-alpha2a (IFN ⁇ 2a) to initiate signal transduction. EGF and IFN ⁇ 2a were connected via a linker that allows both ligands to bind to their receptors on a cell surface, then incorporated a series of mutations into the IFN ⁇ 2a portion that progressively decrease both the on-rate and dissociation constant of the IFN ⁇ 2a/IFN ⁇ receptor 2 (IFNAR2) interaction.
- EGF epidermal growth factor
- IFN ⁇ 2a interferon-alpha2a
- chimeric proteins were designed in which the activation of the IFN ⁇ receptor (IFNAR) in HeLa, A431 and engineered Daudi cells depends on the preysence of EGF receptor (EGFR) on the same cell.
- IFNAR IFN ⁇ receptor
- EGFR EGF receptor
- the mutant chimeric proteins also inhibit proliferation of IFN ⁇ -sensitive cells in an EGFR-dependent manner.
- Biological recognition events are often mediated by modular protein and nucleic acid segments that can be arbitrarily linked to give functional combinations.
- multidomain proteins have been repeatedly generated and constitute a large fraction of the proteins encoded by metazoan genomes.
- an important but under-studied process is the quantitative optimization of the individual modules.
- Pastan's group described a chimeric protein consisting of Pseudomonas exotoxin and IL-2, in which the IL-2 moiety directed the toxin to cells bearing IL-2 receptor (Lorberboum-Galski, H., FitzGerald, D., Chaudhary, V., Adhya, S., Pastan, I., (1998) Proc Natl Acad Sci USA 85(6), 1922-1926); they later described a Pseudomonas exotoxin -TGF ⁇ chimeric protein that binds to EGFR (Siegall, C.
- chimeric activators have the following general structure: an activity element containing at least one mutation, a linker and a targeting element ( FIG. 10A ).
- the example of a general chimeric activator structure shown in FIG. 10A illustrates a ‘targeting element’ connected by a peptide linker to an ‘activity element’ with a mutation that reduces binding to the receptor for the activity element.
- this design takes advantage of multivalent interactions between ligands and cell-surfaces to ensure precise delivery of biological activities.
- Daudi 293-T and HeLa cells were obtained from American type culture collection (Manassas, Va.). A431 cells were a gift from Thomas M. Roberts. A431, 293-T and HeLa cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U ml ⁇ 1 penicillin and 100 ⁇ g ml ⁇ 1 streptomycin. Daudi cells were maintained in RPMI-1640 modified medium supplemented with 10% FBS, 100 U ml ⁇ 1 penicillin and 100 ⁇ g ml ⁇ 1 streptomycin.
- FBS fetal bovine serum
- Daudi cells were maintained in RPMI-1640 modified medium supplemented with 10% FBS, 100 U ml ⁇ 1 penicillin and 100 ⁇ g ml ⁇ 1 streptomycin.
- Stable Daudi-pLPCX-EGFR Stable Daudi-pLPCX-EGFR (Daudi-EGFR) and Daudi-pLPCX cell lines were generated by retroviral infection of Daudi cells following the protocol of Pear et al. (available at the website of the Nolan Laboratory, Stanford University). Infected Daudi cells were first selected with puromycin (1.5 ⁇ g/mL) and then cells were isolated with Dynabeads Pan mouse IgG from Invitrogen (Maryland, USA) pre-coated with anti-EGFR mAb following the manufacturer instructions. The constructs pLPCX and pLPCX-EGFR were kindly provided by Joan S. Brugge, Harvard Medical School (Reginato, M. J., Mills, K. R., Paulus, J. K., Lynch, D. K., Sgroi, D. C., Debnath, J., Muthuswamy, S. K., Brugge, J. S., (2003) Nature Cell Biol 5(8)
- Anti-phospho-STAT1 (Tyr 701 ) rabbit pAb and anti-EGFR rabbit pAb were purchased from Cell Signaling Technology (Beverly, Mass.); PhosohoDetectTM anti-phospho-EGFR (Tyr 1068 ) rabbit pAb, anti-EGFR mouse mAb (EGFR.1), anti-EGFR mouse mAb (528) and anti-EGF rabbit pAb were purchased from Calbiochem (San Diego, Calif.); anti-actin mouse mAb was purchased from Chemicon International (Temecula, Calif.); anti-human IFN ⁇ / ⁇ R1-phycoerythrin mouse mAb was purchased from R&D systems (Minneapolis, Minn.); anti-EGFR R-Phycoerythrin-conjugated mouse mAb was purchased from BD Biosciences (San Jose, Calif.).
- the sequence was sub-cloned (with XhoI and XbaI restriction sites) into the pPICZ ⁇ A vector (Invitrogen), which includes the alcohol oxidase promoter and the ⁇ -factor leader sequence, a c-myc epitope tag and a His 6 tag for purification.
- the final sequence of the constructs was confirmed by DNA sequencing. Approximately 20 ⁇ g of the DNA construct were linearized with Pme I prior to transformation of P. pastoris X33 (Mut + ) and KM71H (Mut S ) cells.
- the electroporation method of the EasySelectTM Pichia expression kit (version H; Invitrogen) was used for transformation, and the transformants were plated on MD and MM agar plates to screen for methanol utilization (Mut) phenotype.
- methanol utilization Mut
- Several Mut + and Mut S clones were put on plates with high zeocin concentrations (0.5 to 1 mg/ml) to select for clones with multiple integration events.
- a Mut S clone was selected for the protein expression.
- Transformants were grown and induced with methanol according to the instructions from Invitrogen.
- the INF ⁇ -2a-(Gly 4 -Ser) 7 -EGF chimeric activator was secreted into the medium and was purified with the ProBondTM purification system (for purification of polyhistidine-containing recombinant proteins, version K, Invitrogen). Purity was checked by Coomassie blue stain and by immunblotting against EGF. The final yield was approximately 1 mg per ml of cell culture.
- Variants of INF ⁇ -2a-(Gly 4 -Ser) 7 -EGF were constructed containing the IFN ⁇ 2a mutations K133A, R144A, and R149A by standard recombinant DNA techniques using the Quick-ChangeTM site-directed mutagenesis kit from Stratagene (CA, USA).
- a set of Pichia expression vectors encoding IFN ⁇ 2a wild-type and mutant proteins lacking the linker and EGF but containing the C-myc and His 6 tags were also constructed by analogous techniques. The correctness of the constructs was confirmed by DNA sequencing. The transformation, expression and purification of the different constructs were performed as described above.
- A431 and HeLa cells were seeded in 60 mm plates, Daudi and Daudi-EGFR were seeded in 50 mL bottles. Once they reached confluence the growth medium was replaced with fresh DMEM without FBS or antibiotics for 3 h (to reduce background signal from the serum).
- EGF E. coli
- chimeric activators E. coli
- Interferon- ⁇ ⁇ A Calbiochem
- vehicle vehicle
- Stimulations were terminated by washing the cells once with ice-cold phosphate-buffered saline, and cells were lysed in NP40 lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% NP-40, 25 mM NaF, 10 mM ⁇ -glycerophosphate, 250 ⁇ M Na 3 VO 4 supplemented with protease inhibitor cocktail tablets (Roche)).
- NP40 lysis buffer 20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% NP-40, 25 mM NaF, 10 mM ⁇ -glycerophosphate, 250 ⁇ M Na 3 VO 4 supplemented with protease inhibitor cocktail tablets (Roche)).
- HeLa cells were seeded as previously described. Once they reach confluence the medium was changed for fresh DMEM and cells were incubated with anti-EGFR mouse mAb 528. After 2 h treatment cells were tested for STAT1 stimulation as described above.
- IFN ⁇ -2a-linker-EGF chimeras corresponding IFN ⁇ 2a proteins
- commercial IFN ⁇ A on Daudi and Daudi-EGFR cell lines was assayed as follows. Proteins that had been previously filtered thorough a 0.2 ⁇ m PDVF filter unit (Millipore, Ireland) and then quantitated were serially diluted. Twenty serial dilutions were prepared in flat-bottomed 96-well plates for each tested protein. Daudi and Daudi-EGFR cells grown in RPMI-1680 medium were added (3 ⁇ 10 4 cells in 100 ⁇ L) to each well and were grown for an additional 60 h. in the presence of the different proteins.
- the number of living cells was then determined using a cell staining kit (Cell proliferation reagent WST-1, Roche) based on the colorimetric detection of the cleavage of the tetrazolium salt WST-1 into formazan.
- the WST-1 reaction solution was added according to the manufacturer's recommendation for a period of 4 h, after which the absorbance at 450 nm and 650 nm (reference wavelength) was recorded in an ELISA reader (Victor V, PerkinElmer).
- chimeric activators with a desired cell specificity requires an understanding of the on-rates, off-rates, and equilibrium constants of each of the receptor-binding elements.
- An important aspect of ligand-receptor interactions is that k on is primarily limited by diffusion.
- the off-rate for ligand-receptor interactions is often slower than the process of receptor-mediated endocytosis, and in such cases k off is not relevant to signaling.
- the binding of a chimeric protein composed of a targeting element and an activity element might not be significantly influenced by the supposed targeting element.
- EGF and IFN ⁇ 2a both have similar on-rates (Table 2) (French, A. R., Tadaki, D.
- a chimeric activator for a chimeric activator to have a cell specificity driven by the targeting element, one or both of the following conditions should be met: the on-rate of the activity element should be lower than that of the targeting element, or if the off rates are faster than the internalization rate, then the equilibrium constant (K on /K off ) of the targeting element should be higher than that of the activity element.
- the on-rate of the activity element should be lower than that of the targeting element, or if the off rates are faster than the internalization rate, then the equilibrium constant (K on /K off ) of the targeting element should be higher than that of the activity element.
- a rationally designed set of chimeric activators were constructed, consisting of wild-type and mutant forms of IFN ⁇ 2a as the activating element, and EGF as the targeting element ( FIG. 10A ).
- a choice of these elements may be based on the following considerations: 1) the three-dimensional structures of the EGF/EGFR and the IFN ⁇ 2a/IFNAR2 complexes have been solved or modeled (Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.
- the targeting element and activation element must be able to bind simultaneously to their respective receptors.
- the published structure of EGFR with a ligand and a model of the IFN ⁇ 2a structure indicate that in these receptor-ligand complexes, the EGF is about 90 ⁇ from the cell surface, and the IFN ⁇ 2a is about 50 ⁇ from the cell surface, so that a linker of at least 40 ⁇ is needed to bridge the two elements.
- chimeric activators were constructed (Table 2). These consist of wild-type or mutant IFN ⁇ 2a at the N-terminus, followed by the 35-amino acid linker, EGF, a myc epitope tag, and a (His) 6 purification tag at the C-terminus.
- the IFN ⁇ 2a mutations used were K133A, R144A, and R149A, which allow the protein to fold correctly but cause stepwise reductions in the on-rate and equilibrium binding of IFN ⁇ 2a for its receptor (Table 2) (Piehler, J., Roisman, L.
- FIG. 10B shows a molecular model of an IFN ⁇ 2a-EGF chimeric activator (space-filling structure), showing how the IFN ⁇ 2a and EGF components can simultaneously interact with their receptors (ribbons).
- Models for EGF/EGFR complex (Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.
- EGF targeting element
- Activation of EGFR was evaluated in HeLa cells by treating them with the four chimeric proteins, a commercial recombinant EGF as a positive control, and IFN ⁇ 2a tagged with c-myc and His 6 as a negative control.
- FIG. 11 illustrates the induction of phosphorylation of the EGFR by the different chimeric proteins as well for the rEGF control (lanes 2 to 7).
- HeLa cells were stimulated for 5 minutes with vehicle (PBS; lane 1) EGF (lane 2), chimeric activators containing wild-type EGF linked to wild-type or mutant IFN ⁇ 2a (lanes 3-7), or wild-type IFN ⁇ 2a protein expressed from Pichia pastoris in the same manner as the chimeric activators (lane 8).
- EGF receptor immunoprecipitated from stimulated HeLa cell lysates were separated by SDS-PAGE, then immunoblotted for Tyr1068-phosphorylated EGF receptor (top) or total EGF receptor (bottom). Cells treated only with PBS (vehicle) or with tagged IFN ⁇ do not show detectable activity (lanes 1 and 8).
- IFN ⁇ 2a-EGF chimeric proteins could signal through IFNAR in an EGFR-dependent manner by comparing their activity with the activity of the corresponding IFN ⁇ 2a (mutant) protein in cells expressing both EGFR and IFNAR.
- Two different epithelial cell lines were used with varying levels of EGFR expression: A431 cells, which show high expression of EGFR ( ⁇ 2 ⁇ 10 6 EGFR/cell), and HeLa cells, which show moderate expression of EGFR (2 ⁇ 10 4 EGFR/cell) (Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., Mendelsohn, J., (1984) Cancer Res 44(3), 1002-1007).
- FIG. 12 starved HeLa (A), A431 (B), Daudi (C), or Daudi-EGFR (D) cells were incubated for 30 minutes with PBS (vehicle), commercial IFN ⁇ A, EGF, IFN ⁇ /EGF chimeric activator proteins containing wild-type or mutant IFN ⁇ -2a (CAwt CAK133A, CAR144A, or CAR149A), or the corresponding wild-type or mutant IFN ⁇ 2a proteins produced from Pichia .
- PBS vehicle
- IFN ⁇ A, EGF, IFN ⁇ /EGF chimeric activator proteins containing wild-type or mutant IFN ⁇ -2a CAwt CAK133A, CAR144A, or CAR149A
- Lysates were prepared and immunoblots performed probing with an anti-STAT1(pTyr701) antibody, and with an anti-actin antibody as a loading control (in some examples, similar immunoblots were prepared in which lanes were scanned with a densitometer and the phospho-STAT1 signal normalized to the actin signal).
- HeLa, A431, and Daudi-EGFR cells express both EGFR and IFNAR, while Daudi cells express only IFNAR. Quantification by FACs analysis confirmed the expression levels of EGFR and IFNAR. The results indicated that an IFN ⁇ 2a-EGF chimeric activator (without a mutation) and IFN ⁇ 2a alone induced interferon signaling with about equal efficiency ( FIGS.
- the chimeric activators with EGF fused to the mutant IFN ⁇ 2a showed higher levels of IFN ⁇ signaling than the corresponding IFN ⁇ 2a mutants alone, however.
- pSTAT1 was activated when cells were treated with CAR44A and CAR9A ( FIGS. 12A and B, lanes 16-18 and 23-25) but not when the cells are treated with the corresponding IFN ⁇ 2a mutants, even at higher concentrations ( FIGS. 12A and B, lanes 22 and 29). No synergistic effect was seen when cells were treated with a combination EGF and any of the various IFN ⁇ 2a mutants ⁇ (data not shown).
- EGFR was introduced into the Daudi cell line, which does not normally express this receptor and compared IFN ⁇ signaling in this engineered line to that seen in the parent cell line.
- the Daudi cell line is derived from a human Burkitt's lymphoma cell, and its proliferation and survival are inhibited by IFN ⁇ (Evinger, M., Pestka, S., (1981) Methods in Enzymology 79(Pt B), 362-368).
- the function of the chimeric activators on Daudi and Daudi-EGFR cells clearly depended on the presence of the receptor for the targeting element ( FIGS. 12C and D).
- the CAR149A protein stimulated STAT1 phosphorylation only in Daudi-EGFR cells ( FIG. 12D , lanes 23-25) and not in the Daudi parental cell line ( FIG. 12C , lanes 26-29).
- the CAwt and IFN ⁇ 2a proteins were active in both cell lines, as expected, whereas the IFN ⁇ 2aR149A mutant showed only slight activity at high concentrations.
- Chimeric activators containing the intermediate-strength mutations CAK133A and CAR144A gave intermediate levels of signaling in Daudi cells, consistent with their predicted properties, and showed quantitative enhancements in signaling relative to IFN ⁇ 2aK133A and IFN ⁇ 2aR144A in Daudi-EGFR cells ( FIG. 12D , lanes 10-22).
- the activities of the chimeric activators differed on the various cell lines ( FIG. 12 ). Without wishing to be bound by theory, these cell-type differences may be due to differences at the level of receptor expression, although the HeLa, Daudi, and A431 cell lines have different tissue origins and oncogenic mutations, so that any comparison of results between these lines can only be suggestive. Daudi cells have 10-20 times more IFNAR molecules at the cell surface than do HeLa and A431 cells, which may explain the greater level of IFNAR activation in Daudi cells, for example in response to CAR144A and IFN ⁇ 2a(R144A).
- FIG. 13 HeLa cells were pre-treated for 2 hours with 1 ⁇ g/mL of mAb 528, a mouse monoclonal antibody which prevents EGF from binding to EGFR (even-numbered lanes), followed by treatment for 30 minutes with vehicle (lanes 1-2), or 1.5 nM of commercial IFN ⁇ A (lanes 3-4), IFN ⁇ /EGF chimeric activator proteins containing wild-type or mutant IFN ⁇ -2a (CAwt, lanes 5-6; CAK133A, lanes 9-10; CAAR144A, lanes 13-14; or CAR149A, lanes 17-18), or the corresponding wild-type or mutant IFN ⁇ 2a proteins (lanes 7-8, 11-12, 15-16, and 19-20).
- FIG. 14 The ability of the chimeric proteins to suppress the proliferation of Daudi and Daudi-EGFR cells is shown in FIG. 14 .
- Daudi and Daudi-EGFR cells were grown for 60 hours in the presence of various concentrations of IFN ⁇ 2a-EGF chimeric proteins or the corresponding IFN ⁇ 2a proteins purified from Pichia .
- the relative number of viable cells was determined by the production of formazan, which absorbs at A460, from tetrazolium. Curves were fit to the data using a 4-parameter fit (Microcal Origin 5.0). In both cell lines, a dose-dependent growth inhibition was observed.
- the chimeric activators relative to their IFN ⁇ counterparts, showed enhanced inhibition of cell proliferation and survival of Daudi-EGFR cells ( FIGS. 14E and F).
- the chimeric activators containing the mutations K133A and R144A were about 10-fold and 100-fold more potent, respectively, than the corresponding IFN ⁇ 2a mutants alone.
- CAR149A weakly inhibited proliferation in a pattern that could not be fit to a sigmoid curve (data not shown) and its activity relative to the corresponding IFN ⁇ 2a mutant therefore could not be quantified.
- Daudi-EGFR cells The behavior of the Daudi-EGFR cells was somewhat affected by the presence of EGFR, which may contribute pro-survival signals.
- the IC 50 s of wild-type and mutant IFN ⁇ s were about 5- to 6-fold higher in Daudi-EGFR ( FIG. 14 ).
- the maximal extent of proliferation inhibition was also less than for cells treated with IFN ⁇ mutants alone.
- the goal of a particular design was to alter the cell-type specificity of IFN ⁇ so that it would only activate its receptor on cells bearing EGFR.
- EGF was attached to IFN ⁇ 2a with a flexible linker, so that both modules could simultaneously bind to their receptors.
- IFN ⁇ 2a also was mutated so that its ability to bind to its receptor would be significantly reduced, using a set of previously defined mutations that reduce the equilibrium binding of IFN ⁇ 2a for its receptor by 10-, 40- and 200-fold (Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433).
- the purpose was to generate a chimeric protein that would be essentially unable to bind directly to IFNARs, but would bind to EGFR with high affinity.
- the IFN ⁇ 2a module would then be able to bind to its receptor.
- IFN ⁇ 2a-EGF (CA-wt) was essentially indistinguishable from wild-type IFN ⁇ 2a; this result is expected because the binding of IFN ⁇ to its receptor is quantitatively similar to that for EGF.
- the activities of the chimerized and unchimerized proteins were compared on Daudi cells and Daudi cells engineered to express EGFR. These results indicated that the enhanced stimulation of STAT1 phosphorylation by the EGF chimeras depended on the presence of EGFR on the cell surface. The improved selectivity of the mutant chimeric activators seen with HeLa and A431 cells was reproduced in Daudi-EGFR cells, but not in parental Daudi cells.
- the stimulation of STAT1 phosphorylation could be inhibited by an anti-EGFR antibody.
- the chimeric activator proteins described here induced a biological response in an EGFR-dependent manner.
- the proliferation and survival of Daudi cells is inhibited by IFN ⁇ 2a.
- Daudi cells expressing EGFR were found to be more sensitive than parental Daudi cells to IFN ⁇ 2a(mutant)-EGF chimeric activators by up to more than order of magnitude ( FIG. 14 ).
- the Daudi-EGFR cells may be considered to represent target cells
- the parental Daudi cells may represent non-target cells where receptor activation results in side effects
- the differential effect corresponds to the therapeutic index of a protein drug.
- the therapeutic index can be improved by more than an order of magnitude.
- the artificial localization/activation system described herein is reminiscent of interactions seen in a number of biological systems.
- kinases such as Raf and PDK1 are recruited to the inner face of the cytoplasmic membrane (McKay, M. M., Morrison, D. K., (2007) Oncogene 26(22), 3113-3121), which may enhance the rate of signal transduction as predicted by Adam and Delbruck (Adam, G., Delbruck, M., (1968) Reduction of dimensionality in biological diffusion processes—in: Rich A, Davidson N, editors, Structural chemistry and molecular biology, San Francisco: W. H. Freeman and Co. p.
- a distinct targeting element the PH domain, interacts with PIP 3 in the membrane so that an activity element, the kinase domain itself, can act on its substrates.
- the binding of HIV gp120 to its target cells also occurs by a two-step process, in which cell-specific targeting occurs through CD4, followed by an activation step mediated by a chemokine receptor (Chan, D. C., Kim, P. S., (1998) Cell 93(5), 681-684; and Blair W S, Lin P-F, Meanwell N A, Wallace O B., (2000) Drug Discovery Today 5(5), 183-194).
- IL-2 The interaction between IL-2 and its receptor can occur through an initial contact with a non-signaling receptor subunit, which is followed by a lower-affinity interaction with signaling receptors (Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A., Wilson, I. A., (2003) Proc Natl Acad Sci USA 103(8), 2788-2793); IL-2 is somewhat analogous to CA-K133A, which has a reduced binding to IFNAR that can be augmented by an additional receptor subunit, with EGFR playing a similar role to the IL-2R ⁇ subunit.
- aspects of the invention take advantage, at least in part, of intellectual developments in quantitative systems biology and differ from other targeting approaches in two key respects.
- aspects of the invention can use a tumor-specific antibody as a targeting element.
- the molecular designs reported here depended in part on structural models of both the IFN ⁇ /IFNAR2 and EGF/EGFR complexes. Use of antibody V regions in chimeric activators will become more feasible as more structures of antibody-receptor complexes are solved (Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., Sliwkowski, M. X., (1994) Cancer Cell 5(4), 317-328; and Cho, H-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney Jr, D. W., Leahy, D. J., (2003) Nature 421(6924), 756-760).
- artificial signaling molecules were constructed based on quantitative principles. According to aspects of the invention, these principles may be used to design and produce chimeric molecules that are useful for therapeutic applications. In addition, further analysis of these principles may allow the further improvement of protein therapeutics and a deeper understanding of the forces that shape natural biological system design.
- CA chimeric activator
- EGF epidermal growth factor
- EGFR epidermal growth factor receptor
- IFN ⁇ 2a interferon-alpha2a
- IFNAR IFN ⁇ receptor
- IL-2 interleukine-2
- Mut + methanol utilization wild-type
- Mut S methanol utilization slow
- TGF ⁇ tumor growth factor ⁇
- STAT-1 signal transducer and activator 1.
- TRAIL also known as Apo2L
- Apo2L is a member of the TNF family of proteins, and binds to ‘death receptors’ such as DR5.
- TRAIL acts similarly to TNF, but it is thought that TRAIL causes only cell death without accompanying inflammation.
- the following sequences were designed in which TRAIL is fused to the V regions of the antibody MR1-1, which is described above.
- the sequences are highlighted so that the first and third segments (regular text) are the heavy chain V region and the light chain V region respectively.
- the second (bolded text) is a linker
- the fourth (underlined text) is a longer linker
- the fifth segment (italicized text) is TRAIL or an active fragment of TRAIL.
- the active fragment corresponds to amino acids 115-281 and is 1.5 times more bioactive than the full-length TRAIL (Hymowitz et al. Biochemistry, Vol. 39, No. 4, p. 633 (2000)).
- EGFRvIII is a deleted derivative of EGFR that is found in some cancers and contains a novel peptide junction that is recognized by the antibody MR1-1.
- Apoptosis assessed by viability assay will be measure by using the cell proliferation reagent WST-1.
- Apoptosis signaling will be measure by caspase activation using antibodies directed against caspase-8 and active caspase-3.
- Carcinoembryonic antigen is a protein that is highly expressed on colon cancers, lung cancers, breast cancers, and other types of cancer. It is expressed in only small amounts on normal tissues in the gastrointestinal tract. CEA is also highly expressed in the tumor cell lines GW39, LS147T and SW1417.
- the CEA protein has seven extra cellular immunoglobulin-family domains and is attached to the cell surface by means of a lipid anchor at its C-terminus; this protein contains no intracellular amino acids.
- T84.66 and MFE-23 are particularly well characterized.
- the antibody T84.66 was chosen because it binds somewhere within the two most membrane-proximal domains (Hass et al. Cancer Research [1991] 51:1876), while MFE-23 binds to a much more membrane-distal domain that might lie more than 200 angstroms from the cell surface (Boehm and Perkins, FEBS Letters [2000] 475:11).
- the T84.66 binding site therefore appears to be about the same height from the cell membrane as the TRAIL N- and C-termini, and also the IFN ⁇ N- and C-termini, when these ligands are bound to their receptors.
- a chimeric activator was designed containing humanized T84.66 V regions and TRAIL.
- Protein activity is measured as in the previous example but using LS147T and SW1417 cell lines.
- Example 10 Antibody-Erythropoietin Chimeric Activators for Treatment of Anemia
- Erythropoietin is a hormone that stimulates production of red blood cells. Epo can be used to treat anemia that may be part of many disease conditions, but is used primarily in two settings. First, kidney failure patients usually do not produce adequate levels of Epo, which is expressed mainly in the kidneys, and are therefore anemic. Second, cancer patients often become anemic as a result of chemotherapy treatment, which kills dividing cells including red blood cell precursors.
- Epo receptors for Epo are sometimes found on cancer cells, and Epo may enhance tumor cell growth and angiogenesis. It would be useful to have a form of Epo that only stimulated red blood cell production and did not bind to Epo receptors on other cells, such as cancer cells or early hematopoietic stem cells that can give rise to other cell types.
- a person is considered to be anemic if their hemoglobin levels are less than 12 grams/deciliter for women or ⁇ 14 g/dl for men. These values correspond to a hematocrit of 37% for women and 40% for men, and a red blood cell count of 4 ⁇ 10 12 /l for women and 4.5 ⁇ 10 12 for men.
- the levels of red blood cells are not fully restored, since this is associated with an increased rate of heart attack and stroke.
- Glycophorin is a highly expressed protein on the surface of red blood cells. Glycophorin is also expressed on the precursors of red blood cells (Southcott et al. Blood 12:4425). During production of red blood cells, precursor hematopoietic stem cells (HSCs) undergo a series of differentiation steps as follows:
- Glycophorin A exists in two allelic forms, M and N, which define the M and N blood groups. These forms differ at the N-terminus as follows (Czerwinski et al [1998] The Journal of Immunology 160: 4406-4417)
- This molecule will be expressed in Pichia pastoris . Because Epo is glycosylated at a number of sites and it will ultimately be useful to have a molecule with mammalian-type glycosylation, a 10F7MN-Epo chimeric activator also will be expressed in a mammalian cell line such as CHO cells.
- a test system that uses one of the following cell lines can be constructed and used: TF-1, UT-7 or ERY-1. These are cells that respond to Epo.
- the cell line can be transfected with an expression construct that expresses human glycophorin, and the chimeric activators can be tested in this pair of cell lines.
- EPO activity will be measured by proliferation and signaling assays. Proliferation will be assessed by using WST-1 reagent while pSTAT5 will be measured for EPO receptor activation.
- Glycophorin is a protein that has changed rapidly in evolution, so that the epitopes recognized by existing anti-human glycophorin are not found in most other animals.
- Lethally irradiated mice that have been reconstituted with human hematopoietic stem cells can be used.
- Ligands may be linked by a long amino acid chain, wherein the length is a determinant of the chimera performance, and it needs to be carefully designed according to the physical and kinetic characteristics of the system.
- the chimera binds initially to one of the receptors (receptor i) with a rate of binding k on;i and dissociation k off;i , internalization by endocytosis of the free receptor k t;i and active receptor k e;i and receptor recycling Q r;i rates equivalent to the non chimeric ligand.
- This first reaction of ligand-receptor i recruits chimeric proteins to the cell membrane, increasing the local concentration of ligand j in the surface of the cell, enhancing interaction of ligand j and its receptor.
- R i and C i are the total number of empty and bound receptor i.
- L is the concentration of chimera in solution.
- the last term of equations 13 and 14 reflects the increase in local concentration of ligand i due to the binding of the ligand j to its receptor.
- N Av is the Avogadro's number
- r is the average cell radius
- C 0j is the concentration of the C j result of the regular binding mechanism, i.e., the number of complexes C j bounded to a chimera that it is not bound to another receptor, responsive of the local concentration increase.
- reaction rate needs to be rescaled having in mind that reaction ligand-receptor-i only occurs when the ligand is in the close vicinity of the receptor.
- the mechanism is illustrated in FIG. 16 , and the reaction only occurs in the dark volume of the semi-sphere of radius a i;j
- h i is the height of the gasket, which corresponds to the location where the ligand can bind to the receptor.
- a 0;j is the radius of the receptor j.
- a i;j is the distance between ligand i and j.
- a 0;i;j is the minimum linker distance, and depends on geometrical characteristics of the receptors involved.
- ⁇ 0,i,j ⁇ square root over (( ⁇ j,0 + ⁇ i,0 ) 2 +
- the model consists of 7 variables, one for each configuration of each of the two receptors and one for the ligand concentration.
- the interacting components with their corresponding relevant chemical parameters are illustrated in FIG. 15 .
- the components of the model are subjected to 4 reversible and 3 irreversible reactions:
- R1 and R2 are the amount of the two cell surface receptors that the chimera ligand L is targeting.
- the variables C 1 , C 2 , C 1 ′ and C 2 ′ correspond to different configurations of the active ligand-receptor complexes.
- Reactions 1 and 2 account for the primary reaction of complex formation of the two species, with their respective affinity (k 1,on ; k 2,on ) and dissociation rates (k 1,off ; k 2,off ). Since every chimera ligand molecule L has two distinct active sites, it can interact with each of the receptors to form two types of complexes C 1 ′ and C 2 ′.
- the quantities C 1 ′ and C 2 ′ represent the total amount of complexes where one of the two active sites of the chimera is free and able to interact with its complementary receptor. This way, when the primary complexes C′1 and C′2 are formed through reaction 1 or 2, a local concentration of the remaining active site is created on the cell surface, which favors the formation of the complementary complex.
- N Av is the Avogadro's number and V 0 is the gasket volume.
- the only contribution to the local concentration comes from the complexes C 01 and C 02 , since the complexes C 1 and C 2 formed through reactions 3 and 4 don't have any free binding sites.
- C 01 and C 02 are the number of receptors that are linked only to one of the ligands i.e., the ones that contribute to increase the local concentration of the other receptor.
- FIG. 17 represents the concentration of complex ligand-receptor 1 in the surface of the cell, for different values of total number of receptors R 1 .
- the equations for the second receptor are equivalent to the first one, but with an additional term which accounts for the ligand concentration that the receptor sees from the first ligand-receptor complex.
- the effective ligand concentration that the second receptor sees depends on the amount of complex ligand-receptor 1 C 1 in the surface of the cell at any time.
- An additional term is added in the second set of equations, which account for the local concentration of ligand close to the cell surface. This concentration is calculated in Equation 27 assuming that the molecules are distributed in a volume gasket V 0 on the cell surface of height the length of the linker. This assumption is justified by the fact that diffusion of the receptors is very fast compared with the internalization times of the receptors.
- k 0on;2 needs to be scaled taking into account the fact that the reaction with the ligand linked to a surface is constrained by structural and geometric aspects of the systems. The fact that receptor diameter is comparable with linker size and that different heights of receptors in the outer part of the cell membrane has to be introduced into the problem.
- D 1 and l 1 are the diffusion coefficient and the height of the receptor R 1 , correspondingly.
- Parameter b 1 is the average distance between free receptors in the cell, calculated considering homogeneous distribution of receptors on the cell, and calculated as follows:
- reaction 5 account for the internalization of the signaling complexes and receptors, respectively, while reaction 7 accounts for the constant production of fresh receptors.
- Chimeras are fusions of usually two or more ligands that target different extracellular receptors. Chimeras have been successfully tested experimentally for targeting selectively cells with different receptor concentration in their surface. Experimental results described herein demonstrate that the combination of chimera design with ligand mutation successfully increases selectivity in interferon targeting in cells overexpressing EGFR.
- the parameter values listed in Table 3 were used, unless specified.
- the parameters correspond to measured values of the wild type EGFR and wild type IFN-R in Hela cells.
- the advantage is that experimental data is already available to validate the model predictions.
- the number of IF receptors is higher in the case of a chimeric protein, due to the concentration of chimera localized in the surface of the cell.
- the model can be used to calculate the optimal linker size depending on the properties of the system (e.g., the number of receptors, ligand receptor affinity, structure of the membrane receptors, etc.). As a numerical example, the number of IFN receptors active for different linker sizes was calculated for the different mutants.
- the linker length dependence at high linker sizes reduces because the local concentration of chimera reduces with the length of the linker. At low values, the dependence is governed by the physical characteristics of the receptors, (a 0 ,h).
- One of the additional issues in the linker length design concerns the time spent by receptor 1 to find the complex C 1 in the cell membrane. This time is dependent on the diffusion coefficient of the membrane receptors, as well as the linker length and the average distance between the two receptors. To estimate this time, the equation for two dimensional diffusion was used. The average distance between two receptors, b i;j , depends on the concentration and distribution of receptors i and j on the cell surface. To calculate this distance, it is assumed that the cell has a spherical shape, and that receptors are evenly distributed through the whole cell surface.
- 2a is the effective target size and D is the diffusion coefficient (assuming both receptor has the same diffusion rate).
- D is the diffusion coefficient (assuming both receptor has the same diffusion rate).
- the distance between the target and the empty receptor depends on the concentration of the complex C 1 , which is time dependent.
- the collision rate is given by
- FIG. 20 is a time plot of the rate of collision.
- Example 12 Chimeric Activators for Treating Asthma
- chimeric activators can be designed to target cells associated with diseases such as asthma.
- a chimeric activator can be designed to kill or inactivate B cells that produce IgE.
- an IgE receptor may be used as a targeting element and FasL may be used as an activity element.
- methods of the invention include modifying, assaying, and/or optimizing one or more of the targeting or activity elements and/or the linker.
- methods of the invention include modifying, assaying, and/or optimizing one or more of the targeting or activity elements and/or the linker.
- Preferred features of each aspect of the invention are as for each of the other aspects mutatis mutandis.
- the documents including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures mentioned herein are hereby incorporated by reference in their entirety. In the event of conflict, the disclosure of present application controls, other than in the event of clear error. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application is a continuation of co-pending U.S. application Ser. No. 12/594,747 filed Apr. 16, 2010, which is a 35 U.S.C. §371 National Phase Entry Application of International Application No. PCT/US08/04435 filed Apr. 5, 2008, which designates the U.S. and which claims the benefit under 35 U.S.C. §119(e) from U.S. provisional applications Ser. No. 60/910,390 filed Apr. 5, 2007, Ser. No. 61/005,775 filed Dec. 7, 2007 and Ser. No. 61/065,937 filed Feb. 15, 2008, the entire contents of which are herein incorporated by reference.
- The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 19, 2017, is named Sequence-Listing-12594747.txt and is 56,625 bytes in size.
- The invention relates to chimeric proteins, fusion proteins, and therapeutic proteins.
- Many therapeutic proteins such as interferon alpha (IFNα), TNF and IL-2 act locally in their natural state. Systemic administration of these proteins results in side effects that limit the dose levels that can be used therapeutically. For example, IFNα is useful in treating hepatitis and certain cancers, but causes side effects such as flu-like symptoms and suicidal thoughts. There are needs for targeting mechanisms to permit therapeutic proteins to be delivered locally and to minimize the side effects of systemic administration of therapeutic proteins.
- Several laboratories have performed protein-based targeting of toxins to cancer cells. The laboratory of Ira Pastan has been working on cancer-targeted toxins for many years. In 1987, this group described a chimeric protein consisting of Pseudomonas exotoxin and TGFα. This toxin normally binds to the cell surface, is internalized into the endosome, and then somehow enters the cytoplasm where it inactivates Elongation Factor II. TGFα is an EGF-like ligand that binds to EGF receptor. Over the years, the Pastan group has fused variants of this exotoxin to diverse ligands and antibody V regions that bind to cell surface receptors. Some of these have been in Phase I/II-type clinical trials, but none have shown enough efficacy to be developed further. Thus, in addition to the needs for targeting mechanisms to permit therapeutic proteins to be delivered locally and to minimize the side effects of systemic administration of therapeutic proteins, there is also a need to maintain the efficacy of therapeutic proteins while meeting one or both of these two needs.
- Another example of protein-based targeting of toxins to cancer cells is Mylotarg™ Mylotarg™ is a monoclonal antibody chemically conjugated to the toxin calicheamycin (Giles et al. (2003) Cancer 98: 2095). Calicheamycin causes double-stranded breaks in DNA and is highly toxic. However, when covalently bonded to an antibody, this chemical is not toxic because it has no access to DNA. When Mylotarg™ binds to the CD33 receptor protein on a tumor cell, the antibody-receptor complex is internalized and the antibody is degraded. The calicheamycin is then liberated to bind to the DNA of the tumor cell. Mylotarg™ received accelerated approval by the FDA for treatment of acute myelogenous leukemia (AML) in 2000.
- Other examples are Zevalin™ and Bexxar™. Zevalin™ and Bexxar™ consist of radioisotopes chemically conjugated to monoclonal antibodies against the B cell marker CD20. These proteins are use to treat B cell lymphoma. The radioisotopes used, yttrium-90 and iodine-131 respectively, have short decay path-lengths, so that when the antibody binds to the surface of a tumor cell, there is local irradiation of the tumor. Zevalin™ was approved by the FDA in 2002. Bexxar™ was approved in 2003.
- Thus far, targeting of toxic molecules to specific cells has been successful for the delivery of small molecules (such as radioisotope delivery by conjugates such as Zevalin™ and Bexxar™ and delivery of a chemical toxin in Mylotarg™), but not for the delivery of cell-killing proteins such as Pseudomonas exotoxin, RNAse, tumor necrosis factor, or interferons. A consistent problem has been that the toxic proteins act on bystander cells as they are being delivered to target tissue.
- Aspects of the invention relate to methods and compositions for specifically targeting the activity of naturally-occurring proteins to certain cells or tissues where their activity can be therapeutically useful. In some aspects, the invention provides therapeutic applications for naturally-occurring proteins that otherwise have serious but finite toxicity. Methods and compositions of the invention can be used to target the cell-activating properties of a protein to a subset of target cells without activating non-target cells. Aspects of the invention relate to chimeric proteins that include a variant of a cell-activating element (also referred to herein as an Activity element) that has reduced cell-activating properties relative to its wild-type counterpart. The chimeric proteins also include a cell-targeting element (also referred to herein as a targeting element) that preferentially binds to target cells of interest. The cell-activating variant and the cell-targeting element are connected via a linker. According to aspects of the invention, the activating and targeting elements are selected so that the resulting chimeric protein only activates cells that are bound by the targeting element. The activating element variant is selected such that it can only activate a cell when present in a sufficiently high amount (e.g., concentration) on or near a cell-surface. The targeting element is selected such that it can target a sufficient amount of the activating element to the surface of a target cell in order to activate it. In some embodiments, the linker is selected so that it allows simultaneous binding of the activating and targeting elements to different receptors on the target cell. Accordingly, chimeric proteins of the invention can be used to avoid or reduce unwanted side effects caused by the activating element activating non-target cells.
- Aspects of the invention are particularly useful for targeting the activity of toxic activating elements to target cells (e.g., to target cytotoxic elements to cancer cells) without killing surrounding non-target cells. Aspects of the invention can be useful to harness certain functions of natural proteins that otherwise may be toxic (or have serious toxic side effects) when administered therapeutically. For example, IFNα is normally secreted by virus-infected cells and promotes the death of cells in the immediate vicinity. TNF is secreted in response to the presence of bacterial molecules such as lipopolysaccharide and is thought to play an important role in wound-healing. Other similar molecules include, but are not limited to, IFNβ, IL-2, IFNγ, and IL-1. These therapeutic proteins are usually administered systemically and all have serious side effects, but nonetheless can be very useful. Erythropoietin can also have serious side effects when treating anemia associated with cancer, since erythropoietin can stimulate the growth and survival of certain cancer cells. However, by using less active variants of these proteins in combination with targeting elements of the invention, the general toxicity of protein drugs can be avoided while retaining desired activities (e.g., cell killing activities, enzymatic activities, signal transduction activities, etc., or any combination thereof).
- In some embodiments, a recombinant protein of the invention includes a first element that binds to a first receptor on a target cell; a second element that binds to a second receptor on the target cell; and, optionally, a linker that connects the first and second elements, wherein the linker allows the first and second elements to bind simultaneously to the first and second receptors on the target cell, wherein the first element comprises a mutation that reduces its binding affinity for its receptors, and wherein the first element transmits a signal to the host cell when it is bound to the first receptor. In some embodiments, the first element is an enzyme, a substrate, a receptor, a ligand, or other peptide that can interact (e.g., bind to and/or catalyze a reaction and/or transduce a signal) to the receptor on the cell surface. It should be appreciated that the receptor may be any cell-surface protein that can receive a signal (e.g., resulting in a molecular and/or cellular change) upon interaction with the first element. In some embodiments, the first element is a variant of an activity element that binds to and/or interacts with more than one receptor (e.g., 2, 3, 4, 5 or more different receptors) in nature. In some embodiments, the variant activity element (e.g., a natural or engineered mutant element) has reduced affinity for one or more of its natural receptors (e.g., for about 10%-20%, about 20%-40%, about 50%, about 40%-60%, about 60%-80%, about 80%-100% or for all of the different natural receptors). In particular, a variant activity element may have reduced binding affinity for the receptor (e.g., a signal transduction receptor, enzyme, or other cell surface molecule that can mediate a signal or other desired biochemical or cellular change) or receptors that are being targeted for activation in the target cells. Accordingly, a variant activity element may have reduced signaling (e.g., more than about 10%, more than about 25%, more than about 50%, more than about 75%, more than about 80%, more than about 90%, or more than about 95% loss of signaling activity, or complete loss of detectable signaling activity) via the receptor(s) of interest in the absence of the targeting element when compared to the wild-type activity element.
- In some embodiments, recombinant proteins of the invention may bind to their target cells as monomers. In some embodiments, the targeting element binds to its target molecule as a monomer (e.g., as a single copy of the targeting element such as a single copy of an antibody). In some embodiments, the activity element interacts with its receptor or target as a monomer. In some embodiments, both the targeting and activity elements interact with their receptors or targets as monomers. In some embodiments, the cell-surface receptors themselves are monomers. However, they may be multimers as the invention is not limited in this respect.
- In some embodiments, the first and second elements are connected via a linker. A linker may be any suitable length as described herein (e.g., about 5-10, about 10-20, about 25, about 20-50, about 50, about 50-70 amino acids long, or longer or shorter). In some embodiments, the linker may be flexible.
- Accordingly, aspects of the invention relate to chimeric activators including an activity element and a targeting element, optionally joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site. In some embodiments the first binding site is a ligand binding site, a receptor, or an epitope on a cell surface. In some embodiments the second binding site is a signal-transduction receptor on a cell surface. In some embodiments the targeting element is an antibody, an antibody fragment, an Fc region, a natural or synthetic ligand, or a protein interaction motif. In some embodiments the activity element is a cytokine, a cytotoxic protein, a regulatory protein, or an active fragment of any one thereof.
- Described herein are chimeric activators wherein the linker length has been optimized. In some embodiments the linker length is at least equal to the minimum distance between the first and second binding sites on the cell surface. In some embodiments the linker length is at least twice the minimum distance between the first and second binding sites on the cell surface. In some embodiments the linker length is at most five-six times the minimum distance between the first and second binding sites on the cell surface. In some embodiments the activity element is mutated such that the binding affinity of the activity element for the second binding site is lower than the binding affinity of the targeting element for the first binding site.
- Aspects of the invention relate to methods for manufacturing a chimeric activator including an activity element and a targeting element joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site. In some embodiments methods include: i) optimizing the linker length as a function of the concentration of the first and second binding sites, the size of the activity element and targeting element, the minimum distance between the binding sites of the targeting element and the activity element, and the affinities of the activity element and the targeting element for the first and second binding sites; and ii) preparing a chimeric activator having an optimal linker length.
- In some embodiments, methods include: i) mutating the activity element such that the binding affinity of the activity element for the second binding site is lower than the binding affinity of the targeting element for the first binding site; i) optimizing the linker length as a function of the concentration of the first and second binding sites, the size of the activity element and targeting element, the minimum distance between the binding sites of the targeting element and the activity element, and the affinities of the activity element and the targeting element for the first and second binding sites; and iii) preparing a chimeric activator.
- Aspects of the invention relate to methods for targeted cellular regulation, the method including: administering to a subject a therapeutically effective amount of a chimeric activator including an activity element and a targeting element joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- Further described herein are methods for treating cancer, the method including: administering to a subject having a cancer a therapeutically effective amount of a composition including a chimeric activator including an activity element and a targeting element joined by a linker, wherein the targeting element binds to a first binding site on a target cell, and wherein the activity element binds to a second binding site on a target cell, and wherein the linker length has been optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site.
- However, it should be appreciated that aspects of the invention may be used to selectively target any activity (e.g., any activity mediated by a cell surface receptor) to target cells that selectively express a cell surface marker that is different (or expressed at different, for example higher, levels) than on non-target cells. Accordingly, aspects of the invention may be used to target cytotoxic or cytostatic activity to any cells associated with a disease or disorder (e.g., cancer cells, immune system cells associated with allergic or chronic inflammatory disorders or reactions, infected cells, pathogen cells, cells that are degenerating, or any other target cells of interest). Aspects of the invention also may be used to selectively deliver other activating signals to target cells (e.g., other than cytotoxic or cytostatic). For example, other activating signals may include on or more proliferation, differentiation, stimulation, or other signals that may be useful in different applications. These and other aspects of the invention are described in more details herein.
-
FIG. 1 illustrates a non-limiting embodiment of a general structure of a Chimeric Activator (“mut” indicates that the activity element has a mutation); -
FIG. 2 shows, without wishing to be bound by theory, a proposed mechanism of specific binding of “Chimeric Activators” to target cells; -
FIG. 3 shows a molecular model of an IFNα-EGF Chimeric Activator; -
FIG. 4 illustrates an example of activation of IFNα signaling by chimeric activators; -
FIG. 5 illustrates an example of the targeting effect in a Daudi cell line constructed to express EGFR; -
FIG. 6 illustrates an example of the dependence of Chimeric Activator function on the receptor for the targeting element; -
FIG. 7 illustrates an example of a Chimeric Activator function blocked by antibodies against the receptor for the targeting element; -
FIG. 8 shows an example of a TNF-EGF Chimeric Activator; -
FIG. 9 illustrates the use of antibody V regions instead of EGF as a targeting element; -
FIG. 10 illustrates non-limiting aspects of chimeric activation, 10A) illustrates a general structure of a chimeric activator, 10B) shows a molecular model of an IFNα2a-EGF chimeric activator (space-filling structure), 10C)-10D) illustrate a mechanism of specific binding of chimeric activators to target cells, in 10C) the chimeric activator binds poorly to non-target cells because the intrinsic binding affinity of the mutant activity element to its receptor is low, in contrast in 10D) the targeting element binds to receptors on a target cell at a high rate (after the targeting element complexes with its receptor, the activity element is in a high local concentration relative to its receptor, so that the activity element can then bind and stimulate signal transduction); -
FIG. 11 illustrates an embodiment of EGFR activation upon treatment with IFNα2a-EGF chimeric activators; -
FIG. 12 illustrates an example of STAT1 activation upon treatment with IFNα2a-EGF chimeric activators; -
FIG. 13 illustrates an example of EGFR neutralization; -
FIG. 14 illustrates an example of EGFR-dependent anti-proliferative activity of IFNα2a-EGF chimeric proteins; -
FIG. 15 shows a schematic of an embodiment of the chimera-receptor binding and receptor endocytosis where all model parameters are represented (the average distance between two receptors is shown as bi;j); -
FIG. 16 shows a schematic of an embodiment of the binding mechanism between a receptor and a free ligand or a chimeric ligand; -
FIG. 17 shows a plot of the C1 concentration in time, for different initial values of total R1; -
FIG. 18 shows plots of C2 over time for different IF mutants (lower darker colored dots correspond to IF, and upper lighter colored dots correspond to chimeric protein); -
FIG. 19 shows a plot of C2 at 30 min versus linker length for different IFN mutants; -
FIG. 20 shows a time plot of an embodiment of the collision rate; and -
FIG. 21 shows a plot of an embodiment of collision rate versus linker size. - Aspects of the invention relate to chimeric proteins that include a targeting element connected to an activity element. In some embodiments, the targeting element binds to molecules that are selectively present on target cells. In some embodiments, the activity element is a variant of a naturally occurring protein that activates cells by binding to one or more cell surface receptors. The variant is selected such that it has reduced or no cell activating properties in the absence of the targeting element. The targeting element is selected such that it selectively binds to target cells thereby increasing the local concentration of the variant activity element on the target cells to a level that results in activation of those cells. In some embodiments, cell activation results in cell death or a reduction or absence of cell proliferation. However, it should be appreciated that other forms of cell activation may be targeted to specific cells using methods and compositions described herein.
- An activity element may be a receptor binding protein (or functional portion or domain thereof) that binds to one or more naturally-occurring receptors on a cell surface, thereby mediating signaling to the cell (e.g., via signal transduction). A variant activity element may include one or more naturally occurring and/or engineered mutations that result in reduced binding to one or more (e.g., all) natural receptors that are bound by the wild-type activity element. For example, the binding affinity of the variant activity element for one or more of its receptors may be at least 2 fold lower and preferably at least 5 fold lower or 8 fold lower (e.g., at least 10 fold lower, about 10-50 fold lower, about 50-100 fold lower, about 100-150 fold lower, about 150-200 fold lower, or more than 200 fold lower) than the binding affinity of the wild-type activity element for its natural receptor(s). As a result, in some embodiments the activity element by itself is significantly less active (e.g., substantially inactive) because it cannot bind to its receptor(s). Accordingly, chimeric proteins of the invention are useful to avoid unwanted side effects caused by the activity element binding to its natural receptor on non-target cells. However, the activity element is active on target cells because the targeting element provides the missing binding affinity required for activation.
- A targeting element may be a receptor binding protein, an antibody, or any other natural or engineered protein that binds to a molecule that is preferentially present on target cells of interest relative to non-target cells. According to some embodiments of the invention, the affinity of the targeting element for its target molecule (e.g., receptor) may be similar to the binding affinity of the variant activity element for its receptor(s). However, the affinity of the targeting element for its target molecule is typically higher (e.g., at least 2 fold, at least 5 fold, about 5-10 fold, about 10-50 fold, about 50-100 fold, about 100-500 fold, about 500-1,000 fold, at least 1,000 fold, at least 10,000 fold, or at least 100,000 fold higher) than the binding affinity of the variant activity element for its receptor(s).
- In some embodiments, the activity and targeting elements are connected via a linker. The linker may be a natural or artificial peptide that provides sufficient flexibility to allow both the targeting element and the activity element of a chimeric activator to bind simultaneously to their targets and/or receptors on a target cell. The linker length may be optimized for the sizes of the target molecules and/or receptors being bound by targeting and activity elements, the sizes of the targeting and activity elements themselves, and other factors described herein in more detail. However, in some embodiments, a linker may not be required (or only a short linker may be required) if one or both of the targeting and activity elements are flexible or are connected to each other by flexible domains.
- Accordingly, aspects of the invention relate to Chimeric Activators—proteins that include a targeting element and an activity element that are capable of simultaneously binding to multiple (two or more) unrelated receptors on the same target cell. In some embodiments, a Chimeric Activator has an activity element, a linker, and a targeting element. See, for example,
FIG. 1 . It should be appreciated that the linker, if present, is located between the targeting and activity elements. However, aspects of the invention are not limited by the relative positions of the targeting and activity elements. For example, the targeting element may be N-terminal to the activity element (regardless of whether a linker separates the two elements). Alternatively, the activity element may be N-terminal to the targeting element (regardless of whether a linker separates the two elements). In addition, proteins of the invention may include one or more additional peptide elements (at the N-terminus, the C-terminus, or within the protein) for purification and/or detection (e.g., peptide tags), stability, function (e.g., secretion and or other function), etc., or any combination thereof. It should be appreciated that targeting and activity elements may bind to overlapping types of molecules (e.g., receptors, substrates, enzymes, or other molecules) that are present on a cell surface. However, in any particular configuration, the element that is being used as a targeting element has sufficient affinity to target a chimeric protein to a cell-surface molecule that is preferentially (e.g., uniquely or selectively or specifically) present or exposed on a target cell of interest. In contrast, an element that is being used as an activity element may have relatively low affinity for a cell surface molecule. However, the element that is being used as an activity element may interact equally with a molecule that is present on all cell types, but only activates the target cell types due to its linkage to the targeting element. However, it should be appreciated that in some embodiments, both the targeting and activity elements interact with different cell surface molecules that all are preferentially present or exposed on the target cells. - Aspects of the invention may be useful to increase the therapeutic index (e.g., by about 2 fold, about 5 fold, about 10 fold, about 50 fold, about 100 fold, about 200 fold, or more) of any protein therapeutic (e.g., based on a naturally occurring or engineered protein or fragment thereof) by reducing the general toxicity of the protein and maintaining or increasing the selective effect of the protein on target cells or tissue. It should be appreciated that aspects of the invention may be used to treat any disease where selective cell activation is beneficial as described herein. In some embodiments, the targeting element may be selected on the basis that it target certain diseased cells (e.g., due to the presence of disease-specific antigens on the target cells). However, in certain embodiments, specific cell types or tissue types may be targeted (e.g., via cell or tissue specific cell surface antigens). In some embodiments, pathogen-specific molecules may be targeted (e.g., on the cells of a pathogen or on host cells infected with a pathogen).
- Accordingly, methods and compositions described herein have broad application to treating disorders, including infections, cancer, anemia, allergy, and many other disorders where it is beneficial to activate (e.g., kill, stimulate or otherwise activate) one or more particular cell types. In some embodiments, the invention is useful to treat cancer. Cancer is disease characterized by uncontrolled cell proliferation and other malignant cellular properties. As used herein, the term cancer includes, but is not limited to, the following types of cancer: breast cancer; biliary tract cancer; bladder cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia; T-cell acute lymphoblastic leukemia/lymphoma; hairy cell leukemia; chronic myelogenous leukemia, multiple myeloma; AIDS-associated leukemias and adult T-cell leukemia/lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer including melanoma, Merkel cell carcinoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma (teratomas, choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and medullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor. Other cancers will be known to one of ordinary skill in the art.
- In some embodiments, a targeting element comprises a protein component that selectively directs the binding of the chimeric protein to the surface of a desired cell or cells. Accordingly, a targeting element binds specifically to a cell-surface moiety (e.g., an antigen, epitope, protein, glycoprotein, lipid, carbohydrate, or other molecule or portion thereof) that is either only present or exposed on the target cell or is present or exposed in higher amounts on the target cell relative to non-target cells (e.g., about 2 fold, about 5 fold, about 10 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, about 1,000 fold, about 10,000 fold, or more on the target cell). The targeting element can be any protein that binds to a cell-surface molecule. Targeting elements typically target to a subset of cells, such as tumor cells. In some embodiments a targeting element is an antibody or a portion of an antibody. In certain embodiments a targeting element is a ligand (e.g., a naturally occurring ligand or portion thereof that retains binding properties, or a synthetic ligand that binds, for example, to a receptor on a target cell).
- In specific embodiments, the targeting element binds to cancers cells (e.g., is a cancer targeting element). In some embodiments, the targeting element is an antibody, a growth factor, a hormone, a peptide, an aptamer, a cytokine, interferon, vitamin, or a mixture thereof, for example. The antibody may be further defined as a full-length antibody, chimeric antibody, Fab′, Fab, F(ab′)2, single domain antibody (DAB), Fv, single chain Fv (scFv), minibody, diabody, triabody, or a mixture thereof, for example. In particular embodiments, the antibody is an anti-HER-2/neu antibody, such as scFv23, for example. In additional specific embodiments, the antibody is an anti-gp240 antigen antibody, such as one that comprises scFvMEL, for example.
- Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W. R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc′ and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc′ region has been enzymatically cleaved, or which has been produced without the pFc′ region, designated an F(ab′)2 fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.
- Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.
- It is now well established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of “humanized” antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc′ regions to produce a functional antibody. See, e.g., U.S. Pat. Nos. 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies will have human immunoglobulin amino acid sequences and therefore will not provoke human anti-mouse antibody (HAMA) responses when administered to humans.
- Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab′)2, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab′)2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies. In some embodiments, the targeting element of a chimeric protein is an antibody moiety that has been expressed from a single linear nucleic acid as a single peptide and that can fold into a fully functional antibody. In some embodiments, the chimeric protein is expressed from a nucleic acid that encodes a portion of an antibody (e.g., a heavy chain, a light chain, or a portion thereof as described herein) fused to the activity element (via the optional linker). The remainder of the antibody required for specific binding can be provided in trans (e.g., expressed from a different coding sequence in the same cell or expressed in a different cells and mixed in vitro, etc., or any combination thereof). Accordingly, it should be appreciated that a chimeric protein of the invention may be a single linear polypeptide chain or it may include additional polypeptide chains of an antibody or other binding protein required for specific binding to a target molecule.
- In some embodiments, the targeting element comprises one or more growth factors, such as, for example, transforming growth factor, epidermal growth factor, insulin-like growth factor, fibroblast growth factor, heregulin, platelet-derived growth factor, vascular endothelial growth factor, or hypoxia inducible factor. In an additional specific embodiment, the cancer cell-targeting moiety comprises one or more hormones, such as human chorionic gonadotropin, gonadotropin releasing hormone, an androgen, an estrogen, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, prolactin, growth hormone, adrenocorticotropic hormone, antidiuretic hormone, oxytocin, thyrotropin-releasing hormone, growth hormone releasing hormone, corticotropin-releasing hormone, somatostatin, dopamine, melatonin, thyroxine, calcitonin, parathyroid hormone, glucocorticoids, mineralocorticoids, adrenaline, noradrenaline, progesterone, insulin, glucagon, amylin, erythropoitin, calcitriol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin, neuropeptide Y, ghrelin, PYY3-36, insulin-like growth factor-1, leptin, thrombopoietin, angiotensinogen, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and/or, IL-36, for example, and/or a combination thereof.
- In some embodiments, the targeting element comprises one or more cytokines, such as IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12, IL13, IL14, IL15, IL-16, IL-17, IL-18, granulocyte-colony stimulating factor, macrophage-colony stimulating factor, granulocyte-macrophage colony stimulating factor, leukemia inhibitory factor, erythropoietin, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, IFN-γ, IFN-α, IFN-β, LT-β, CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, TGF-β, IL 1β, IL-1β, IL-1 RA, MIF, IGIF, and/or a combination thereof.
- In some embodiments, a targeting element binds to one or more tissue-specific cell surface markers. In some embodiments, a targeting element is based on the natural ligand of tissue-specific cell surface marker (e.g., a targeting element is a recombinant version of a natural ligand or fragment thereof). In some embodiments, a targeting element is binding agent, such as a peptide, antibody, or aptamer, that binds to one or more tissue-specific cell surface markers. Appropriate cell surface markers are known by the skilled artisan. A non-limiting list of exemplary tissue-specific markers includes: B cell surface markers: (Activated B Cells) CD28, CD38, CD69, CD80, CD83, CD86, DPP4, FCER2, IL2RA, TNFRSF8, TNFSF7; (Mature B Cells) CD19, CD22, CD24, CD37, CD40, CD72, CD74, CD79A, CD79B, CR2, IL1R2, ITGA2, ITGA3, MS4A1, ST6GAL1; (Other B cell surface markers) CD1C, CHST10, HLA-A, HLA-DRA, NTSE. T cell surface markers: (Cytotoxic T Cells) CD8A, CD8B1; Helper T Cells: CD4; (Activated T Cells) ALCAM, CD2, CD38, CD40LG, CD69, CD83, CD96, CTLA4, DPP4, HLA-DRA, IL12RB1, IL2RA, ITGA1, TNFRSF4, TNFRSF8, TNFSF7; (Other T cell surface markers) CD160, CD28, CD37, CD3D, CD3G, CD3Z, CD5, CD6, CD7, FAS, KLRB1, KLRD1, NT5E, ST6GAL1; (Natural Killer (NK) cell surface markers) CD2, CD244, CD3Z, CD7, CD96, CHST10, FCGR3B, IL12RB1, KLRB1, KLRC1, KLRD1, LAG3, NCAM1; Monocyte/macrophage surface markers: (Activated Macrophages) CD69, ENG, FCER2, IL2RA; (Other Monocyte/macrophage cell surface markers) ADAMS, C5R1, CD14, CD163, CD33, CD40, CD63, CD68, CD74, CD86, CHIT1, CHST10, CSF1R, DPP4, FABP4, FCGR1A, HLA-DRA, ICAM2, IL1R2, ITGA1, ITGA2, S100A8, TNFRSF8, TNFSF7; Endothelial cell surface markers: ACE, CD14, CD34, CDH5, ENG, ICAM2, MCAM, NOS3, PECAM1, PROCR, SELE, SELP, TEK, THBD, VCAM1, VWF; Smooth muscle cell surface markers: ACTA2, MYH10, MYH11, MYH9, MYOCD; Dendritic cell surface markers: CD1A, CD209, CD40, CD83, CD86, CR2, FCER2, FSCN1; Mast cell surface markers: C5R1, CMA1, FCER1A, FCER2, TPSAB1; Fibroblast (stromal) cell surface markers: ALCAM, CD34, COL1A1, COL1A2, COL3A1, PH-4; Epithelial cell surface markers: CD1D, K6IRS2, KRT10, KRT13, KRT17, KRT18, KRT19, KRT4, KRT5, KRT8, MUC1, TACSTD1; and Adipocyte surface markers: ADIPOQ, FABP4, RETN, and/or a combination of two or more thereof.
- According to aspects of the invention, an activity element comprises a protein component that has the desired signaling activity. This component normally binds to a receptor on the surface of the desired target cell. The activity element can be any protein that binds to a cell-surface receptor and stimulates signal transduction. In some embodiments, the activity element is a variant form (e.g., it is mutated) that has an intrinsic binding to its receptor that is weak as compared to the wild-type protein, to the point that binding of the chimeric protein to a cell is driven by the binding of the targeting element to its receptor. For example, the Chimeric Activator first binds to a cell through the targeting element, and after this initial binding step, the mutated activity element is in a high local concentration relative to its own receptor, so binding takes place in spite of the mutation. In contrast, the chimeric protein may not significantly bind to cells that have only the activity element receptor and not the targeting element receptor, because the inherent binding of the activity element is simply too weak. The presence of one or more weakening mutations can be essential to reduce side effects from activation of non-target cells.
- It should be appreciated that the choice of a particular mutation can be tuned to the on-rates and dissociation constants of the naturally occurring targeting element and activity element, the relative numbers of receptors of each type on the target cell, and the binding enhancement factor resulting from pre-binding of the chimeric protein to the receptor for the targeting element. In practice, mutations with a range of different strengths may be tested empirically using techniques known to one of ordinary skill in the art.
FIG. 2 illustrates a non-limiting example of these processes. In A), a target cell expresses the Receptors for both the targeting element (RT) and Receptors for the Activating Element (RA). The Chimeric Activator first binds to the target cell surface via the targeting element (T). The resulting complex then undergoes two-dimensional diffusion in the cell membrane, and when the Activating Element (A) is near its receptor, binding will be driven by the high local concentration, in spite of the mutation in the Activating Element that reduces binding. Signal transduction results (lightning). In B), the chimeric activator does not bind to non-target cells because the intrinsic binding of the mutant Activator Element to its receptor is simply too low. - Aspects of the invention relate to creating mutations in the activity element, such that the mutated form of the activity element binds to its receptor with a reduced affinity relative to a wild-type form of the activity element. Accordingly, chimeric activators differ from fusion proteins in which an element with signaling activity may bind to more than one receptor type, and a mutation is introduced into this element to modulate the receptor type that is used (e.g., certain TNF chimeras, see also for example US20060263368). In contrast, Chimeric Activators of the invention differ from such distinct fusion proteins in that the signaling by a Chimeric Activator is directed through the receptor for which affinity has been reduced by the mutation in the activity element. As used herein, a “mutation” refers to a change in the nucleotide sequence encoding the activity element, relative to a wild-type form of the gene. A change in the nucleotide sequence may or may not lead to a change in the amino acid sequence, the three-dimensional structure of the protein, and/or the activity of the protein, relative to the wild-type form of the protein. In some embodiments a mutation may be a naturally occurring variant of the gene. In some embodiments a mutation may be a single amino acid substitution, two or more amino acid substitutions, one or more deletions, one or more insertions, or any combination of two or more thereof, in the protein sequence of the activity element. It will be understood that the selection of a suitable mutation in an activity element for the creation of a chimeric molecule will depend on multiple factors and in some embodiments will need to be determined empirically for different proteins.
- It should be appreciated that variant activity elements of the invention may have a reduced binding affinity for their receptor(s) without a loss (or without a significant loss) of signal function (e.g., they substantially or completely retain their ability to promote signal transduction when bound to their receptor(s) even though their affinity for the receptor(s) may be significantly reduced). It also should be appreciated that the reduced binding affinity of the variant activity element preferably does not result in a protein element that will not bind to its natural receptor(s), for example, due to steric hindrance or charge repulsion or other negative interaction between the variant activity element and its natural receptor(s), even when the targeting element binds to a target molecule on the same cell (thereby increasing the local concentration of the variant activity element in the vicinity of its natural receptor(s)).
- In some embodiments, appropriate levels of reduced binding affinity can be obtained by introducing one or more mutations in charged or hydrophilic amino acids (or amino acids thought to be pointing outward) that have the effect of shortening the side chain of the amino acid(s). According to aspects of the invention, the charged or hydrophilic side chains are likely to be pointing outward and not into the middle of the protein. Reducing the size of the amino acid side chain(s) removes a contact, but does not create steric hindrance that would completely block binding or signaling. In some embodiments, mutants may be created in an activity element, and those that reduce but do not abolish binding may be selected (e.g., using one or more binding and/or activity assays known to one of skill in the art) and used to construct a Chimeric Activator.
- According to aspects of the invention, variant activity elements of the invention can be identified or selected for any appropriate cell-surface receptor that is involved in a signaling activity that is useful for a particular application of interest.
- For example, tumor necrosis factor receptors (TNFR) (e.g., CD120), or death receptors, are a family of cytokine receptors that bind to various tumor necrosis factors (TNF) (e.g., TNF-alpha). Exemplary tumor necrosis factor receptor family members include: CD120a (TNFRSF1A), CD120b (TNFRSF1B), Lymphotoxin beta receptor (LTBR, TNFRSF3), CD134 (TNFRSF4), CD40 (CD40, TNFRSF5), FAS (FAS, TNFRSF6), TNFRSF6B (TNFRSF6B), CD27 (CD27, TNFRSF7), CD30 (TNFRSF8), CD137 (TNFRSF9), TNFRSF10A (TNFRSF10A), TNFRSF10B, (TNFRSF10B), TNFRSF10C (TNFRSF10C), TNFRSF10D (TNFRSF10D), RANK (TNFRSF11A), Osteoprotegerin (TNFRSF11B), TNFRSF12A (TNFRSF12A), TNFRSF13B (TNFRSF13B), TNFRSF13C (TNFRSF13C), TNFRSF14 (TNFRSF14), Nerve growth factor receptor (NGFR, TNFRSF16), TNFRSF17 (TNFRSF17), TNFRSF18 (TNFRSF18), TNFRSF19 (TNFRSF19), TNFRSF21 (TNFRSF21), and TNFRSF25 (TNFRSF25). Several groups have demonstrated that human tumor cells can display between 100 and 5000 TNF receptor sites per cell (Rosenblum et al., 1991; Rosenblum et al., 1995). Thus, TNFRs represent an attractive target for inhibiting cancer cell growth and/or survival.
- In some embodiments, the activity elements of the invention are ligands (agonists or antagonists) that bind to one or more tumor necrosis factor receptors known in the art or disclosed herein. In some embodiments, the activity elements of the invention are tumor necrosis factors or fragments thereof, such as TNF-alpha or TNF-beta (lymphotoxin). In some embodiments, the activity elements are selected from the TNF Ligand Family: LTA (TNF-α), TNF (TNF-α), TNFSF5 (CD40 Ligand), TNFSF6 (FasL), TNFSF7 (CD27 Ligand), TNFSF8 (CD30 Ligand), TNFSF9 (4-1BB Ligand), TNFSF10 (TRAIL), TNFSF14 (HVEM-L), TNFSF18, or fragments thereof. In some embodiments, the activity elements of the invention are tumor necrosis factors or fragments thereof, such as TNF-alpha or TNF-beta (lymphotoxin). In some embodiments, the activity elements of the invention are tumor necrosis factors with attenuated function. In some embodiments, the attenuated function is a reduced binding affinity for target receptors.
- It should be appreciated that certain peptide elements may be used as targeting elements in some embodiments (e.g., a cytokine that can be used to target cells that express the cytokine receptor) and activity elements in different embodiments (e.g., the same cytokine could be used to activate cells that are targeted using a different targeting element in other embodiments). When a peptide is used as a targeting element, its natural affinity for the target molecule may be retained in the chimeric molecule. In some embodiments, the affinity of a natural peptide for a target molecule may be increased (e.g., by mutation) in order to improve its use as a targeting element. In certain embodiments, the binding affinity may be retained and/or increased but the function activity (e.g., signal transduction or enzymatic activity) may be decreased or removed (e.g., by mutation) if that particular function is not required or is undesirable. In contrast, if the same peptide is being used as an activity element in a different chimeric molecule, a variant form (e.g., a naturally occurring or engineered mutated form) may be used to reduce binding affinity of the activity element to non-target cells as described herein. Accordingly, one or more of the growth factors and/or cytokines described or listed herein as candidates for targeting elements also may be used as activity elements in other embodiments where they may be mutated to reduce their binding affinity for their receptor or substrate or target molecule.
- One criterion that may be evaluated in selecting activity elements and targeting elements is the affinity of the activity element for its receptor, and the ratio of the affinity of the activity element for its receptor relative to the affinity of the targeting element for its receptor. In some embodiments mutated activity elements will be selected such that the activity element has a lower affinity for its receptor than the affinity of the targeting element for its receptor, thus allowing the targeting element to control which cells are bound by the chimeric molecule. In some embodiments the affinity ratio may be 1/2, 1/5, 1/10, 1/25, 1/50, 1/75, 1/100, 1/500, 1/1000, or an intermediate value, or a smaller value. Another set of criteria that may be evaluated in selecting activity elements and targeting elements include the on-rates, off-rates, and dissociation constants for the binding of the activity element to its receptor and the targeting element to its receptor. In some embodiments mutated activity elements will be selected wherein one or both of the following conditions are met: the on-rate of the activity element is lower than that of the targeting element, or if the off-rates are faster than the internalization rate, then the equilibrium constant (Kon/Koff) of the targeting element is higher than that of the activity element.
- Another criterion that may be involved in selecting mutated activity elements is an evaluation of the activity level of the activity element alone, and the activity level of the activity element when it is linked to the targeting element. In some embodiments mutated activity elements may be selected that have reduced activity or are inactive alone, relative to a wildtype form of the protein, due to their reduced binding efficiency, but are active when linked to a targeting element, because the binding of a targeting element to its receptor at the cell surface increases the local concentration of the activity element in the vicinity of its receptor at the cell surface. It should be appreciated that appropriate activity levels for a given protein and a given mutation will need to be determined empirically. In some embodiments wherein an activity element is being targeted to a cancer cell in order to kill the cell, a mutated activity element will be selected such that the mutated activity element will not have sufficient activity to kill a cell when the activity element is alone, due to its reduced binding capacity for its receptor. When the activity element is linked to a targeting element, the increased local concentration of the activity element at the cell surface allows it to be active and bind to its receptor and kill the cell.
- In some embodiments, targeting and activity elements are attached by a linker. The linker can be any amino acid sequence that allows the simultaneous binding of the activity element and the targeting element to their receptors on a given cell surface. Typically the linker is a non-folding, protease-resistant polypeptide segment that permits the targeting element and the activity element to bind to their cell-surface receptors, typically on the same cell surface, at the same time. Linkers may be of varied length (e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 amino acids long or intermediate or longer lengths) and/or amino acid composition. Linkers may be flexible or rigid.
- In some embodiments linker length will be optimized for maximizing binding efficiency of the activity element to the second binding site when the targeting element is bound to the first binding site. Optimal linker length for a given chimeric activator can be determined at least in part using models disclosed herein. In optimizing linker length, multiple factors will be considered including, but not limited to: the concentration of the first and second binding sites, the sizes of the activity element and targeting element, the minimum distance between the binding sites of the targeting element and the activity element, and the affinities of the activity element and the targeting element for the first and second binding sites. In some embodiments a linker length will be chosen that is at least equal to the minimum distance between the first and second binding sites on the cell surface. In other embodiments a linker length will be chosen that is at least twice the minimum distance between the first and second binding sites on the cell surface. In some embodiments a linker length will be chosen that is at most five-six times the minimum distance between the first and second binding sites on the cell surface. It will be understood that optimal linker length will vary depending on the specific proteins selected as activity elements and targeting elements. In some embodiments a protein which is blocked at the N- or C-terminus may be selected as an activity element or a targeting element. In these embodiments a linker may be added elsewhere on the protein.
- In some embodiments, the linker length is chosen based in part on the known or surmised heights from the cell surface of the targeting element and activity element when each is bound to its receptor. For example, when EGF is bound to EGFR, its N- and C-termini are about 90 Angstroms from the cell surface, and when interferon alpha is bound to its receptor, its N- and C-termini are about 75 Angstroms from the cell surface, so that a linker of at least 15 Angstroms must be used.
- The invention also provides methods for calculating an optimal linker length for a chimeric protein with two elements that simultaneously bind to a cell surface, based on the density of the receptors for each of the two elements on a cell surface and the difference in height from the cell surface of the termini of the two elements when bound to their receptors. The method optionally involves knowledge of the on-rates and off-rates of each element for its receptor. The method optionally involves calculating, as linker length is increased, the trade-off on the one hand between the increasing volume that can be occupied by one element when the other is bound to its receptor on a cell surface (which negatively impacts on a second binding event), and the increasing portion of cell surface area that may be sampled by one element when the other is bound to its receptor on that cell surface (which positively impacts on a second binding event). For many situations the density of a targeting element receptor is more than 10,000 per cell and the difference in height from the cell membrane of the bound elements is less than about 50 Angstroms, and in such situations a linker of about 25 to 70 amino acids is found to be optimal, with a linker length of about 30 to 40 amino acids often being more optimal. The linker should be flexible.
- In many cases it is preferable to have both a targeting element and an activity element that engage their receptors through monomeric interactions. For example, in an interferon alpha-EGF Chimeric Activator, both the interferon alpha element and the EGF element are monomeric. This is in contrast to the activity elements TNF and TRAIL, which are trimeric, and to targeting elements consisting of antibodies, which are generally dimeric or have higher-order multivalent binding properties. One advantage of using targeting elements and activity elements that function as monomers is that it is easier to quantitatively predict their properties and thus to design specific molecules with desired features. It is also generally easier to predict the structure of the complex on the cell surface in which the targeting element and activity element are simultaneously bound. Examples of functionally monomeric activity elements include interferon alpha, interferon beta, IL-1, IL-2, IL-3, IL-4, IL-6, IL-11, IL-12, IL-13, IL-15, IL-18, erythropoietin, insulin, insulin-like growth factor, thrombopoietin, EGF, and CNTF. Examples of functionally monomeric targeting elements include single-chain Fv proteins and Fabs, as well as CD4, IL-1, IL-2, IL-3, IL-4, IL-6, IL-11, IL-12, IL-13, IL-15, IL-18, erythropoietin, insulin, insulin-like growth factor, thrombopoietin, EGF, and CNTF. Therefore, the invention provides Chimeric Activators that contain a monomerically functioning activity element and a monomerically functioning targeting element. More broadly, the invention provides proteins comprising two monomerically binding peptide moieties, optionally connected by a linker, such that both moieties can simultaneously bind to their receptors and/or target molecules on a single cell surface, in which at least one moiety signals through its receptor, and for which the signaling moiety contains a mutation relative to its naturally occurring form that reduces the binding to the receptor through which the signaling moiety signals. In some embodiments, a monomeric portion of a naturally multimeric targeting element and/or activity element may be used (e.g., by removing a multimerization domain). In these embodiments, the activity element also may include an additional mutation to reduce its affinity for its receptor as described herein.
- In some embodiments, a chimeric protein of the invention may include a recombinant binding protein such as recombinant antibody instead of the activity element. The binding protein may be engineered to have very low affinity (relative to specific antibody binding affinity) for a target molecule that can transduce a signal (or result in another biological or cellular response) upon binding by the binding protein (e.g., low affinity antibody). Accordingly, aspects of the invention described in the context of a chimeric protein including a variant activity element also may be used in connection with an chimeric protein that includes a low affinity engineered binding protein instead. The same considerations for the targeting element and the optional linker apply.
- As used herein, the term “binding” refers to a non-covalent or a covalent interaction, preferably non-covalent, that holds two molecules together. For example, two such molecules could be an enzyme and an inhibitor of that enzyme. Another example would be an enzyme and its substrate. A third example would be an antibody and an antigen. Non-covalent interactions include, but are not limited to, hydrogen bonding, ionic interactions among charged groups, van der Waals interactions, and hydrophobic interactions among non-polar groups. One or more of these interactions can mediate the binding of two molecules to each other. Binding may exhibit discriminatory properties such as specificity or selectivity. Binding affinities may range from mM to pM (e.g., micromolar or nanomolar binding affinities) depending on the concentration of the receptors and the activity of the activator elements.
- The term “HIS-tag” refers to an affinity tag consisting of multiple consecutive histidine amino acids. Generally six (hexa-HIS) residues are used, or multiples thereof. His-tagged proteins have a high selective affinity for Ni+ and a variety of other immobilized metal ions. Consequently a protein containing a His-tag generally can be selectively bound to a metal ion charged medium while other cellular proteins bind weakly or are washed out with binding or wash buffers. His-tags are small and therefore, tend to be less disruptive to the properties of the proteins on which they are attached.
- The term “myc tag” refers to an epitope tag derived from myc protein, generally comprising the sequence amino acid SEQ ID NO: 17: EQKLISEEDL. A number of different antibodies are known to recognize the myc epitope tag, for example 9B11 and 9E10.
- The term “RNA equivalent” refers to an RNA sequence corresponding to a DNA or amino acid sequence. Such equivalents may correspond directly to the original sequence (in the case of a protein the “coding sequence”), or may include additional sequence, such as untranslated regions and introns. In the case of an RNA equivalent for DNA the correspondence may be complementary to the DNA strand or anti-sense, allowing for the fact that in RNA “U” replaces “T” in the genetic code. DNA/RNA sequences of the sequence listing may be considered to follow this guidance.
- Nucleic acids of the invention include isolated or recombinant nucleic acids comprising coding sequences for Chimeric Activators or components thereof described herein. The nucleic acids may be on vectors. The nucleic acids may be in host cells. It should be appreciated that the nucleic acids also may include regulatory sequences for transcription (e.g., promoters, activators, terminators, etc.) and translation (e.g., ribosome binding sequences, IRES elements, terminators, etc.) of the chimeric proteins in addition to sequences required for vector replication and/or selection and/or packaging in host cells (e.g., prokaryotic or eukaryotic host cells, including, but not limited to bacterial, mammalian, yeast, insect, and/or other host cells). Accordingly, aspects of the invention relate to recombinant vectors which include one or more nucleic acids of the invention (e.g., SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, and 15), as well as host cells containing the vectors or which are otherwise engineered to contain or express nucleic acids or polypeptides of the invention, and methods of making such vectors and host cells and their use in production of polypeptides of the invention by recombinant or synthetic techniques. In some embodiments, Targeting and activity elements may be isolated (e.g. expressed and purified) independently and linked via a synthetic linker.
- In some embodiments, the polynucleotides of the invention are joined to a vector (e.g., a cloning or expression vector). The vector may be, for example, a phage, plasmid, or viral vector. Viral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells. The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Introduction of the vector construct into the host cell can be effected by techniques known in the art which include, but are not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. (1986) Basic Methods In Molecular Biology.
- The polypeptides of the invention or fragments thereof may be provided in substantially pure form, that is to say free, to a substantial extent, from other proteins. Thus, a polypeptide may be provided in a composition in which it is the predominant component present (i.e., it is present at a level of at least 50%; preferably at least 75%, at least 90%, or at least 95%; when determined on a weight/weight basis excluding solvents, carriers, or coupling agents).
- Polypeptides of the invention can be recovered and purified from recombinant cell cultures or organisms by well-known methods including, ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, affinity chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography, molecular sieving chromatography, centrifugation methods, electrophoresis methods and lectin chromatography. In one embodiment, Chimeric Activator proteins are expressed in and secreted from the yeast Pichia pastoris. In one embodiment, a combination of these methods is used. In another embodiment, high performance liquid chromatography is used. In a further embodiment, an antibody which specifically binds to a polypeptide of the invention can be used to deplete a sample comprising a polypeptide of the invention of the polypeptide or to purify the polypeptide. Techniques well-known in the art, may be used for refolding to regenerate native or active conformations of the polypeptides of the invention when the polypeptides have been denatured during isolation and or purification, should such be desired.
- Polypeptides of the invention (and their corresponding DNA and RNA coding sequences) may comprise sequences, for example, epitope or affinity tags, that may aid in isolation or purification of the protein. However, they need not do so. For example, proteins of the invention (e.g., SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16) may be purified through use of reagents that bind myc and/or HIS tags, but the invention also contemplates embodiments in which the proteins lack the myc and/or HIS tags, or which utilize different epitope or affinity tags.
- Chimeric Activator nucleic acids and/or polypeptides may be screened, such as in high-throughput screening of a library of Chimeric Activators to select for a Chimeric Activator of the desired characteristics, or may be screened individually. For example, measurement of signal transduction in mammalian cells using Western blots that detect phosphorylation at specific sites may be used to screen for Chimeric Activators of a desired signal transduction activity.
- Chimeric activators may be of various functions, e.g., having activity working against cancer, viral infection, and obesity. Diverse proteins can be used as activity elements and targeting elements. These proteins can be structurally varied, including monomers, trimers, and heterodimers of alpha helices and beta sheets. Some design considerations are illustrated in the Examples. Activity elements may be a non-toxic pro-drug that is activated in the target locale, for example, by cancer cells. It should be appreciated that many functions are compatible with the chimeric activators of the claimed invention. In some embodiments, the targeting element targets the activity element to a specific cell or cell type in order to kill a specific cell or cell type. In other embodiments the targeting element targets the activity element to a specific cell or cell type, for a purpose other than to kill the specific cell or cell type (e.g. to upregulate or downregulate one or more proteins or cellular properties such as cell growth, or proliferation).
- Chimeric Activator nucleic acids and/or polypeptides may be used in gene therapy or in pharmaceutical compositions. Chimeric Activator nucleic acids and/or polypeptides may be used in treatment of a subject or patient, and may be used in combination with other therapies. Use of Chimeric Activator nucleic acids and/or polypeptides may be indicated by a diagnostic or theranostic, for example, a biopsy, for the appropriate presence of receptors for the Targeting and/or activity element.
- Aspects of the invention relate to the use of chimeric activator proteins in the treatment of disorders. In some embodiments chimeric activator proteins are used to treat subjects who have cancer. As used herein, the term “subject” refers to a human or non-human mammal or animal. Non-human mammals include livestock animals, companion animals, laboratory animals, and non-human primates. Non-human subjects also specifically include, without limitation, chickens, horses, cows, pigs, goats, dogs, cats, guinea pigs, hamsters, mink, and rabbits. In some embodiments of the invention, a subject is a patient. As used herein, a “patient” refers to a subject who is under the care of a physician or other health care worker, including someone who has consulted with, received advice from or received a prescription or other recommendation from a physician or other health care worker. A patient is typically a subject having or at risk of having cancer. The term “treatment” or “treating” is intended to refer to prophylaxis, amelioration, prevention and/or cure of a condition (e.g., cancer). Treatment after a condition (e.g., cancer) that has started aims to reduce, ameliorate or altogether eliminate the condition, and/or its associated symptoms, or prevent it from becoming worse. Treatment of subjects before a condition (e.g., cancer) has started (i.e., prophylactic treatment) aims to reduce the risk of developing the condition and/or lessen its severity if the condition does develop. As used herein, the term “prevent” refers to the prophylactic treatment of a subject who is at risk of developing a condition (e.g., cancer) resulting in a decrease in the probability that the subject will develop the disorder, and to the inhibition of further development of an already established disorder.
- As used herein, the term “cancer” refers to an uncontrolled growth of cells that may interfere with the normal functioning of the bodily organs and systems, and includes both primary and metastatic tumors. Primary tumors or cancers that migrate from their original location and seed vital organs can eventually lead to the death of the subject through the functional deterioration of the affected organs. A metastasis is a cancer cell or group of cancer cells, distinct from the primary tumor location, resulting from the dissemination of cancer cells from the primary tumor to other parts of the body. Metastases may eventually result in death of a subject.
- As used herein, the term “cancer” includes, but is not limited to, the following types of cancer: breast cancer (including carcinoma in situ), biliary tract cancer; bladder cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia; T-cell acute lymphoblastic leukemia/lymphoma; hairy cell leukemia; chromic myelogenous leukemia, multiple myeloma; AIDS-associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; mesothelioma, neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer including melanoma, Merkel cell carcinoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma (teratomas, choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and medullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor. Non-limiting examples of precancerous conditions include dysplasia, premalignant lesions, adenomatous colon polyp, and carcinoma in-situ such as Ductal carcinoma in-situ (DCIS), etc. Other cancers that can be treated with methods of the invention will be known to those of ordinary skill in the art. In some embodiments of the invention, the cancer is melanoma. In certain embodiments the cancer is adenocarcinoma. In some embodiments the cancer is a solid tumor cancer.
- Compositions of the invention may be administered in effective amounts. An effective amount is a dosage of the composition of the invention sufficient to provide a medically desirable result. An effective amount means that amount necessary to delay the onset of, inhibit the progression of or halt altogether the onset or progression of the particular condition (e.g., cancer) being treated. An effective amount may be an amount that reduces one or more signs or symptoms of the condition (e.g., cancer). When administered to a subject, effective amounts will depend, of course, on the particular condition being treated (e.g., the cancer), the severity of the condition, individual subject parameters including age, physical condition, size and weight, concurrent treatment, frequency of treatment, and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
- Actual dosage levels of active ingredients in the compositions of the invention can be varied to obtain an amount of the composition of the invention that is effective to achieve the desired therapeutic response for a particular subject, compositions, and mode of administration. The selected dosage level depends upon the activity of the particular composition, the route of administration, the severity of the condition being treated, the condition, and prior medical history of the subject being treated. However, it is within the skill of the art to start doses of the composition at levels lower than required to achieve the desired therapeutic effort and to gradually increase the dosage until the desired effect is achieved. In some embodiments, lower dosages would be required for combinations of multiple compositions than for single compositions.
- It should be appreciated that an optimized dosage may be based, at least in part, on the residual non-specific toxicity of the activity element in a chimeric activator, the concentration of target molecules on the target cells, the binding affinity of the targeting element of the chimeric activator for the target molecules, and the length and flexibility of the linker. The amount of compound added should be sufficient to obtain a concentration of chimeric activator on the target cells that is sufficient to promote the desired response in the target cells. However, the amount should not be higher than necessary to avoid exposing non-target cells with levels of variant activity element that would be sufficient to activate the non-target cells. It should be appreciated that the optimal amount may be different for different chimeric activators (e.g., with different relative binding of targeting and activity elements, etc.).
- The compositions of the invention, can be administered to a subject by any suitable route. For example, the compositions can be administered orally, including sublingually, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically and transdermally (as by powders, ointments, or drops), bucally, or nasally. The term “parenteral” administration as used herein refers to modes of administration other than through the gastrointestinal tract, which include intravenous, intramuscular, intraperitoneal, intrasternal, intramammary, intraocular, retrobulbar, intrapulmonary, intrathecal, subcutaneous and intraarticular injection and infusion. Surgical implantation also is contemplated, including, for example, embedding a composition of the invention in the body such as, for example, in the brain, in the abdominal cavity, under the splenic capsule, or in the cornea.
- Dosage forms for topical administration of a composition of this invention include powders, sprays, ointments, and inhalants as described herein. The composition is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants that may be required.
- Pharmaceutical compositions of the invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions also can contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It also may be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents that delay absorption, such as aluminum monostearate or gelatin.
- In some cases, in order to prolong the effect of the composition, it is desirable to slow the absorption of the composition from subcutaneous or intramuscular injection. This result can be accomplished by the use of a liquid suspension of crystalline or amorphous materials with poor water solubility. The rate of absorption of the composition then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered composition from is accomplished by dissolving or suspending the composition in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the composition in biodegradable polymers such a polylactide-polyglycolide. Depending upon the ratio of composition to polymer, and the nature of the particular polymer employed, the rate of composition release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- The injectable formulations can be sterilized, for example, by filtration through a bacterial- or viral-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- The invention provides methods for oral administration of a pharmaceutical composition of the invention. Oral solid dosage forms are described generally in Remington's Pharmaceutical Sciences, 18th Ed., 1990 (Mack Publishing Co. Easton Pa. 18042) at Chapter 89. Solid dosage forms for oral administration include capsules, tablets, pills, powders, troches or lozenges, cachets, pellets, and granules. Also, liposomal or proteinoid encapsulation can be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673). As is known in the art, liposomes generally are derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any nontoxic, physiologically acceptable, and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p 33, et seq. Liposomal encapsulation may include liposomes that are derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556). In general, the formulation includes a composition of the invention and inert ingredients which protect against degradation in the stomach and which permit release of the biologically active material in the intestine.
- In such solid dosage forms, the composition is mixed with, or chemically modified to include, a least one inert, pharmaceutically acceptable excipient or carrier. The excipient or carrier preferably permits (a) inhibition of proteolysis, and (b) uptake into the blood stream from the stomach or intestine. In one embodiment, the excipient or carrier increases uptake of the composition of the invention, overall stability of the composition, and/or circulation time of the composition in the body. Excipients and carriers include, for example, sodium citrate, or dicalcium phosphate, and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, cellulose, modified dextrans, mannitol, and silicic acid, as well as inorganic salts such as calcium triphosphate, magnesium carbonate and sodium chloride, and commercially available diluents such as FAST-FLO®, EMIDEX®, STA-RX 1500®, EMCOMPRESS® and AVICEL®, (b) binders such as, for example, methylcellulose ethylcellulose, hydroxypropyhnethyl cellulose, carboxymethylcellulose, gums (e.g., alginates, acacia), gelatin, polyvinylpyrrolidone, and sucrose, (c) humectants, such as glycerol, (d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium carbonate, starch including the commercial disintegrant based on starch, EXPLOTAB®, sodium starch glycolate, AMBERLITE®, sodium carboxymethylcellulose, ultramylopectin, gelatin, orange peel, carboxymethyl cellulose, natural sponge, bentonite, insoluble cationic exchange resins, and powdered gums such as agar, karaya or tragacanth; (e) solution retarding agents such a paraffin, (f) absorption accelerators, such as quaternary ammonium compounds and fatty acids including oleic acid, linoleic acid, and linolenic acid (g) wetting agents, such as, for example, cetyl alcohol and glycerol monosterate, anionic detergent surfactants including sodium lauryl sulfate, dioctyl sodium sulfosuccinate, and dioctyl sodium sulfonate, cationic detergents, such as benzalkonium chloride or benzethonium chloride, nonionic detergents including lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65, and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose; (h) absorbents, such as kaolin and bentonite clay, (i) lubricants, such as talc, calcium sterate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils, waxes, CARBOWAX® 4000, CARBOWAX® 6000, magnesium lauryl sulfate, and mixtures thereof; (j) glidants that improve the flow properties of the drug during formulation and aid rearrangement during compression that include starch, talc, pyrogenic silica, and hydrated silicoaluminate. In the case of capsules, tablets, and pills, the dosage form also can comprise buffering agents.
- Solid compositions of a similar type also can be employed as fillers in soft and hard-filled gelatin capsules, using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.
- The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They optionally can contain opacifying agents and also can be of a composition that they release the active ingredients(s) only, or preferentially, in a part of the intestinal tract, optionally, in a delayed manner. Exemplary materials include polymers having pH sensitive solubility, such as the materials available as EUDRAGIT® Examples of embedding compositions that can be used include polymeric substances and waxes.
- The composition of the invention also can be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the composition of the invention, the liquid dosage forms can contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol ethyl carbonate ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydroflirfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, and mixtures thereof.
- Besides inert diluents, the oral compositions also can include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, coloring, flavoring, and perfuming agents. Oral compositions can be formulated and further contain an edible product, such as a beverage.
- Suspensions, in addition to the composition of the invention, can contain suspending agents such as, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- Also contemplated herein is pulmonary delivery of the composition of the invention. The composition is delivered to the lungs of a mammal while inhaling, thereby promoting the traversal of the lung epithelial lining to the blood stream. See, Adjei et al., Pharmaceutical Research 7:565-569 (1990); Adjei et al., International Journal of Pharmaceutics 63:135-144 (1990) (leuprolide acetate); Braquet et al., Journal of Cardiovascular Pharmacology 13 (suppl.5): s. 143-146 (1989)(endothelin-1); Hubbard et al., Annals of Internal Medicine 3:206-212 (1989)(α1-antitrypsin); Smith et al., J. Clin. Invest. 84:1145-1146 (1989) (α1-proteinase); Oswein et al., “Aerosolization of Proteins,” Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colo., March, 1990 (recombinant human growth hormone); Debs et al., The Journal of Immunology 140:3482-3488 (1988) (interferon-γ and tumor necrosis factor α) and Platz et al., U.S. Pat. No. 5,284,656 (granulocyte colony stimulating factor).
- Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including, but not limited to, nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
- Some specific examples of commercially available devices suitable for the practice of the invention are the ULTRAVENT® nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the ACORN II® nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the VENTOL® metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, N.C.; and the SPINHALER® powder inhaler, manufactured by Fisons Corp., Bedford, Mass.
- All such devices require the use of formulations suitable for the dispensing of a composition of the invention. Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants, and/or carriers useful in therapy.
- The composition may be prepared in particulate form, preferably with an average particle size of less than 10 μm, and most preferably 0.5 to 5 μm, for most effective delivery to the distal lung.
- Carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations may include lipids, such as DPPC, DOPE, DSPC and DOPC, natural or synthetic surfactants, polyethylene glycol (even apart from its use in derivatizing the inhibitor itself), dextrans, such as cyclodextran, bile salts, and other related enhancers, cellulose and cellulose derivatives, and amino acids.
- In addition, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
- Formulations suitable for use with a nebulizer, either jet or ultrasonic, typically comprise a composition of the invention dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation also can include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation also can contain a surfactant to reduce or prevent surface-induced aggregation of the inhibitor composition caused by atomization of the solution in forming the aerosol.
- Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the composition of the invention suspended in a propellant with the aid of a surfactant. The propellant can be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid also can be useful as a surfactant.
- Formulations for dispensing from a powder inhaler device comprise a finely divided dry powder containing the composition of the invention and also can include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol, in amounts that facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
- Nasal delivery of the composition of the invention also is contemplated. Nasal delivery allows the passage of the composition to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran. Delivery via transport across other mucous membranes also is contemplated.
- Compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the composition of the invention with suitable nonirritating excipients or carriers, such as cocoa butter, polyethylene glycol, or suppository wax, which are solid at room temperature, but liquid at body temperature, and therefore melt in the rectum or vaginal cavity and release the active compound.
- The following examples are intended to be illustrative of certain embodiments and are non-limiting. Any of the linkers, activity elements, targeting elements or other components described herein may be combined independently with each other according to the teachings herein.
- In some embodiments, a Chimeric Activator protein was constructed with the following protein components: a mutated version of interferon alpha (IFNα) as the Activating Element, a linker, and epidermal growth factor (EGF) as the targeting element. An embodiment of this chimeric protein is illustrated in
FIG. 3 . InFIG. 3 , the IFNα activity element is shown in region (1), the (Gly4Ser)7 linker is shown in region (2), and the EGF targeting element is shown in region (3). InFIG. 3 , the Chimeric Activator is bound to both IFNαR2 (shown as region (4)) and an active EGFR dimer (shown as region (5)). The figure shows only the extracellular domains of the receptors. The membrane-spanning domains would be at the bottom of the figure. - These elements were chosen based on the following considerations. The published structure of EGF receptor with a ligand (Garrett et al. (2002) Cell 110: 763-773) and a model of the IFNα structure (Quadt-Akabayov et al. (2006) Protein Sci. 15: 2656-2668) indicated that, in these receptor-ligand complexes, the EGF is about 90 Angstroms from the cell surface, and the IFNα is about 75 Angstroms from the cell surface, so that a linker of at least 15 Angstroms could bridge the two elements. A standard glycine-serine linker of 35 ([Gly4Ser1]7) amino acids (Huston and Oppermann, 1993) was chosen. The structures also were useful for choosing whether to use the N-terminus or C-terminus of EGF and IFNα, and to design a linker of the right length. In addition, Piehler et al. (2000) J Biol Chem. 275: 40425-40433 published a precise characterization of the on-rates, off-rates, and KDs of a series of IFNα alanine-scanning mutants, so that a series of IFNα mutants with step-wise losses in binding affinity could be chosen (see Table 1 below). The on-rates and binding constants of EGF and IFNα are similar. The on-rates of both proteins are faster than diffusion-limited, because they are driven by charge-complementarity between these ligands and their receptors. It also was known that both EGF and IFNα could be expressed in Pichia pastori to give active proteins. Finally, IFNα and its PEGylated derivatives are used as drugs in the treatment of hepatitis B, hepatitis C, and certain forms of cancer. Side effects of IFNα treatment include flu-like symptoms, depression, and myelosuppression, which limit the dose and limit the therapeutic index. An engineered form of IFNα with reduced side effects may have the potential to replace IFNα for many diseases, and open up new treatments. A review of the literature on IFNα and cancer suggests that this protein ‘almost works’ for treatment of breast cancer, but is only somewhat too toxic to use—in other words, an improvement in therapeutic index of as little as 2- to 5-fold could dramatically extend the use of an IFNα-based compound to other types of cancer beyond melanoma and a few others. In contrast, other cell-killing elements such as Pseudomonas exotoxin are extremely toxic and might need an improvement in therapeutic index of >100-fold to become useful.
- Although the considerations described in the preceding paragraph are helpful, it should be appreciated that compositions of the invention can be performed in the absence of such information as described herein.
- Table 1 shows the binding characteristics of EGF and IFNα, and compares them with an anti-EGFR antibody that has been used in targeting studies.
-
TABLE 1 On-rates, off-rates, and dissociation constants of EGF, wild-type and mutant IFNα, and an anti- EGFR antibody. Based on these numbers, the binding of an IFNα-EGF Chimeric Activator should be driven by EGF. Note that the anti-EGFR antibody MR1-1 has an on-rate that is much lower than EGF or IFNα. Kon Koff Kd Reference EGF 2.5 × 106/M/sec Bellot et al. (1990) J Cell Biol. 110: 491-502 IFNa (wild-type) 3.7 × 106/M/ sec 1 × 10−2/ sec 3 × 10−9 M Piehler et al. (2000) J Biol Chem. 275: 40425-40433 IFNa (K133A) 0.7 × 106/M/sec 1.8 × 10−2/ sec 26 × 10−9 M Piehler et al. (2000) J Biol Chem. 275: 40425-40433 IFNa (R144A) 0.36 × 106/M/ sec 4 × 10−2/ sec 120 × 10−9 M Piehler et al. (2000) J Biol Chem. 275: 40425-40433 IFNa (R149A) Too low to measure 538 × 10−9 M Piehler et al. (2000) J Biol Chem. 275: 40425-40433 Anti-EGFRvIII (MR1-1) 0.8 × 106 1.2 × 10−3/sec 1.5 × 10−9 Kuan et al. (2000) Int J Cancer. 88: 962-969
Based on these quantitative and structural considerations, four chimeric activators were constructed: - 1. IFNα (wild-type)-(Gly4Ser)7-EGF;
- 2. IFNα (Lys133Ala)-(Gly4Ser)7-EGF;
- 3. IFNα (Arg144Ala)-(Gly4Ser)7-EGF;
- 4. IFNα (Arg149Ala)-(Gly4Ser)7-EGF.
- These proteins were expressed as well as EGF alone and the corresponding individual IFNα mutants in the yeast Pichia pastoris. All of the proteins were epitope-tagged. The proteins were expressed at high levels. All of the Chimeric Activators showed EGF activity, based on their ability to stimulate phosphorylation of EGF receptor (data not shown).
- The chimeric activators and the corresponding IFNα mutant proteins were compared for their ability to activate the IFNα receptor in HeLa cells, which naturally express EGFR and IFNαR. To measure IFNα signaling, STAT1 phosphorylation was detected by Western blotting; STAT1 tyrosine 701 is directly phosphorylated upon activation of IFNα receptor. The results shown in
FIG. 4 indicate that an IFNα-EGF chimeric protein (without a mutation) and IFNα alone induce IFN signaling with about equal efficiency. The IFNα mutant proteins K133A, R144A, and R149A, which respectively are reduced by 10×, 40×, and 200× for IFNαR binding, show corresponding low levels of IFNα signaling. However, the Chimeric Activators with IFNα mutations fused to EGF show much higher levels of IFNα signaling than the corresponding IFNα mutants alone. InFIG. 4 , chimeric activators (diamonds attached to octagons) and the corresponding IFNα protein without EGF (octagons) were added to cultures of HeLa cells at 0.3 nM, 0.8 nM, and 1.5 nM for 5 minutes. Cells were lysed, samples run on an SDS gel, blotted to nitrocellulose, and probed with an anti-phosphoSTAT1 antibody, which reflects IFNα signaling. Mutant IFNα proteins showed reduced signaling in a manner correlated with their reduced binding to IFNα receptor, while the IFNα-EGF mutant chimeric proteins showed much higher levels of signaling through STAT1. All lanes were loaded with an essentially equal amount of total cell protein. - To verify that the enhancement of IFNα signaling depended on binding to EGF receptor, a Daudi cell line was constructed to express EGFR and compared to the parent cell line for signaling induced by the chimeric activators. Daudi cells are a human Burkitt's lymphoma cell line whose proliferation and survival are inhibited by IFNα, but does not express EGFR. The results in
FIG. 5 illustrate the experiments with the EGFR-expressing Daudi cell line. Cells were transfected with a plasmid that constitutively expresses EGFR. Parental cells, cells transfected with an empty plasmid vector, and EGFR-transfected cells were treated with EGF, and then phosphorylation of EGFR was detected by Western blotting. By comparing the activity of chimeric activators on cells with and without EGFR, the targeting effect can be demonstrated - When the chimeric activators were tested on Daudi and Daudi-EGFR cells (see
FIG. 6 ), the results clearly indicated that their function depended on the presence of the receptor for the targeting element, in this case EGF receptor. Daudi cells engineered to express EGFR (FIG. 5 ) and parental Daudi cells were treated with Chimeric Activators and mutant IFNα proteins, and STAT1 phosphorylation was measured by Western blot. The IFNα(R149A)-EGF protein specifically induced signal transduction in cells expressing EGFR. The EGFR-expressing cells correspond to therapeutic target cells, while the cells lacking EGFR correspond to ‘side-effect’ cells. On cells with only IFNα receptor, activation with the mutant IFNα Chimeric Activator protein was poor or undetectable. Specifically, the IFNα(R149A)-EGF protein stimulated STAT1 phosphorylation only in Daudi-EGFR cells, while the IFNα-EGF protein and IFNα alone were active in both cell lines and the IFNα mutant did not work in either cell line. Chimeric activators with the intermediate-strength mutations K133A and R144A showed intermediate reductions in signaling in Daudi cells, consistent with their predicted quantitative properties (data not shown). - Accordingly, this experiment was useful to compare cells with and without EGFR, the Daudi-EGFR cells correspond to tumor cells expressing EGFR or another target receptor, and the parental Daudi cells are analogous to “side-effect cells”—other cells in the body with little or no target receptor. It was estimated that the addition of the EGF targeting element enhances the specificity of IFNα signaling by at least 20-fold in this system.
- As a final control, it was tested whether the signaling by IFNα(mutant)-EGFR chimeric activators could be inhibited by an antibody against the receptor for the targeting element. The data illustrated below indicates that this is the case. Pre-binding of an anti-EGFR antibody (monoclonal 528 (Calbiochem, La Jolla, Calif.)) blocks the signaling of the IFNα(R149A)-EGF chimeric activator in HeLa cells. This is illustrated in
FIG. 7 . HeLa cells were treated with either IFNα, IFNα(R149A)-EGF, or IFNα(R149A), and STAT1 signaling was measured by Western blot. The IFNα(R149A)-EGF protein was not able to induce interferon-mediated signal transduction when EGFR was blocked with a neutralizing anti-EGFR antibody - Chimeric Activators of Example 1 can be tested/screened for activity in animal tumor models. Pharmaceutical Product Development, Inc. (New York, N.Y.) can be used as a contract testing service to perform these tests. This type of experiment is standard in the development of anti-cancer drugs, and involves injection of human tumor cells into mice that have immune-suppressing mutations so that the tumor cells will not be rejected. In one form of the experiment, tumor cells are injected subcutaneously and then grow into a lump that can be measured with calipers. Once a tumor has reached a measurable size, treatment is started and the extent of tumor growth inhibition or shrinkage can be charted with time.
- Using IFNα(R149A)-EGF as the test molecule, experiments can be performed in parallel sets of animals used paired tumor cell lines, one of which expresses the receptor for the targeting element, and one of which does not. The Daudi and Daudi-EGFR cells described above in Example 1 may be used. The host animal can be Nude mice, which are immunodeficient and therefore do not reject the tumor cells as foreign; use of Nude mice also means that the mice will not generate antibodies against the injected proteins.
- PPD, Inc. offers testing for the Daudi models. They can also pre-test the engineered cell lines to verify that Daudi-EGFR cells can be used to generate tumors. PPD, Inc. can also perform mycoplasma testing on the tumor cell lines before they are used.
- The treatment groups can be:
-
- a. A chemotherapeutic agent as a positive control, such as cyclophosphamide for Daudi cells.
- b. As a negative control, the appropriate IFNα mutant without the targeting element. About 10 micrograms of protein per dose will be given.
- c. A low-dose treatment group with a Chimeric Activator with the molar equivalent of 2 micrograms of IFNα.
- d. A high-dose treatment group with a Chimeric Activator with the molar equivalent of 10 micrograms of IFNα.
- In some experiments, 8 to 10 mice may be used per group, for a total of about 80 mice for four dose groups in mice with the two different cell lines.
- The amount of protein needed for these experiments may be less than 2 mgs for the entire experiment. The productivity of these Pichia pastoris lines is such that the culture supernatant contains about 1 mg/ml of the desired chimeric protein, and only small amounts of other proteins. The proteins, which contain a histidine tag, will be purified using a nickel column by standard techniques.
- The protein can be administered by injection directly into subcutaneous tumors three times a week for three weeks. Tumor growth/shrinkage can be measured over a period of about a month. It can be tested whether appropriate signal transduction is activated in the tumor cells in vivo. Tumor biopsies can be frozen in liquid nitrogen, stored, and transferred back for Western blot analysis. The methods of Starostik et al. ((1998) Cancer Res. 58: 4552-4557) and Menon et al. ((2003) Am J Physiol Heart Circ Physiol. 284: H317-329) can be used to analyze the tissue for STAT1 phosphorylation.
- To demonstrate the breadth of the Chimeric Activator concept, each element (activity element, a linker, and a targeting element) of the constructs of Example 1 can be replaced with an alternative component that is structurally different and/or has a different biological function. This is illustrated in this example and those that follow. These experiments may provide a molecule for testing in animals.
- To demonstrate that IFNα can be replaced by other activators of signal transduction, a series of proteins with wild-type and mutant versions of Tumor Necrosis Factor (TNFα) can be constructed. Specifically, the following series of mutations defined by Zhang et al. ((1992) J Biol Chem. 267: 24069-24075) can be used:
-
Mutation Relative activity Wild- type 100% N39Y 30 % S147Y 7% Y87H 0.6% - TNF is a trimer with a completely different structure from IFNα. The structure of the TNF/TNF receptor complex has been solved. The N-terminus and C-terminus are not part of the interface with the receptor, so they are free for linker attachment. Specifically, a chimeric protein with the TNF at the N-terminus followed by the linker and the EGF can be made. As for the IFNα-EGF chimeric proteins described in Example 1 above, a series of proteins with various mutations, as well as control wild-type and mutant TNF proteins lacking EGF, can be made. The proteins can have a histidine tag to aid in purification.
- Molecular models of the TNF-linker-EGF Chimeric Activator by itself and in a complex with TNF receptor (see
FIG. 8 ) illustrate how the TNF portion can still bind to its receptor when attached to the linker at EGF. Note that TNF has a trimeric structure, such that the chimeric protein is also a trimer in embodiments that include the trimerization domains. - TNF receptors are expressed on HeLa cells (Baglioni et al. (1985) J Biol Chem. 260: 13395-13397). TNF signaling will be measured using the same type of phosphorylation/Western blot analysis as described above for IFNα. TNF signaling by a molecule such as TNF(S147Y)-EGF may depend on the EGF-EGF receptor interaction, which can be tested by showing that TNF signaling can be inhibited by an anti-EGF antibody, and that signaling by the corresponding TNF(S147Y) mutant protein without EGF is much weaker or undetectable.
- EGFRde(2-7) is a mutant form of the EGF receptor with a deletion in the extracellular domain that creates a novel junction. (
Exons 2 through 7 are deleted, creating a novel protein joint fromexon 1 andexon 8.) This mutant form of the receptor is oncogenic and is naturally found on many tumor types, glioblastoma in particular. Since EGFRde(2-7) comes about by a mutation in cancer cells, it is not present at all in normal cells and thus it is an absolutely cancer-specific surface protein. The Pastan and Bigner groups have generated and characterized an antibody that recognizes the novel peptide junction. The antibody, termed MR1-1, has been affinity-optimized and has an on-rate that is only about 4-fold lower than the on-rate of EGF (Kuan et al. (2000) Int J Cancer. 88: 962-969; see Table 1 above). - Experiments with an IFNα-MR1-1 Chimeric Activator can be performed. These may be analogous to the experiments performed above with the IFNα-EGF proteins, replacing the EGF targeting element with MR1-1 antibody V regions that recognize a tumor-specific EGFR variant, EGFRde(2-7). There are two publicly available cancer cell lines, U87MG and U87MG-EGFRde(2-7), where the second cell line was derived from the first by transfection with an expression construction for the EGFRde(2-7) mutant protein. The antibody MR1-1 only binds to the U87MG-EGFRde(2-7) line, allowing Chimeric Activators to be tested on both lines and determine whether a signaling event depends on the MR1-1 targeting element (see
FIG. 9 ). InFIG. 9 , EGFRvIII is a deleted form of EGF receptor that is only expressed on tumor cells. The deletion junction creates a novel amino acid sequence (*). MR1-1 is an antibody that recognizes this deletion junction, and does not recognize normal EGF receptor. A Chimeric Activator based on MR1-1 should be completely tumor-specific. - These paired cell lines have been extensively used and can be used in mouse tumor models. The U87MG nude mouse model is sensitive to IFNα (Iqbal Ahmed et al. (2001) Cancer Gene Ther. 8: 788-795). U87MG is derived from a human glioblastoma cell line.
- Glioblastoma is one of the most difficult types of human cancer to treat, and many patients die within a year of diagnosis. Most glioblastoma tumor cells have the EGFRde(2-7) deletion, so an IFNα-MR1-1 Chimeric Activator should work in this type of patient. Because glioblastoma patients rarely respond to treatment and progress so quickly, it may be possible to detect responses to an IFNα-MR1-1 Chimeric Activator during the Phase I stage of clinical trials.
- IFNα-MR1-1 Chimeric Activators can be constructed with wild-type IFNα and the same three mutants used above (K133A, R144A, and R149A). Specifically, the MR1-1 antibody V regions can be formatted as a “single-chain Fv” (scFv) to make molecules with IFNα at the N-terminus, a 35 amino acid glycine/serine linker, the heavy chain V region of MR1-1, a 15 amino acid glycine/serine linker, the light chain V region of MR1-1, and a histidine tag for purification. These chimeric proteins will be expressed in Pichia pastoris and purified as for the IFNα-EGF Chimeric Activators. Pichia is known to be a good system for expression of antibody V regions formatted as single-chain Fv molecules.
- IFNα signaling can be measured using the STAT1 phosphorylation/Western blot assay described above. In order to test the impact of different linker lengths on the results, signaling can be measured using different linker lengths (e.g., the 35 amino acid glycine/serine linker can be doubled or tripled to create linkers of 70 and 105 amino acids between the IFNα and MR1-1 parts of the protein). It may also be necessary to introduce other amino acids besides glycine and serine, simply because the DNA sequences encoding the repeating peptide units may undergo genetic recombination because of the corresponding repeats in the DNA.
- Leptin is a hormone that is produced by adipocytes (fat cells) and also binds to receptors on adipocytes. At one time, leptin was thought to be a potential treatment for obesity, but further research indicated that in the vast majority of obese people, leptin is produced at high levels. In this example, leptin serves as a targeting element and its biological activity is not important to the function of the TNF-leptin Chimeric Activator.
- One of the effects of TNF is to stimulate burning of lipids in adipocytes to help create fever. By targeting a mutated, less active TNF to adipocytes, fat burning and weight loss may result, as it does during illness, but without the other side effects of illness. Increased body temperature may still result from treatment with TNF-leptin, as this is a direct result of lipid oxidation in adipocytes. Leptin receptors are present on only a few other cell types in the body, such as cells in the hypothalamus that are thought to influence feeding and hunger. The action of TNF-leptin on these cells may be to inhibit feeding.
- A series of TNF-leptin Chimeric Activators can be constructed using the same TNF mutations described above to bind to adipocytes (fat cells) and stimulate fat-burning for obesity treatment. Leptin would be the targeting element and a mutant form of TNF would be the activity element. The Chimeric Activators will have leptin at the C-terminus, since leptin has a disulfide bond that involves a cysteine at its very C-terminus, and a construct with the other orientation might have defective disulfide bond formation. The configuration of the leptin/leptin receptor complex is thought to be similar to the IFNα/IFNα receptor complex, and is favorable for the construction of a Chimeric Activator, as the C-terminus of TNF and the N-terminus of leptin are expected to be about the same distance away from the cell membrane.
- To assay the activity of the TNF-leptin molecules, a stably transfected cell line that already expresses TNF receptor with an expression plasmid expressing a leptin receptor can be used. The activity of the TNF-leptin chimeric activators in the pair of cell lines with and without leptin receptor can be compared to demonstrate a specific requirement for the leptin receptor.
- The biological activity of the TNF-leptin molecule can be tested in overweight mice. These would be normal mice that are fed a high-fat diet, which are a good representation of human obesity.
- CD4 is a surface protein on T cells that is the receptor for the HIV envelope protein, gp120. During later stages of HIV infection, the envelope protein appears on the cell surface and could be targeted by a Chimeric Activator with CD4 as a targeting element. The structures of the gp120/CD4 complex has been solved (Zhou et al. Nature 445: 732-737), and it indicates that the N-terminus of CD4 could be used as a junction for a protein fusion. The same IFNα mutations described above can be used. In some embodiments, only the N-terminal domain of CD4 is used, as depicted in the crystal structure, and IFNα-CD4 Chimeric Activators are constructed with a CD4 targeting element, targeting to the HIV envelope protein on HIV-infected cells.
- To assay the activity of the IFNα-CD4 Chimeric Activator, a stably transfected Daudi cell line that already expresses IFNα receptor with an expression plasmid expressing gp120 can be used. The activity of the Chimeric Activators can be compared in the pair of cell lines with and without gp120, to demonstrate a specific requirement for the gp120.
- The standard animal test system for HIV drugs is the SCID-hu mouse. In this system, an immunodeficient SCID mouse is populated with human immune cells, then infected with HIV.
- Evolution modulates the quantitative characteristics of protein interactions, and often uses combinations of weak interactions to achieve a particular specificity. How quantitative optimization might be used in the design of multidomain proteins was evaluated using a chimera containing epidermal growth factor (EGF) as a cell targeting element and interferon-alpha2a (IFNα2a) to initiate signal transduction. EGF and IFNα2a were connected via a linker that allows both ligands to bind to their receptors on a cell surface, then incorporated a series of mutations into the IFNα2a portion that progressively decrease both the on-rate and dissociation constant of the IFNα2a/IFNα receptor 2 (IFNAR2) interaction. Using this strategy, chimeric proteins were designed in which the activation of the IFNα receptor (IFNAR) in HeLa, A431 and engineered Daudi cells depends on the preysence of EGF receptor (EGFR) on the same cell. The mutant chimeric proteins also inhibit proliferation of IFNα-sensitive cells in an EGFR-dependent manner. These results provide insights into the quantitative requirements for specific binding to multi-subunit receptors, and illustrate the value of a quantitative approach in the design of synthetic-biological constructs.
- Biological recognition events are often mediated by modular protein and nucleic acid segments that can be arbitrarily linked to give functional combinations. In the course of evolution, multidomain proteins have been repeatedly generated and constitute a large fraction of the proteins encoded by metazoan genomes. In the evolutionary improvement of such chimeras after a genetic rearrangement, an important but under-studied process is the quantitative optimization of the individual modules.
- For many years, researchers have also constructed chimeric proteins with properties that derive from the parental modules. For example, one therapeutic approach has sought to use cell surface proteins as addresses to direct the delivery of specific molecules, such as toxins to tumor cells. In 1988, Pastan's group described a chimeric protein consisting of Pseudomonas exotoxin and IL-2, in which the IL-2 moiety directed the toxin to cells bearing IL-2 receptor (Lorberboum-Galski, H., FitzGerald, D., Chaudhary, V., Adhya, S., Pastan, I., (1998) Proc Natl Acad Sci USA 85(6), 1922-1926); they later described a Pseudomonas exotoxin-TGFα chimeric protein that binds to EGFR (Siegall, C. B., Xu, Y-H., Chaudhary, V. K., Adhya, S., Fitzgerald, D., Pastan, I., (1989) FASEB J 3(14), 2647-2652; Heimbrook, D. C., Stirdivant, S. M., Ahern, J. D., Balishin, N. L., Edwards, G. M., Defeo-Jones, D., FitzGerald, D. J., Pastan, I, Oliff. A., (1990) Proc Natl Acad Sci USA 87(12), 4697-4701; and Pai, L. H., Gallo, M. G., FitzGerald, D. J., Pastan, I., (1991) Cancer Res 51(11), 2808-2812), a hallmark of many tumors (Liu, T. F., Tatter, S. B., Willingham, M. C., Yang, M., Hu, J. J., Frankel, A. E., (2003) Mol Cancer Ther 2(8), 783-787). Similar strategies have been adapted by many groups (Kreitman, R. J., Pastan, I., (1999) Handbook of Experimental Pharmacology: Novel Therapeutics from Modern Biotechnology—Berlin, N.Y.: Springer-Verlag, p. 89-110; and Todhunter, D. A., Hall, W. A., Rustamzadeh, E., Shu, Y., Doumbia, S. O., Vallera, D. A., (2004) Protein Eng Des Sel 17(2), 157-164). A universal problem with this kind of approach is that when any targeted agent is administered to a patient, unwanted effects will occur as the drug travels through the body before reaching its target.
- A strategy based on quantitative modulation of the signaling part of a targeted molecule was evaluated. Aspects of the invention build on the ideas of Adam and Delbruck (Adam, G., Delbruck, M., (1968) Reduction of dimensionality in biological diffusion processes—in: Rich A, Davidson N, editors, Structural chemistry and molecular biology, San Francisco: W. H. Freeman and Co. p. 198-215), who proposed that in biological systems, reaction rates are often enhanced by reduction of the dimension of a space in which diffusion occurs. According to aspects of the invention, but without wishing to be bound by theory, an initial rapid binding reaction to one cell surface protein could drive a second weak interaction on the same cell surface, because a cell surface is effectively two-dimensional. Accordingly, if the binding affinities of both the targeting agent and the activating ligand are tuned appropriately, a mutant chimeric protein can be developed that would show negligible activation on cells expressing just one of the relevant receptors. This strategy was tested using EGF as the targeting agent and IFNα2a as the toxin.
- By combining quantitative information about protein binding kinetics and affinities with structural information about protein ligands and their cell-surface receptors, a new class of artificial proteins was developed that simultaneously bind to distinct cell surface receptors to create ligands with new cell-type specificities. In some embodiments, these proteins, termed “chimeric activators” have the following general structure: an activity element containing at least one mutation, a linker and a targeting element (
FIG. 10A ). The example of a general chimeric activator structure shown inFIG. 10A illustrates a ‘targeting element’ connected by a peptide linker to an ‘activity element’ with a mutation that reduces binding to the receptor for the activity element. According to aspects of the invention, this design takes advantage of multivalent interactions between ligands and cell-surfaces to ensure precise delivery of biological activities. - Cell Lines and Culture Conditions:
- Daudi, 293-T and HeLa cells were obtained from American type culture collection (Manassas, Va.). A431 cells were a gift from Thomas M. Roberts. A431, 293-T and HeLa cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U ml−1 penicillin and 100 μg ml−1 streptomycin. Daudi cells were maintained in RPMI-1640 modified medium supplemented with 10% FBS, 100 U ml−1 penicillin and 100 μg ml−1 streptomycin. Stable Daudi-pLPCX-EGFR (Daudi-EGFR) and Daudi-pLPCX cell lines were generated by retroviral infection of Daudi cells following the protocol of Pear et al. (available at the website of the Nolan Laboratory, Stanford University). Infected Daudi cells were first selected with puromycin (1.5 μg/mL) and then cells were isolated with Dynabeads Pan mouse IgG from Invitrogen (Maryland, USA) pre-coated with anti-EGFR mAb following the manufacturer instructions. The constructs pLPCX and pLPCX-EGFR were kindly provided by Joan S. Brugge, Harvard Medical School (Reginato, M. J., Mills, K. R., Paulus, J. K., Lynch, D. K., Sgroi, D. C., Debnath, J., Muthuswamy, S. K., Brugge, J. S., (2003) Nature Cell Biol 5(8), 733-740).
- Antibodies:
- Anti-phospho-STAT1 (Tyr701) rabbit pAb and anti-EGFR rabbit pAb were purchased from Cell Signaling Technology (Beverly, Mass.); PhosohoDetect™ anti-phospho-EGFR (Tyr1068) rabbit pAb, anti-EGFR mouse mAb (EGFR.1), anti-EGFR mouse mAb (528) and anti-EGF rabbit pAb were purchased from Calbiochem (San Diego, Calif.); anti-actin mouse mAb was purchased from Chemicon International (Temecula, Calif.); anti-human IFNα/β R1-phycoerythrin mouse mAb was purchased from R&D systems (Minneapolis, Minn.); anti-EGFR R-Phycoerythrin-conjugated mouse mAb was purchased from BD Biosciences (San Jose, Calif.).
- Gene Synthesis, Protein Expression and Purification:
- The coding sequence for the ‘wild-type’ chimeric activator, INFα-2a-(Gly4-Ser)7-EGF, consisting of the 165 amino acids of mature INFα-2a (GI:2781226), the 35 amino acid linker and the 53 amino acids of mature EGF (GI:24987355), was synthesized by Top Gene Technologies (Quebec, Canada). This sequence was codon optimized for expression in P. pastoris. The sequence was sub-cloned (with XhoI and XbaI restriction sites) into the pPICZα A vector (Invitrogen), which includes the alcohol oxidase promoter and the α-factor leader sequence, a c-myc epitope tag and a His6 tag for purification. The final sequence of the constructs was confirmed by DNA sequencing. Approximately 20 μg of the DNA construct were linearized with Pme I prior to transformation of P. pastoris X33 (Mut+) and KM71H (MutS) cells. The electroporation method of the EasySelect™ Pichia expression kit (version H; Invitrogen) was used for transformation, and the transformants were plated on MD and MM agar plates to screen for methanol utilization (Mut) phenotype. Several Mut+ and MutS clones were put on plates with high zeocin concentrations (0.5 to 1 mg/ml) to select for clones with multiple integration events. A MutS clone was selected for the protein expression. Transformants were grown and induced with methanol according to the instructions from Invitrogen. The INFα-2a-(Gly4-Ser)7-EGF chimeric activator was secreted into the medium and was purified with the ProBond™ purification system (for purification of polyhistidine-containing recombinant proteins, version K, Invitrogen). Purity was checked by Coomassie blue stain and by immunblotting against EGF. The final yield was approximately 1 mg per ml of cell culture.
- Variants of INFα-2a-(Gly4-Ser)7-EGF were constructed containing the IFNα2a mutations K133A, R144A, and R149A by standard recombinant DNA techniques using the Quick-Change™ site-directed mutagenesis kit from Stratagene (CA, USA). To produce control proteins, a set of Pichia expression vectors encoding IFNα2a wild-type and mutant proteins lacking the linker and EGF but containing the C-myc and His6 tags were also constructed by analogous techniques. The correctness of the constructs was confirmed by DNA sequencing. The transformation, expression and purification of the different constructs were performed as described above.
- Cell Stimulation, Protein Extraction, Immunoblotting and Immunoprecipitation:
- A431 and HeLa cells were seeded in 60 mm plates, Daudi and Daudi-EGFR were seeded in 50 mL bottles. Once they reached confluence the growth medium was replaced with fresh DMEM without FBS or antibiotics for 3 h (to reduce background signal from the serum).
- EGFR Stimulation:
- Cells were stimulated with human recombinant EGF from E. coli (Cell Signaling Technology), the chimeric activators, and Interferon-α □ A (Calbiochem) or vehicle (as negative controls) for 5 min at 37° C. and 5% CO2. Stimulations were terminated by washing the cells once with ice-cold phosphate-buffered saline, and cells were lysed in NP40 lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% NP-40, 25 mM NaF, 10 mM β-glycerophosphate, 250 μM Na3VO4 supplemented with protease inhibitor cocktail tablets (Roche)). Cells were solubilized for 15 min at 4° C. in lysis buffer follow by centrifugation at 15,000 g for 15 min at 4° C., the detergent extracts (supernatant) were then subjected to immunoprecipitation. Lysates were incubated with 1 μg of anti-EGFR (EGFR.1) mouse monoclonal antibody overnight at 4° C. EGFR was immunoprecipitated with a mixture of Protein A and G-Sepharose beads (Amersham Bioscience) for 1 h. at 4° C. Beads were washed with NP-40 lysis buffer and boiled in SDS sample buffer. Proteins were resolved on 8% SDS-polyacrylamide, transferred to nitrocellulose, and detected by immunoblotting using the anti-phosphoEGFR(Tyr1068) antiserum.
- STAT1 Stimulation:
- As described above cells were stimulated with the chimeric activators, the IFNα-only counterparts, Interferon-α A, or EGF or vehicle (as negative controls) for 30 min at 37° C. and 5% CO2. Stimulations were terminated by washing the cells once with ice-cold phosphate-buffered saline, and lysed in RIPA buffer (150 mM NaCl, 1% Deoxycholate, 10 mM Tris-HCL at pH 7.2, 0.1% SDS, 1.0% Triton X-100, 5 mM EDTA, 25 mM NaF, 10 mM β-glycerophosphate, 250 μM Na3VO4 supplemented with protease inhibitor cocktail tablets (Roche)). Proteins were resolved on 10% SDS-polyacrylamide, transferred to nitrocellulose, and detected by immunoblotting with anti-phospho STAT1(pTyr701) antiserum.
- Neutralization of EGF Receptor and STAT1 Stimulation:
- HeLa cells were seeded as previously described. Once they reach confluence the medium was changed for fresh DMEM and cells were incubated with
anti-EGFR mouse mAb 528. After 2 h treatment cells were tested for STAT1 stimulation as described above. - Anti Proliferative Assay:
- The anti-proliferative activity of IFNα-2a-linker-EGF chimeras, corresponding IFNα2a proteins, and commercial IFNα A on Daudi and Daudi-EGFR cell lines was assayed as follows. Proteins that had been previously filtered thorough a 0.2 μm PDVF filter unit (Millipore, Ireland) and then quantitated were serially diluted. Twenty serial dilutions were prepared in flat-bottomed 96-well plates for each tested protein. Daudi and Daudi-EGFR cells grown in RPMI-1680 medium were added (3×104 cells in 100 μL) to each well and were grown for an additional 60 h. in the presence of the different proteins. The number of living cells was then determined using a cell staining kit (Cell proliferation reagent WST-1, Roche) based on the colorimetric detection of the cleavage of the tetrazolium salt WST-1 into formazan. The WST-1 reaction solution was added according to the manufacturer's recommendation for a period of 4 h, after which the absorbance at 450 nm and 650 nm (reference wavelength) was recorded in an ELISA reader (Victor V, PerkinElmer).
- Quantitative Rationale for Design of Chimeric Activators:
- The design of chimeric activators with a desired cell specificity requires an understanding of the on-rates, off-rates, and equilibrium constants of each of the receptor-binding elements. An important aspect of ligand-receptor interactions is that kon is primarily limited by diffusion. The off-rate for ligand-receptor interactions is often slower than the process of receptor-mediated endocytosis, and in such cases koff is not relevant to signaling. As a result, the binding of a chimeric protein composed of a targeting element and an activity element might not be significantly influenced by the supposed targeting element. For example, EGF and IFNα2a both have similar on-rates (Table 2) (French, A. R., Tadaki, D. K., Niyogi, S. K., Lauffenburger, D. A., (1995) J Biol Chem 270(9), 4334-4340; and Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433), so that fusion of EGF to IFNα2a may have very little effect on the binding of the latter to its receptor.
-
TABLE 2 On-rates, off-rates, and dissociation constants of EGF, and wild-type and mutant IFNα2. Kon Koff Kd (1/M · seg) (1/sec) (M) Chimeric Activators (CA) EGF 1 × 106 2.6 × 10−3 2.6 × 10−9 IFNα-2a (wild-type) 3.7 × 106 1 × 10−2 3 × 10−9 IFNα-2a (wild-type) - (Gly4Ser)7 - EGF (CA-wt) IFNα-2a (K133A) 0.7 × 106 1.8 × 10−2 26 × 10−9 IFNα-2a (K133A) - (Gly4Ser)7 - EGF (CA-K133A) IFNα-2a (R144A) 0.36 × 106 4 × 10−2 120 × 10−9 IFNα-2a (R144A) - (Gly4Ser)7 - EGF (CA-R144A) IFNα-2a (R149A) Too low to 538 × 10−9 IFNα-2a (R149A) - (Gly4Ser)7 - measure EGF (CA-R149A) - In some embodiments, but without wishing to be bound by theory, for a chimeric activator to have a cell specificity driven by the targeting element, one or both of the following conditions should be met: the on-rate of the activity element should be lower than that of the targeting element, or if the off rates are faster than the internalization rate, then the equilibrium constant (Kon/Koff) of the targeting element should be higher than that of the activity element. Once such a chimeric activator binds to a cell surface via the receptor for the targeting element, binding of the activity element to its receptor should in principle be driven by its high local concentration relative to its receptor (
FIGS. 10C and D). - A rationally designed set of chimeric activators were constructed, consisting of wild-type and mutant forms of IFNα2a as the activating element, and EGF as the targeting element (
FIG. 10A ). A choice of these elements may be based on the following considerations: 1) the three-dimensional structures of the EGF/EGFR and the IFNα2a/IFNAR2 complexes have been solved or modeled (Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., Yokoyama, S., (2002) Cell 110(6), 775-787; Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H. J., Walker, F., Frenkel, M. J., Hoyne, P. A., Jorissen, R. N., Nice, E. C., Burgess, A. W., Ward, C. W., (2002) Cell 110(6), 763-773; and Roisman, L. C., Piehler, J., Trosset, J-Y., Scheraga, H. A., Schreiber, G., (2001) Proc Natl Acad Sci USA 98(23), 13231-13236), allowing appropriate positions to be chosen for linking and to design a linker of the right length; 2) a precise characterization of the on-rates, off-rates, and KDs of a series of IFNα alanine-scanning mutants was previously reported (Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433), so that a series of IFNα2a mutants could be chosen with step-wise reductions in on-rates and affinity (Table 2); and 3) the on-rates and binding constants of wild-type EGF and IFNα are similar, so that the effect of mutations should be significant. The on-rates of both proteins are thought to be faster than diffusion-limited, because they are driven by charge-complementarity between these ligands and their receptors (Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433; and Piehler, J., Schreiber, G., (1999) J Mol Biol 289(1), 57-67). Another consideration was that the molecules described here could serve as a proof-of-concept for a protein drug, and that targeting might improve the therapeutic index of a toxic molecule only by a limited amount. Thus, the fact that IFNα already has a preferential activity against abnormal cells such as cancer cells and virus-infected cells made it an attractive candidate (Platanias, L. C., (2005) Nat Rev Immunol 5(5), 375-386). - For the chimeric activator concept to work, the targeting element and activation element must be able to bind simultaneously to their respective receptors. The published structure of EGFR with a ligand and a model of the IFNα2a structure indicate that in these receptor-ligand complexes, the EGF is about 90 Å from the cell surface, and the IFNα2a is about 50 Å from the cell surface, so that a linker of at least 40 Å is needed to bridge the two elements. A standard glycine-serine linker of 35 amino acids ([Gly4Ser]7 was selected with a length of roughly 120 Å;
FIG. 10B (Huston, J. S., Tai, M. S., McCartney, J., Keck, P., Oppermann, H., (1993) Cell Biophys 22(1-3), 189-224). Four chimeric activators were constructed (Table 2). These consist of wild-type or mutant IFNα2a at the N-terminus, followed by the 35-amino acid linker, EGF, a myc epitope tag, and a (His)6 purification tag at the C-terminus. The IFNα2a mutations used were K133A, R144A, and R149A, which allow the protein to fold correctly but cause stepwise reductions in the on-rate and equilibrium binding of IFNα2a for its receptor (Table 2) (Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433). The chimeric activators carrying wild-type INFα2a and these mutant forms were termed CA-wt, CA-K133A, CA-R144A and CA-R149A, respectively.FIG. 10B shows a molecular model of an IFNα2a-EGF chimeric activator (space-filling structure), showing how the IFNα2a and EGF components can simultaneously interact with their receptors (ribbons). Models for EGF/EGFR complex (Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., Yokoyama, S., (2002) Cell 110(6), 775-787; and Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H. J., Walker, F., Frenkel, M. J., Hoyne, P. A., Jorissen, R. N., Nice, E. C., Burgess, A. W., Ward, C. W., (2002) Cell 110(6), 763-773), and the IFNα2a/IFNAR2 complex (Roisman, L. C., Piehler, J., Trosset, J-Y., Scheraga, H. A., Schreiber, G., (2001) Proc Natl Acad Sci USA 98(23), 13231-13236; Quadt-Akabayov, S. R., Chill, J. H., Levy, R., Kessler, N., Anglister, J., (2006) Protein Sci 15(11), 2656-2668), are shown with the C-termini of the receptor extracellular domains at the bottom. In each case, these C-termini are followed by the membrane-spanning segment of the receptor. - These chimeric activators and the corresponding individual IFNα2a and IFNα2a mutants were expressed in the yeast Pichia pastoris according to published methods, and purified them from culture supernatant (Clare, J. J., Romanos, M. A., Rayment, F. B., Rowedder, J. E., Smith, M. A., Payne, M. M., Sreekrishna, K., Henwood, C. A. (1991) Gene 105(2), 205-212; and Garcia, J. N., Aguiar, J. A., Gill, M., Alvarez, A., Morales, J., Ferrero, J., Gonzalez, B., Padron, G., Menendez, A., (1995)
Biotecnologia Aplicada 12, 152-155). All proteins were epitope-tagged and His6-tagged for further detection and purification. The proteins were expressed at high levels and recovered at high purity (see Experimental Procedures). - Functionality of Parts within Chimeric Activators:
- The biological activity of the targeting element, EGF, was verified in the chimeric activators by testing its ability to stimulate phosphorylation of tyrosine-1068 in EGFR. Activation of EGFR was evaluated in HeLa cells by treating them with the four chimeric proteins, a commercial recombinant EGF as a positive control, and IFNα2a tagged with c-myc and His6 as a negative control.
FIG. 11 illustrates the induction of phosphorylation of the EGFR by the different chimeric proteins as well for the rEGF control (lanes 2 to 7). HeLa cells were stimulated for 5 minutes with vehicle (PBS; lane 1) EGF (lane 2), chimeric activators containing wild-type EGF linked to wild-type or mutant IFNα2a (lanes 3-7), or wild-type IFNα2a protein expressed from Pichia pastoris in the same manner as the chimeric activators (lane 8). EGF receptor immunoprecipitated from stimulated HeLa cell lysates were separated by SDS-PAGE, then immunoblotted for Tyr1068-phosphorylated EGF receptor (top) or total EGF receptor (bottom). Cells treated only with PBS (vehicle) or with tagged IFNα do not show detectable activity (lanes 1 and 8). To test the activity of the IFNα portion of the chimeric activators, the phosphorylation of STAT1 tyrosine 701 (a consequence of IFN-α receptor activation;FIG. 12 ) was examined by Western blot. These experiments demonstrated that the EGF and IFNα2a components of the chimeric proteins were both active and that the mutations K133A, R144A, and R149A reduced the activity of the tagged IFNα2a to a degree similar to the reductions previously reported (Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433). - Activity of IFNα2a-EGF Chimeric Activators Depends on EGFR:
- It was tested whether the IFNα2a-EGF chimeric proteins could signal through IFNAR in an EGFR-dependent manner by comparing their activity with the activity of the corresponding IFNα2a (mutant) protein in cells expressing both EGFR and IFNAR. Two different epithelial cell lines were used with varying levels of EGFR expression: A431 cells, which show high expression of EGFR (˜2×106 EGFR/cell), and HeLa cells, which show moderate expression of EGFR (2×104 EGFR/cell) (Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., Mendelsohn, J., (1984) Cancer Res 44(3), 1002-1007). In
FIG. 12 , starved HeLa (A), A431 (B), Daudi (C), or Daudi-EGFR (D) cells were incubated for 30 minutes with PBS (vehicle), commercial IFNα A, EGF, IFNα/EGF chimeric activator proteins containing wild-type or mutant IFNα-2a (CAwt CAK133A, CAR144A, or CAR149A), or the corresponding wild-type or mutant IFNα2a proteins produced from Pichia. Lysates were prepared and immunoblots performed probing with an anti-STAT1(pTyr701) antibody, and with an anti-actin antibody as a loading control (in some examples, similar immunoblots were prepared in which lanes were scanned with a densitometer and the phospho-STAT1 signal normalized to the actin signal). HeLa, A431, and Daudi-EGFR cells express both EGFR and IFNAR, while Daudi cells express only IFNAR. Quantification by FACs analysis confirmed the expression levels of EGFR and IFNAR. The results indicated that an IFNα2a-EGF chimeric activator (without a mutation) and IFNα2a alone induced interferon signaling with about equal efficiency (FIGS. 12A and B, lanes 4-9), and that the IFNα2a mutant proteins K133A, R144A, and R149A, which respectively are reduced by 10×, 40×, and 200× for IFNAR binding (Table 1), show correspondingly low levels of IFNα signaling (FIGS. 12A and B, lanes 13-15, 19-22 and 26-29). - The chimeric activators with EGF fused to the mutant IFNα2a showed higher levels of IFNα signaling than the corresponding IFNα2a mutants alone, however. For example, in HeLa and A431 cells pSTAT1 was activated when cells were treated with CAR44A and CAR9A (
FIGS. 12A and B, lanes 16-18 and 23-25) but not when the cells are treated with the corresponding IFNα2a mutants, even at higher concentrations (FIGS. 12A and B,lanes 22 and 29). No synergistic effect was seen when cells were treated with a combination EGF and any of the various IFNα2a mutants□ (data not shown). - As a second way to test whether the enhancement of IFNα signaling depends on binding to EGFR, EGFR was introduced into the Daudi cell line, which does not normally express this receptor and compared IFNα signaling in this engineered line to that seen in the parent cell line. The Daudi cell line is derived from a human Burkitt's lymphoma cell, and its proliferation and survival are inhibited by IFNα (Evinger, M., Pestka, S., (1981) Methods in Enzymology 79(Pt B), 362-368). The function of the chimeric activators on Daudi and Daudi-EGFR cells clearly depended on the presence of the receptor for the targeting element (
FIGS. 12C and D). The CAR149A protein stimulated STAT1 phosphorylation only in Daudi-EGFR cells (FIG. 12D , lanes 23-25) and not in the Daudi parental cell line (FIG. 12C , lanes 26-29). The CAwt and IFNα2a proteins were active in both cell lines, as expected, whereas the IFNα2aR149A mutant showed only slight activity at high concentrations. Chimeric activators containing the intermediate-strength mutations CAK133A and CAR144A gave intermediate levels of signaling in Daudi cells, consistent with their predicted properties, and showed quantitative enhancements in signaling relative to IFNα2aK133A and IFNα2aR144A in Daudi-EGFR cells (FIG. 12D , lanes 10-22). - The activities of the chimeric activators differed on the various cell lines (
FIG. 12 ). Without wishing to be bound by theory, these cell-type differences may be due to differences at the level of receptor expression, although the HeLa, Daudi, and A431 cell lines have different tissue origins and oncogenic mutations, so that any comparison of results between these lines can only be suggestive. Daudi cells have 10-20 times more IFNAR molecules at the cell surface than do HeLa and A431 cells, which may explain the greater level of IFNAR activation in Daudi cells, for example in response to CAR144A and IFNα2a(R144A). - As an additional control, it was tested whether signaling by IFNα2a(mutant)-EGF chimeric activators could be inhibited by an antibody against the receptor for the targeting element (
FIG. 13 ). InFIG. 13 , HeLa cells were pre-treated for 2 hours with 1 μg/mL ofmAb 528, a mouse monoclonal antibody which prevents EGF from binding to EGFR (even-numbered lanes), followed by treatment for 30 minutes with vehicle (lanes 1-2), or 1.5 nM of commercial IFNα A (lanes 3-4), IFNα/EGF chimeric activator proteins containing wild-type or mutant IFNα-2a (CAwt, lanes 5-6; CAK133A, lanes 9-10; CAAR144A, lanes 13-14; or CAR149A, lanes 17-18), or the corresponding wild-type or mutant IFNα2a proteins (lanes 7-8, 11-12, 15-16, and 19-20). Pre-treatment of HeLa cells for 2 h. with the mouse monoclonalanti-EGFR antibody 528 inhibits the activation of the STAT1 signaling pathway by the K144A and R149A mutant chimeric activators (FIG. 13 , lanes 13-14 and 17-18), but not the activation caused by the non-chimeric IFNα2a and mutants. Neither the wild-type IFNα2a nor the CAwt showed inhibition (FIG. 13 , lanes 5-6, 9-10), as expected. The 528 antibody does not itself activate the EGF or the IFNα signal cascades. Treatment withmAb 528 appeared to have no effect on signaling induced by the CA-K133A protein. Since the IFNα element retains significant binding to the IFNAR, it is possible that this chimera was able to displace the antibody from the EGFR during the 30-minute course of the experiment. - EGFR-Dependent Inhibition of Cell Proliferation by Chimeric Activators:
- The ability of the chimeric proteins to suppress the proliferation of Daudi and Daudi-EGFR cells is shown in
FIG. 14 . InFIG. 14 , Daudi and Daudi-EGFR cells were grown for 60 hours in the presence of various concentrations of IFNα2a-EGF chimeric proteins or the corresponding IFNα2a proteins purified from Pichia. The relative number of viable cells was determined by the production of formazan, which absorbs at A460, from tetrazolium. Curves were fit to the data using a 4-parameter fit (Microcal Origin 5.0). In both cell lines, a dose-dependent growth inhibition was observed. When Daudi cells were treated with the chimeric activators and their IFNα2a counterparts, essentially no difference in their IC50s was found (FIGS. 14A-C ). Furthermore, the ability to inhibit proliferation diminished according to the ability to bind to IFNAR and activate STAT1. - The chimeric activators, relative to their IFNα counterparts, showed enhanced inhibition of cell proliferation and survival of Daudi-EGFR cells (
FIGS. 14E and F). The chimeric activators containing the mutations K133A and R144A were about 10-fold and 100-fold more potent, respectively, than the corresponding IFNα2a mutants alone. CAR149A weakly inhibited proliferation in a pattern that could not be fit to a sigmoid curve (data not shown) and its activity relative to the corresponding IFNα2a mutant therefore could not be quantified. - The behavior of the Daudi-EGFR cells was somewhat affected by the presence of EGFR, which may contribute pro-survival signals. The IC50s of wild-type and mutant IFNαs were about 5- to 6-fold higher in Daudi-EGFR (
FIG. 14 ). The maximal extent of proliferation inhibition was also less than for cells treated with IFNα mutants alone. These results are consistent with previous observations that EGF can antagonize the antiproliferative and pro-death effects of IFNα (Caraglia, M., Abbruzzese, A., Leardi, A., Pepe, S., Budillon, A., Baldassare, G., Selleri, C., Lorenzo, S. D., Fabbrocini, A., Giuberti, G., Vitale, G., Lupoli, G., Bianco, A. R., Tagliaferri, P., (1999) Cell Death Differ 6(8), 773-780). - Accordingly, in the experiments described herein, it was evaluated whether the cell-type specificity of an extracellular signaling protein could be altered by a combination of genetic fusion followed by quantitative modulation. The results have implications for understanding the natural design of multisubunit proteins and ligand-receptor interactions, as well as for the design of artificial proteins targeted to cancer cells and other types of disease-causing cells.
- In some embodiments, the goal of a particular design was to alter the cell-type specificity of IFNα so that it would only activate its receptor on cells bearing EGFR. EGF was attached to IFNα2a with a flexible linker, so that both modules could simultaneously bind to their receptors. IFNα2a also was mutated so that its ability to bind to its receptor would be significantly reduced, using a set of previously defined mutations that reduce the equilibrium binding of IFNα2a for its receptor by 10-, 40- and 200-fold (Piehler, J., Roisman, L. C., Schreiber, G., (2000) J Biol Chem 275(51), 40425-40433). The purpose was to generate a chimeric protein that would be essentially unable to bind directly to IFNARs, but would bind to EGFR with high affinity. By virtue of the high local concentration of the chimera on the cell surface, the IFNα2a module would then be able to bind to its receptor.
- Several lines of evidence indicated that the resulting chimerized, mutated proteins induced IFNα signaling in an EGFR-dependent manner. First, a comparison of IFNα2a(mutant)-EGF chimeras with their unchimerized IFNα2a(mutant) counterparts in HeLa and A431 cells, which express both EGFR and IFNAR, showed that the chimeric proteins were more potent in inducing STAT1 phosphorylation, which results specifically from the activation of IFNAR (
FIG. 12 ). As expected, the differential effect was particularly pronounced for chimeric activators carrying mutations that significantly reduce IFNα binding to its receptor. In contrast, IFNα2a-EGF (CA-wt) was essentially indistinguishable from wild-type IFNα2a; this result is expected because the binding of IFNα to its receptor is quantitatively similar to that for EGF. Second, the activities of the chimerized and unchimerized proteins were compared on Daudi cells and Daudi cells engineered to express EGFR. These results indicated that the enhanced stimulation of STAT1 phosphorylation by the EGF chimeras depended on the presence of EGFR on the cell surface. The improved selectivity of the mutant chimeric activators seen with HeLa and A431 cells was reproduced in Daudi-EGFR cells, but not in parental Daudi cells. Third, the stimulation of STAT1 phosphorylation could be inhibited by an anti-EGFR antibody. - The chimeric activator proteins described here induced a biological response in an EGFR-dependent manner. The proliferation and survival of Daudi cells is inhibited by IFNα2a. Daudi cells expressing EGFR were found to be more sensitive than parental Daudi cells to IFNα2a(mutant)-EGF chimeric activators by up to more than order of magnitude (
FIG. 14 ). In a therapeutic context, the Daudi-EGFR cells may be considered to represent target cells, the parental Daudi cells may represent non-target cells where receptor activation results in side effects, and the differential effect corresponds to the therapeutic index of a protein drug. Thus, by reducing the binding of a given activator and attaching it to a targeting element, the therapeutic index can be improved by more than an order of magnitude. - According to aspects of the invention, the artificial localization/activation system described herein is reminiscent of interactions seen in a number of biological systems. For example, during signal transduction, kinases such as Raf and PDK1 are recruited to the inner face of the cytoplasmic membrane (McKay, M. M., Morrison, D. K., (2007) Oncogene 26(22), 3113-3121), which may enhance the rate of signal transduction as predicted by Adam and Delbruck (Adam, G., Delbruck, M., (1968) Reduction of dimensionality in biological diffusion processes—in: Rich A, Davidson N, editors, Structural chemistry and molecular biology, San Francisco: W. H. Freeman and Co. p. 198-215), by reducing the dimensionality in which substrates can diffuse. In the case of PDK1, a distinct targeting element, the PH domain, interacts with PIP3 in the membrane so that an activity element, the kinase domain itself, can act on its substrates. The binding of HIV gp120 to its target cells also occurs by a two-step process, in which cell-specific targeting occurs through CD4, followed by an activation step mediated by a chemokine receptor (Chan, D. C., Kim, P. S., (1998) Cell 93(5), 681-684; and Blair W S, Lin P-F, Meanwell N A, Wallace O B., (2000) Drug Discovery Today 5(5), 183-194). The interaction between IL-2 and its receptor can occur through an initial contact with a non-signaling receptor subunit, which is followed by a lower-affinity interaction with signaling receptors (Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A., Wilson, I. A., (2003) Proc Natl Acad Sci USA 103(8), 2788-2793); IL-2 is somewhat analogous to CA-K133A, which has a reduced binding to IFNAR that can be augmented by an additional receptor subunit, with EGFR playing a similar role to the IL-2Rα subunit. These results suggest that such natural interactions can evolve from rather arbitrary associations of transmembrane proteins—for example, there does not need to be any pre-existing interaction between CD4 and chemokine receptors or between IL-2Rα and the other IL-2 receptors for HIV or IL-2 respectively to bind to these combinations of proteins.
- Aspects of the invention take advantage, at least in part, of intellectual developments in quantitative systems biology and differ from other targeting approaches in two key respects. First, anticipating that the improvement in cell-type specificity of a chimeric activator might be modest in an initial design, an activator with well-characterized side effects was chosen: IFNα2a by itself is already an approved drug for certain diseases. Second, the chimeric molecule was designed to bind simultaneously to two receptors so that the effect of a reduction-of-function mutation in the activity element is reduced or eliminated by the high local concentration of this element in the neighborhood of its receptor after binding to the targeting receptor.
- In some embodiments, aspects of the invention can use a tumor-specific antibody as a targeting element. The molecular designs reported here depended in part on structural models of both the IFNα/IFNAR2 and EGF/EGFR complexes. Use of antibody V regions in chimeric activators will become more feasible as more structures of antibody-receptor complexes are solved (Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., Sliwkowski, M. X., (1994) Cancer Cell 5(4), 317-328; and Cho, H-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney Jr, D. W., Leahy, D. J., (2003) Nature 421(6924), 756-760).
- In summary, artificial signaling molecules were constructed based on quantitative principles. According to aspects of the invention, these principles may be used to design and produce chimeric molecules that are useful for therapeutic applications. In addition, further analysis of these principles may allow the further improvement of protein therapeutics and a deeper understanding of the forces that shape natural biological system design.
- The abbreviations used in the description of these examples are as follows: CA, chimeric activator; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; IFNα2a, interferon-alpha2a; IFNAR, IFNα receptor; IL-2, interleukine-2; Mut+, methanol utilization wild-type; MutS, methanol utilization slow; TGFα, tumor growth factor α; STAT-1, signal transducer and
activator 1. - TRAIL, also known as Apo2L, is a member of the TNF family of proteins, and binds to ‘death receptors’ such as DR5. TRAIL acts similarly to TNF, but it is thought that TRAIL causes only cell death without accompanying inflammation. The following sequences were designed in which TRAIL is fused to the V regions of the antibody MR1-1, which is described above.
-
PROTEIN SEQUENCE: ATR14: SEQ ID NO: 18: QVKLQQSGGGLVKPGASLKLSCVTSGFTFRKFGMSWVRQTSDKRLEWVAS ISTGGYNTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCTRGY SPYSYAMDYWGQGTTVTVS (HEAVY) SEQ ID NO: 19: SSGGGSGGGGSGGGGS SEQ ID NO: 20: DIELTQSPASLSVATGEKVTIRCMTSTDIDDDMNWYQQKPGEPPKFLISE GNTLRPGVPSRFSSSGTGTDFVFTIENTLSEDVGDYYCLQSWNVPLTFGd GTKLEIK (Light) LINKER: SEQ ID NO: 21: GGGGSGGGSSGGGSSSGGGGSGGGGSSGGGSGGGS TRAIL: SEQ ID NO: 22: RERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFL SNIHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYT SYPAPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEH LIDMDREASFFGAFLVG MR1-1: SEQ ID NO: 23: QVKLQQSGGGLVKPGASLKLSCVTSGFTFRKFGMSWVRQTSDKRLEWVAS ISTGGYNTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCTRGY SPYSYAMDYWGQGTTVTVSSSGGGSGGGGSGGGGSDIELTQSPASLSVAT GEKVTIRCMTSTDIDDDMNWYQQKPGEPPKFLISEGNTLRPGVPSRFSSS GTGTDFVFTIENTLSEDVGDYYCLQSWNVPLTFGdGTKLEIKGGGGSGGG SSGGGSSSGGGGSGGGGSSGGGSGGGS RERGPQRVAAHITGTRGRSNTLS SPNSKNEKALGRKINSWESSRSGHSFLSNIHLRNGELVIEEKGFYYIYSQ TYFRFQEEIKENTKNDKQMVQYIYKYTSYPAPILLMKSARNSCWSKDAEY GLYSIYQGGIFELKENDRIFVSVTNEHLIDMDEEASFFGAFLVG DNA SEQUENCE: SEQ ID NO: 24: CAAGTTAAGTTGCAACAATCCGGTGGTGGTTTGGTTAAGCCAGGTGCTTC TTTGAAGTTGTCTTGTGTTACTTCTGGTTTTACTTTTAGAAAGTTTGGTA TGTCTTGGGTTAGACAAACTTCTGATAAGAGATTGGAATGGGTTGCTTCT ATTTCTACTGGTGGTTACAACACTTACTACTCTGATAACGTTAAGGGTAG ATTTACTATTTCCAGAGAGAACGCTAAGAACACTTTGTACTTGCAAATGT CTTCTTTGAAGTCTGAAGATACTGCTTTGTACTACTGTACTAGAGGTTAC TCTCCATACTCTTACGCTATGGATTACTGGGGTCAAGGTACTACTGTTAC TGTTTCTTCCTCCGGTGGAGGTTCCGGTGGTGGAGGATCTGGTGGTGGTG GTTCTGATATTGAGTTGACTCAATCTCCAGCTTCTTTGTCTGTTGCTACT GGTGAGAAGGTTACTATTAGATGTATGACTTCTACTGATATTGATGATGA TATGAACTGGTACCAACAAAAGCCAGGTGAACCACCAAAGTITTTGATTT CTGAAGGTAACACTTTGAGACCAGGTGTTCCATCCAGATTTTCTTCTTCT GGTACTGGTACTGATTTTGTTTTTACTATTGAGAACACTTTGTCTGAAGA TGTTGGTGATTACTACTGTTTGCAATCTTGGAACGTTCCATTGACTTTTG GTGATGGTACTAAGTTGGAGATTAAGGGAGGAGGTGGTTCCGGTGGTGGT TCTTCCGGAGGTGGTTCTTCCTCTGGAGGTGGTGGTTCAGGTGGAGGTGG TTCCTCTGGAGGTGGTTCTGGTGGAGGTTCC AGAGAAAGAGGTCCACAAA GAGTTGCTGCTCACATTACTGGTACTAGAGGTAGATCTAACACTTTGTCT TCTCCAAACTCTAAGAACGAAAAGGCTTTGGGTAGAAAGATTAACTCTTG GGAGTCTTCCAGATCTGGTCATTCTTTCTTGTCTAACTTGCATTTGAGAA ACGGTGAATTGGTTATTCATGAGAAGGGTTTCTACTACATTTACTCTCAA ACTTACTTTAGATTTCAAGAAGAAATTAAGGAGAACACTAAGAACGATAA GCAAATGGTTCAATACATTTACAAGTACACTTCTTACCCAGCTCCAATTT TGTTGATGAAGTCTGCTAGAAACTCTTGTTGGTCTAAGGATGCTGAATAC GGTTTGTACTCTATTTACCAAGGTGGTATTTTCGAATTGAAGGAGAACGA TAGAATTTTCGTTTCTGTTACTAACGAACATTTGATTGATATGGATCACG AAGCTTCTTTCTTTGGTGCTTTTTTGGTTGGT - The sequences are highlighted so that the first and third segments (regular text) are the heavy chain V region and the light chain V region respectively. The second (bolded text) is a linker, the fourth (underlined text) is a longer linker, and the fifth segment (italicized text) is TRAIL or an active fragment of TRAIL. In the case of the sequence shown, the active fragment corresponds to amino acids 115-281 and is 1.5 times more bioactive than the full-length TRAIL (Hymowitz et al. Biochemistry, Vol. 39, No. 4, p. 633 (2000)).
- Three different mutant forms of TRAIL can be used, containing the mutations:
- The chimeric proteins containing normal TRAIL and the mutations X, Y, and Z were tested for their ability to induce apoptosis in the glioblastoma cells U87MG and their engineered derivative U87MG-EGFRvIII. EGFRvIII is a deleted derivative of EGFR that is found in some cancers and contains a novel peptide junction that is recognized by the antibody MR1-1.
- The following results will be obtained. Plus signs indicate levels of apoptosis by viability and apoptosis signaling assays. Apoptosis assessed by viability assay will be measure by using the cell proliferation reagent WST-1. Apoptosis signaling will be measure by caspase activation using antibodies directed against caspase-8 and active caspase-3.
-
U87MG U87MG-EGFRvIII TRAIL (+) ++++ ++++ TRAIL (Q205A) ++ ++ TRAIL (Y216A) + + TRAIL (Y237A) − − MR1-1 - TRAIL (+) ++++ ++++ MR1-1 - TRAIL (Q205A) ++ ++++ MR1-1 - TRAIL (Y216A) + +++ MR1-1 - TRAIL (Y237A) − ++ - Sequences of chimeric activators also were designed using the antibody V regions from a humanized version of the antibody T84.66, which is directed against carcinoembryonic antigen (CEA). Carcinoembryonic antigen is a protein that is highly expressed on colon cancers, lung cancers, breast cancers, and other types of cancer. It is expressed in only small amounts on normal tissues in the gastrointestinal tract. CEA is also highly expressed in the tumor cell lines GW39, LS147T and SW1417.
- The CEA protein has seven extra cellular immunoglobulin-family domains and is attached to the cell surface by means of a lipid anchor at its C-terminus; this protein contains no intracellular amino acids. A large number of antibodies against CEA have been identified, of which T84.66 and MFE-23 are particularly well characterized. The antibody T84.66 was chosen because it binds somewhere within the two most membrane-proximal domains (Hass et al. Cancer Research [1991] 51:1876), while MFE-23 binds to a much more membrane-distal domain that might lie more than 200 angstroms from the cell surface (Boehm and Perkins, FEBS Letters [2000] 475:11). The T84.66 binding site therefore appears to be about the same height from the cell membrane as the TRAIL N- and C-termini, and also the IFNα N- and C-termini, when these ligands are bound to their receptors.
- Based on these considerations, a chimeric activator was designed containing humanized T84.66 V regions and TRAIL.
-
PROTEIN SEQUENCE: T84.66: SEQ ID NO: 25: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYMHWVRQAPGKGLEWVAR IDPANGNSKYVPKFQGRATISADTSKNTAYLQMNSLRAEDTAVYYCAPFG YYVSDYAMAYWGQGTLVTVSS (HEAVY) SEQ ID NO: 26: SSSGGGSGGGGSGGGGS SEQ ID NO: 27: DIQLTQSPSSLSASVGDRVTITCRAGESVDIFGVGFLHWYQQKPGKAPKL LIYRASNLESGVPSRFSGSGSRTDFTLTISSLQPEDFATYYCQQTNEDPY TF GQGTKVEIK (light) LINKER: SEQ ID NO: 28: GGGGSGGGSSGGGSSSGGGGSGGGGSSGGGSGGGS TRAIL: SEQ ID NO: 29: RERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFL SNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYT SYPAPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEH LIDMDHEASFFGAFLVG T84.66: SEQ ID NO: 30: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYMHWVRQAPGKGLEWVAR IDPANGNSKYVPKFQGRATISADTSKNTAYLQMNSLRAEDTAVYYCAPFG YYVSDYAMAYWGQGTLVTVSSSSSGGGSGGGGSGGGGSDIQLTQSPSSLS ASVGDRVTITCRAGESVDIFGVGFLHWYQQKPGKAPKLLIYRASNLESGV PSRFSGSGSRTDFTLTISSLQPEDFATYYCQQTNEDPYTFGQGTKVEIKG GGGSGGGSSGGGSSSGGGGSGGGGSSGGGSGGGS RERGPQRVAAHITGTR GRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKG FYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPAPILLMKSARNSC WSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLV G DNA SEQUENCE: SEQ ID NO: 31: GAAGTTCAATTGGTTGAATCTGGAGGTGGTTTGGTTCAACCAGGTGGTTC TTTGAGATTGTCTTGTGCTGCTTCTGGTTTTAACATTAAGGATACTTACA TGCATTGGGTTAGACAAGCTCCAGGTAAGGGTTTGGAATGGGTTGCTAGA ATTGATCCAGCTAACGGTAACTCTAAGTACGTTCCAAAGTTTCAAGGTAG AGCTACTATTTCTGCTGATACTTCTAAGAACACTGCTTACTTGCAAATGA ACTCTTTGAGAGCTGAAGATACTGCTGTTTACTACTGTGCTCCATTTGGT TACTACGTTTCTGATTACGCTATGGCTTACTGGGGTCAAGGTACTTTGGT TACTGTTTCTTCCTCCTCTTCTGGTGGAGGTTCTGGAGGTGGTGGATCTG GTGGAGGTGGTTCTGATATTCAATTGACTCAATCTCCATCTTCTTTGTCT GCTTCTGTTGGTGATAGAGTTACTATTACTTGTAGAGCTGGTGAATCTGT TGATATTTTTGGTGTTGGTTTTTTGCATTGGTACCAACAAAAGCCAGGTA AGGCTCCAAAGTTGTTGATTTACAGAGCTTCTAACTTGGAATCTGGTGTT CCATCCAGATTTTCTGGTTCTGGTTCCAGAACTGATTTTACTTTGACTAT TTCTTCTTTGCAACCAGAAGATTTTGCTACTTACTACTGTCAACAAACTA ACGAAGATCCATACACTTTTGGTCAAGGTACTAAGGTTGAAATTAAGGGT GGAGGAGGTTCTGGTGGTGGATCTTCCGGAGGTGGTTCTTCCTCTGGAGG TGGTGGTTCAGGTGGAGGTGGTTCCTCTGGAGGTGGTTCTGGTGGAGGTT CC AGAGAAAGAGGTCCACAAAGAGTTGCTGCTCACATTACTGGTACTAGA GGTAGATCTAACACTTTGTCTTCTCCAAACTCTAAGAACGAAAAGGCTTT GGGTAGAAAGATTAACTCTTGGGAGTCTTCCAGATCTGGTCATTCTTTCT TGTCTAACTTGCATTTGAGAAACGGTGAATTGGTTATTCATGAGAAGGGT TTCTACTACATTTACTCTCAAACTTACTTTAGATTTCAAGAAGAAATTAA GGAGAACACTAAGAACGATAAGCAAATGGTTCAATACATTTACAAGTACA CTTCTTACCCAGCTCCAATTTTGTTGATGAAGTCTGCTAGAAACTCTTGT TGGTCTAAGGATGCTGAATACGGTTTGTACTCTATTTACCAAGGTGGTAT TTTCGAATTGAAGGAGAACGATAGAATTTTCGTTTCTGTTACTAACGAAC ATTTGATTGATATGGATCACGAAGCTTCTTTCTTTGGTGCTTTTTTGGTT GGT - Protein activity is measured as in the previous example but using LS147T and SW1417 cell lines.
- Erythropoietin (Epo) is a hormone that stimulates production of red blood cells. Epo can be used to treat anemia that may be part of many disease conditions, but is used primarily in two settings. First, kidney failure patients usually do not produce adequate levels of Epo, which is expressed mainly in the kidneys, and are therefore anemic. Second, cancer patients often become anemic as a result of chemotherapy treatment, which kills dividing cells including red blood cell precursors.
- Use of erythropoietin can also affect platelet production, possibly because receptors for Epo are also found on hematopoietic precursor cells that give rise to platelets. In addition, Epo receptors are sometimes found on cancer cells, and Epo may enhance tumor cell growth and angiogenesis. It would be useful to have a form of Epo that only stimulated red blood cell production and did not bind to Epo receptors on other cells, such as cancer cells or early hematopoietic stem cells that can give rise to other cell types.
- By way of background, a person is considered to be anemic if their hemoglobin levels are less than 12 grams/deciliter for women or <14 g/dl for men. These values correspond to a hematocrit of 37% for women and 40% for men, and a red blood cell count of 4×1012/l for women and 4.5×1012 for men. Usually when people are treated with Epo, the levels of red blood cells are not fully restored, since this is associated with an increased rate of heart attack and stroke.
- Recent studies suggest that Epo may in fact accelerate tumor growth in human patients (reviewed by Khuri, F R [2007] New England Journal of Medicine 356:24:2445-2448; and Crawford, [2007] Journal of Clinical Oncology 25:9:1021-1023). This is disappointing, because it had been thought that increasing red blood cell counts in cancer patients would increase their quality of life, and also increase the oxygenation of tumors, making them more sensitive to radiation and other types of treatments.
- In one study, patients with non-small cell lung cancer were given erythropoietin or a placebo, and the treated group was found to have decreased overall survival (Wright et al. 25:9:1027-1032). In another study, breast cancer patients received Epo or a placebo, and again the treated group had decreased survival (Leyland-Jones et al. [2005] Journal of Clinical Oncology 23:25:5960-5972). In this study, the patients in each group with higher hemoglobin levels survived longer, so it does not appear that the increase in red blood cells caused by Epo was the cause of the decreased survival. In an important pair of studies, Henke et al. studied the effect of Epo treatment on patients with head and neck cancer, and found that the treated group survived less well than the placebo group (Henke et al. [2003] Lancet 362:9392:1255-60). They then tested the tumors from these patients for expression of Epo receptors, and found that, in the Epo-treated group, patients with tumors expressing Epo receptors did not survive as long as patients whose tumors did not express Epo receptors. In the placebo group, patients did about equally well regardless of whether their tumors expressed Epo receptors (Henke et al. [2006] Journal of Clinical Oncology 24:29:4708-4713). These results strongly indicate that Epo can shorten the survival of cancer patients by bind to Epo receptors on tumor cells and enhancing the growth or survival of the tumor cells.
- Glycophorin is a highly expressed protein on the surface of red blood cells. Glycophorin is also expressed on the precursors of red blood cells (Southcott et al. Blood 12:4425). During production of red blood cells, precursor hematopoietic stem cells (HSCs) undergo a series of differentiation steps as follows:
-
- HSCs→BFU-E→CFU-E→terminal red blood cells
where BFU-E and CFU-E are ‘blast-forming unit’ and ‘colony-forming unit’. BFU-E cells produce about 50,000 red blood cells, while CFU-E cells produce about 1,000 red blood cells. CFU-E cells are particularly dependent on erythropoietin for survival and cell division (Adamson et al. Blood Cells [1978] 4:89). By constructing a molecule that is targeted to glycophorin-expressing cells, red blood cell production may be stimulated without affecting other cell types.
- HSCs→BFU-E→CFU-E→terminal red blood cells
- Glycophorin A exists in two allelic forms, M and N, which define the M and N blood groups. These forms differ at the N-terminus as follows (Czerwinski et al [1998] The Journal of Immunology 160: 4406-4417)
-
1 2 3 4 5 M: NH2 Ser Ser Thr Thr Gly . . . . (SEQ ID NO: 32) N: NH2 Leu Ser Thr Thr Glu . . . . (SEQ ID NO: 33)
Catimel B. et al. Journal of Immunological Methods [1993] 165:183 described a monoclonal antibody, 10F7MN that recognizes the N and M-type of glycophorin A. It should be noted that certain serine and threonine residues in glycophorin are 0-glycosylated, and the 10F7MN antibody actually recognized a combination of the amino acid and sugar structures. Based on the sequence of the 10F7MN V regions and human erythropoietin, a series of chimeric activators were designed with the following general structure: 10F7MN (heavy chain V region)-short linker-10F7MN (light chain V region)-long linker-erythropoietin. The specific sequence design shown below uses the original mouse-derived V regions of 10F7MN, but it is also possible to use a humanized pair of V regions. (Use of other monoclonal antibody directed against glycophorin is also possible, such as GPA105, [Wasniowska et al., Mol. Immunol. {1992} 29:6:783-91] or 5F4). -
PROTEIN SEQUENCE: 10F7MN: SEQ ID NO: 34: MAQVKLQQSGAELVKPGASVKLSCKASGYTFNSYFMHWMKQRPVQGLEW IGMIRPNGGTTDYNEKFKNKATLTVDKSSNTAYMQLNSLTSGDSAVYYC ARWEGSYYALDYWGQGTTVTVSS (HEAVY) SEQ ID NO: 35: GGGGSGGGGSSGGGGSS SEQ ID NO: 36: DIELTQSPAIMSATLGEKVTMTCRASSNVKYMYWYQQKSGASPKLWIYY TSNLASGVPGRFSGSGSGTSYSLTISSVEAEDAATYYCQQFTSSPYTFG GGTKLEIKRAAA (light) Linker: SEQ ID NO: 37: GGGGSGGGSSGGGSSSGGGGSGGGGSSGGGSGGGS EPO: SEQ ID NO: 38: APPRLICDSRVLQRYLLEAKEAENITTGCAEHCSLNENITVPDTKVNF YAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVD KAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRV YSNFLRGKLKLYTGEACRTGDR 10F7MN: SEQ ID NO: 39: MAQVKLQQSGAELVKPGASVKLSCKASGYTFNSYFMHWMKQRPVQGLE WIGMIRPNGGTTDYNEKFKNKATLTVDKSSNTAYMQLNSLTSGDSAVY YCARWEGSYYALDYWGQGTTVTVSSGGGGSGGGGSSGGGGSSDIELTQ SPAIMSATLGEKVTMTCRASSNVKYMYWYQQKSGASPKLWIYYTSNLA SGVPGRFSGSGSGTSYSLTISSVEAEDAATYYCQQFTSSPYTFGGGTK LEIKRAAAGGGGSGGGSSGGGSSSGGGGSGGGGSSGGGSGGGS APPRL ICDSRVLQRYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKR MEVGQQAVEVWQGLALLSEAVLRGQALLVMSSQPWEPLQLHVDKAVSG LRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFL RGKLKLYTGEACRTGDR DNA SEQUENCE: SEQ ID ND: 40: ATGGCTCAAGTTAAGTTGCAACAATCTGGTGCTGAATTGGTTAAGCCA GGTGCTTCTGTTAAGTTGTCTTGTAAGGCTTCTGGTTACACCTTCAAC TCTTACTTTATGCATTGGATGAAGCAAAGACCAGTTCAAGGTTTGGAA TGGATTGGTATGATTAGACCAAACGGTGGTACTACCGATTACAACGAG AAGTTTAAGAACAAGGCTACTTTGACTGTTGATAAGTCCTCTAACACT GCTTACATGCAATTGAACTCTTTGACTTCTGGTGATTCTGCTGTTTAC TACTGTGCTAGATGGGAAGGTTCTTACTACGCTTTGGATTACTGGGGT CAAGGTACCACTGTTACTGTTTCTTCCGGTGGAGGTGGATCTGGTGGT GGAGGATCTTGAGGAGGTGGTGGATCTTCCGATATTGAGTTGACTCAA TCTCCAGCTATTATGTCTGCTACCTTGGGTGAGAAGGTTACTATGACT TGTAGAGCTTCATCTAACGTTAAGTACATGTACTGGTACCAACAGAAG TCTGGTGCTTCTCCAAAGTTGTGGATTTACTACACTTCTAACTTGGCT TCTGGTGTTCCAGGTAGATTTTCTGGTTCAGGTTCTGGTACTTCCTAC TCTTTGACTATTTCCTCTGTTGAAGCTGAAGATGCTGCTACTTACTAC TGTCAACAATTCACTTCTTCCCCATACACTTTTGGAGGAGGTACTAAG TTGGAAATCAAGAGAGCTGCCGCAGGTGGAGGTGGTTCCGGAGGAGGA TCTTCCGGTGGTGGATCTTCTTCTGGAGGTGGAGGATCCGGTGGTGGA GGATCATCTGGTGGAGGATCTGGTGGTGGTTCC GCTCCACCTAGATTG ATTTGTGATTCCAGAGTTTTGGAAAGATACTTGTTGGAAGCTAAGGAG GCTGAAAAGATTACTACTGGTTGTGCTGAACATTGTTCTTTGAACGAG AAGATTACTGTTCCAGATACTAAGGTTAACTTTTACGCTTGGAAGAGA ATGGAAGTTGGTCAGCAAGCTGTTGAAGTTTGGCAAGGTTTGGCTTTG TTGTCTGAAGCTGTTTTGAGAGGTCAAGCTTTGTTGGTTAAGTCTTCT CAACCATGGGAACCATTGCAATTGCATGTTGATAAGGCTGTTTCTGGT TTGAGATCTTTGACTACCTTGTTGAGAGCTTTGGGTGCTCAAAAGGAA GCTATTTCTCCTCCAGATGCTGCTTCTGCCGCTCCATTGAGAACTATT ACTGCTGATACTTTTAGAAAGTTGTTTAGAGTTTACTCTAACTTCTTG AGAGGTAAGTTGAAGTTGTACACTGGTGAAGCTTGTAGAACTGGTGAT AGA
(The length of the long linker may need to be varied depending on which anti-glycophorin antibody is used and where the epitope is.) - This molecule will be expressed in Pichia pastoris. Because Epo is glycosylated at a number of sites and it will ultimately be useful to have a molecule with mammalian-type glycosylation, a 10F7MN-Epo chimeric activator also will be expressed in a mammalian cell line such as CHO cells.
- To reduce the activity of the Epo portion, a mutation that reduces the affinity of Epo for its receptor will be introduced. Elliott et al. (Blood [1997] 89:2:493-502) described a series of mutations in erythropoietin that reduce its activity. In some embodiments, at least one or more of the following mutations may be used:
- To test the chimeric activators, a test system that uses one of the following cell lines can be constructed and used: TF-1, UT-7 or ERY-1. These are cells that respond to Epo. The cell line can be transfected with an expression construct that expresses human glycophorin, and the chimeric activators can be tested in this pair of cell lines.
- EPO activity will be measured by proliferation and signaling assays. Proliferation will be assessed by using WST-1 reagent while pSTAT5 will be measured for EPO receptor activation.
- The following results will be obtained:
-
TF-1 TF-1_Glycophorin A EPO ++++ ++++ EPO (N147A) ++ ++ EPO (R150A) − + + EPO (R150E) − + + EPO (N147K) − − 10F7MN - EPO ++++ ++++ 10F7MN - EPO (N147A) ++ ++++ 10F7MN - EPO (R150A) + +++ 10F7MN - EPO (R150E) − ++ 10F7MN - EPO (N147K) − + - For a test in an animal system, the following strategy can be used. Glycophorin is a protein that has changed rapidly in evolution, so that the epitopes recognized by existing anti-human glycophorin are not found in most other animals. Lethally irradiated mice that have been reconstituted with human hematopoietic stem cells can be used.
- Aspects of theoretical chimera design appear to be a difficult task, and no theoretical approaches have been focused on the field. Many variables are involved, both physical and kinetic, as well as concentrations, and dynamics. In addition, the size of the receptors need to be taken into account for an optimal chimera design and maximum selectivity. Ligands may be linked by a long amino acid chain, wherein the length is a determinant of the chimera performance, and it needs to be carefully designed according to the physical and kinetic characteristics of the system.
- Over the past years, theoretical efforts have been mainly focused on understanding and modeling single receptor-ligand interaction and internalization. Here a successful theoretical approach for single receptor signaling has been extended to chimeras interacting with an arbitrary number of different receptors. To test the results, the case of a simple homodimer and a heterodimer were explored, and the theoretical predictions were compared with experimental data. In addition, the theoretical prediction of the optimal length of the linker in the case of a heterodimer was compared with experimental results.
- Herein a general theory for chimera design is presented, for testing mutant ligands with known affinity and for designing optimal linker length for increased selectivity. The theory is presented for chimeras designed by binding of an arbitrary number n linked by amino acid chains of different lengths.
- The process of binding is assumed to occur in the following steps: the chimera binds initially to one of the receptors (receptor i) with a rate of binding kon;i and dissociation koff;i, internalization by endocytosis of the free receptor kt;i and active receptor ke;i and receptor recycling Qr;i rates equivalent to the non chimeric ligand. This first reaction of ligand-receptor i recruits chimeric proteins to the cell membrane, increasing the local concentration of ligand j in the surface of the cell, enhancing interaction of ligand j and its receptor.
- The effect of the two dimensional diffusion of the receptors is neglected (if compared with other dynamical processes in the system, it can be considered instantaneous).
- Certain equations described herein are useful to model generalized chimeric binding systems, with an additional term that accounts for the coupling between ligand concentration due to the chimera. The general equations for a set of n ligands and n receptors are as follows.
-
- where Ri and Ci are the total number of empty and bound receptor i. L is the concentration of chimera in solution. The last term of
equations - Once the ligand j is bound to the receptor j, an increase in the local concentration of ligand i close to the cell membrane is created, and the ligand i can be assumed to be distributed in a volume gasket which depends on the distance between ligand i and j. This local concentration of i due to the binding of the j ligand-receptor complex can be calculated as follows.
-
- where NAv is the Avogadro's number, r is the average cell radius and C0j is the concentration of the Cj result of the regular binding mechanism, i.e., the number of complexes Cj bounded to a chimera that it is not bound to another receptor, responsive of the local concentration increase.
-
- Regarding the binding mechanism between a receptor and a free ligand or a chimeric ligand, it is reasonable to assume certain scaling in the reaction rate, due to the geometrical characteristics of the problem. So, in the last term of
equations FIG. 16 , and the reaction only occurs in the dark volume of the semi-sphere of radius ai;j - This way, the rescaled reaction rate is in the form:
-
- here, hi is the height of the gasket, which corresponds to the location where the ligand can bind to the receptor. a0;j is the radius of the receptor j.
- It is assumed that the free end of the chimera is distributed over time in the two regions V0 i;j and Vi;j proportionally to their size, so the reaction rate needs to be scaled according to this.
- The quantity ai;j is the distance between ligand i and j. a0;i;j is the minimum linker distance, and depends on geometrical characteristics of the receptors involved.
-
α0,i,j=√{square root over ((αj,0+αi,0)2 +|l i −l j|2)} (21) - For a given ligand concentration L, the previous equations will give the number of free molecules of the receptor i in the cell surface (Ri), and the number of complex ligand-receptor molecules in the surface prior to internalization (Ci).
- The theory is now restricted to a case of a hetero-dimer, e.g., two different ligands linked to a receptor. This particular situation is the common scenario for chimera design. As a numerical approach, values are used for the case of EGF linked to different mutants of the IF molecule. The result will be compared with experimental values that predict greater selectivity for various mutants compared with the wild type case.
- The model consists of 7 variables, one for each configuration of each of the two receptors and one for the ligand concentration. The interacting components with their corresponding relevant chemical parameters are illustrated in
FIG. 15 . The components of the model are subjected to 4 reversible and 3 irreversible reactions: - Where R1 and R2 are the amount of the two cell surface receptors that the chimera ligand L is targeting. The variables C1, C2, C1′ and C2′ correspond to different configurations of the active ligand-receptor complexes.
-
Reactions reaction - In other words, when a C1′ complex is formed through
reaction 1, a local concentration of ligand with only the second binding site available is created on the cell surface. This local concentration, referred to as L2, is able to interact with R2 throughreaction 3 to form a C2 complex. In the same way, the C2′ complexes formed throughreaction 2 give rise to L1, favoring the formation of the complex C1 throughreaction 4. These local concentrations L1 and L2 are distributed in a spherical gasket of inner diameter equal to the cell diameter r and height equal to the size of the linker a between the two ligands of the chimera. - Expressions for the calculation of the L1 and L2 local concentrations are:
-
- where NAv is the Avogadro's number and V0 is the gasket volume. The only contribution to the local concentration comes from the complexes C01 and C02, since the complexes C1 and C2 formed through
reactions - The equations for the first ligand-receptor system are as follows:
-
- with L being the total concentration of ligand. C01 and C02 are the number of receptors that are linked only to one of the ligands i.e., the ones that contribute to increase the local concentration of the other receptor. These values can be calculated as follows. In this case
-
-
FIG. 17 represents the concentration of complex ligand-receptor 1 in the surface of the cell, for different values of total number of receptors R1. - The equations for the second receptor are equivalent to the first one, but with an additional term which accounts for the ligand concentration that the receptor sees from the first ligand-receptor complex.
- The effective ligand concentration that the second receptor sees depends on the amount of complex ligand-receptor 1 C1 in the surface of the cell at any time. An additional term is added in the second set of equations, which account for the local concentration of ligand close to the cell surface. This concentration is calculated in
Equation 27 assuming that the molecules are distributed in a volume gasket V0 on the cell surface of height the length of the linker. This assumption is justified by the fact that diffusion of the receptors is very fast compared with the internalization times of the receptors. - The value of k0on;2 needs to be scaled taking into account the fact that the reaction with the ligand linked to a surface is constrained by structural and geometric aspects of the systems. The fact that receptor diameter is comparable with linker size and that different heights of receptors in the outer part of the cell membrane has to be introduced into the problem.
- While the dissociation rates for each binding reaction k1;off, k2;off are equivalent in
reaction reaction Reactions - This special configuration induces as set constrains that reduce and modulate the affinity rates k1;on and k2;on. First of all, reaction between two molecules in a two dimensional surface is modulated by diffusion rate.
-
- where the diffusion rate kdiff (expressed in the appropriate units of M−1 min-1) for two-dimensional collision is calculated based on physical considerations as follows:
-
- D1 and l1 are the diffusion coefficient and the height of the receptor R1, correspondingly.
- Parameter b1 is the average distance between free receptors in the cell, calculated considering homogeneous distribution of receptors on the cell, and calculated as follows:
-
- The rest of the reactions account for the trafficking of the receptor-ligand complexes inside the cell.
Reaction 5 andReaction 6 account for the internalization of the signaling complexes and receptors, respectively, whilereaction 7 accounts for the constant production of fresh receptors. - Chimeras are fusions of usually two or more ligands that target different extracellular receptors. Chimeras have been successfully tested experimentally for targeting selectively cells with different receptor concentration in their surface. Experimental results described herein demonstrate that the combination of chimera design with ligand mutation successfully increases selectivity in interferon targeting in cells overexpressing EGFR.
- The fact that the ligand spends time in the regions where it can not react with its receptors will clearly reduce the reaction rate. These aspects were introduced by defining a new reaction rate in the following way.
-
- For the numerical analysis, the parameter values listed in Table 3 were used, unless specified. The parameters correspond to measured values of the wild type EGFR and wild type IFN-R in Hela cells. The advantage is that experimental data is already available to validate the model predictions.
- To test the model predictions, reproduction was attempted of experimental observations, where different chimeras where designed with various mutants of a IF1 ligand. The different mutant designs were shown to have increased selectivity. The dependence on the total amount of C2 for various interferon mutants, which exhibit different affinities with the IR, was analyzed. The goal was to test the selectivity of the chimeric protein among cells with higher EGFR expression levels. Results are shown in
FIG. 18 . -
TABLE 3 numerical kinetic and physical parameters Parameter Value R 1, T 2 × 104 k1, off 0.24 min−1 k1, e 0.15 nM−1 k1, D 2.47 nM h1 0.005 μm a0, 1 0.01 μm l1 lhjfldf R2, T 2 × 102 k2, off WT 0.011 min−1 k2, DWT 3.7 nM k2, off K133A 0.018 min−1 k2, DK133A 26 nM k2, off K144A 0.073 min−1 k2, DK144A 120 nM k2, off K149A 0.043 min−1 k2, DK149A 538 nM k 2, e 0 ???? nM−1 h2 0.005 μm a0, 2 0.01 μm l2 lhjfldf L0 0.5 nM a 125 × 10−4 μm D 5.1 μm s−1 r 8.5 μm - In all cases, the number of IF receptors is higher in the case of a chimeric protein, due to the concentration of chimera localized in the surface of the cell. These results are in good qualitative agreement with the experimental results. Selectivity of the mutants depends, among other parameters, on the number of IF receptors necessary to induce apoptotic signaling in the cell. Signaling from the IF pathway can be measured to scale the numerical values obtained from the simulations.
- It is reasonable to assume that for a relatively small number of active IF receptors in the cell, the pathway is saturated. Based on an analysis of the experimental data of the wild type IF without linker at a concentration of 0.5 nM, the pathway is saturated already or close to saturation. If this information is compared with the model results presented herein, it turns out that the pathway is close to saturation when the number of total active IF receptors at t=30 min is around 7. From here, selectivity occurs for active IF receptors below this value. On the other hand, experimentally measured signal is negligible in the case of mutant R144A at concentration 0.5 nM. In this case the model predicts a number of IFN receptors at time t=30 min of C2=0.69.
- These values can be used to scale the model from number of active IF receptors with actual signal measured in the cell.
- The model can be used to calculate the optimal linker size depending on the properties of the system (e.g., the number of receptors, ligand receptor affinity, structure of the membrane receptors, etc.). As a numerical example, the number of IFN receptors active for different linker sizes was calculated for the different mutants. The linker length dependence at high linker sizes reduces because the local concentration of chimera reduces with the length of the linker. At low values, the dependence is governed by the physical characteristics of the receptors, (a0,h).
- One of the additional issues in the linker length design concerns the time spent by
receptor 1 to find the complex C1 in the cell membrane. This time is dependent on the diffusion coefficient of the membrane receptors, as well as the linker length and the average distance between the two receptors. To estimate this time, the equation for two dimensional diffusion was used. The average distance between two receptors, bi;j, depends on the concentration and distribution of receptors i and j on the cell surface. To calculate this distance, it is assumed that the cell has a spherical shape, and that receptors are evenly distributed through the whole cell surface. -
- In this equation, 2a is the effective target size and D is the diffusion coefficient (assuming both receptor has the same diffusion rate). The distance between the target and the empty receptor depends on the concentration of the complex C1, which is time dependent. The collision rate is given by
-
- where r is the average cell radius. The collision rate was computed (inverse of the collision time) for this case study (with Hela cells, EGFR and IF).
FIG. 20 is a time plot of the rate of collision. - It should be appreciated that the analysis described herein may be used to design optimal linker lengths for chimeric activators described herein (where the chimeric activators are designed to bind to cell surface receptors, and wherein one of the binding elements may be mutated to have a lower binding affinity for its receptor). However, aspects of the invention also may be used to optimize linker lengths for other chimeric molecules where two components that bind to different binding sites are connected via a linker.
- In some embodiments, chimeric activators can be designed to target cells associated with diseases such as asthma. In one example a chimeric activator can be designed to kill or inactivate B cells that produce IgE. In some embodiments, an IgE receptor may be used as a targeting element and FasL may be used as an activity element.
- It will be clear that the invention may be practiced other than as particularly described in the foregoing description and examples. In some embodiments, methods of the invention include modifying, assaying, and/or optimizing one or more of the targeting or activity elements and/or the linker. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the claims. Preferred features of each aspect of the invention are as for each of the other aspects mutatis mutandis. The documents including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures mentioned herein are hereby incorporated by reference in their entirety. In the event of conflict, the disclosure of present application controls, other than in the event of clear error. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.
Claims (42)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/626,439 US20170306030A1 (en) | 2007-04-05 | 2017-06-19 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91039007P | 2007-04-05 | 2007-04-05 | |
US577507P | 2007-12-07 | 2007-12-07 | |
US6593708P | 2008-02-15 | 2008-02-15 | |
PCT/US2008/004435 WO2008124086A2 (en) | 2007-04-05 | 2008-04-05 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US59474710A | 2010-04-16 | 2010-04-16 | |
US15/626,439 US20170306030A1 (en) | 2007-04-05 | 2017-06-19 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/594,747 Continuation US11535673B2 (en) | 2007-04-05 | 2008-04-05 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
PCT/US2008/004435 Continuation WO2008124086A2 (en) | 2007-04-05 | 2008-04-05 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170306030A1 true US20170306030A1 (en) | 2017-10-26 |
Family
ID=39831522
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/594,747 Active 2028-10-18 US11535673B2 (en) | 2007-04-05 | 2008-04-05 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US15/626,439 Pending US20170306030A1 (en) | 2007-04-05 | 2017-06-19 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US17/579,683 Pending US20220162324A1 (en) | 2007-04-05 | 2022-01-20 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/594,747 Active 2028-10-18 US11535673B2 (en) | 2007-04-05 | 2008-04-05 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/579,683 Pending US20220162324A1 (en) | 2007-04-05 | 2022-01-20 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
Country Status (2)
Country | Link |
---|---|
US (3) | US11535673B2 (en) |
WO (1) | WO2008124086A2 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
EP2718457A4 (en) * | 2011-06-06 | 2014-12-24 | Immungene Inc | Engineered antibody-tnfsf member ligand fusion molecules |
KR102037541B1 (en) | 2011-10-28 | 2019-10-29 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Polypeptide constructs and uses thereof |
JP6416628B2 (en) | 2012-01-20 | 2018-10-31 | ブイアイビー ブイゼットダブリュVib Vzw | Targeted variant alpha helix bundle cytokine |
PL2822575T3 (en) * | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EA033115B1 (en) | 2013-04-29 | 2019-08-30 | Тева Фармасьютикалз Острэйлиа Пти Лтд. | Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b |
US10640542B2 (en) * | 2013-07-18 | 2020-05-05 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
SG10202010429YA (en) | 2013-07-19 | 2020-11-27 | Vib Vzw | Targeting of cytokine antagonists |
BR112016001114B1 (en) | 2013-07-19 | 2023-02-14 | Vib Vzw | COMPOSITION COMPRISING A FUSION PROTEIN AND USE OF SUCH COMPOSITION |
CA2918518C (en) * | 2013-07-19 | 2022-08-16 | Universiteit Gent | Targeted modified il-1 family members |
US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
IL251822B2 (en) | 2014-10-29 | 2023-03-01 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha2b variants |
WO2017015141A1 (en) * | 2015-07-17 | 2017-01-26 | President And Fellows Of Harvard College | Humanized anti-glycophorin a antibodies and uses thereof |
ES2863278T3 (en) | 2015-10-02 | 2021-10-11 | Silver Creek Pharmaceuticals Inc | Bispecific therapeutic proteins for tissue repair |
EP3371311B1 (en) * | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
EP3998281A1 (en) | 2016-02-05 | 2022-05-18 | Orionis Biosciences BV | Cd8 binding agents |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
EP3426278B1 (en) | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
JP7105200B2 (en) | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | Targeted mutant interferon-beta and its uses |
ES2917000T3 (en) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Target mutant interferon-gamma and uses thereof |
EP3315139B1 (en) * | 2016-10-28 | 2021-12-15 | Technische Universität Dresden | A delivery system for targeted delivery of a therapeutically active payload |
KR102642385B1 (en) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | Targeted chimeric proteins and uses thereof |
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
WO2019032661A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
WO2019032663A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Pd-1 and pd-l1 binding agents |
US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
US20230184766A1 (en) * | 2020-05-01 | 2023-06-15 | The Johns Hopkins University | Compositions and methods for coronavirus detection |
KR20230125236A (en) * | 2020-12-23 | 2023-08-29 | 리제너론 파마슈티칼스 인코포레이티드 | Nucleic Acids Encoding Anchor Modified Antibodies and Uses Thereof |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
EP4352098A1 (en) | 2021-06-09 | 2024-04-17 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022272026A1 (en) * | 2021-06-24 | 2022-12-29 | President And Fellows Of Harvard College | Methods and compositions relating to tissue-protective erythropoietin |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2055168A1 (en) * | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
US5606023A (en) * | 1994-05-24 | 1997-02-25 | Thomas Jefferson University | Mutant tumor necrosis factor proteins |
US6517834B1 (en) | 1995-08-04 | 2003-02-11 | Geron Corporation | Purified telomerase |
US20030026779A1 (en) * | 1999-10-15 | 2003-02-06 | Liming Yu | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc |
EP1019515A1 (en) * | 1997-10-01 | 2000-07-19 | G.D. SEARLE & CO. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment |
ATE419354T1 (en) | 2000-02-25 | 2009-01-15 | Us Gov Health & Human Serv | SCFV MOLECULES AGAINST EGFRVIII WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREOF, AND METHODS OF USE THEREOF |
US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
US7294472B2 (en) | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
PT1454138E (en) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
CA2504267A1 (en) * | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
WO2004062603A2 (en) | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Methods of treating lung diseases |
WO2004111089A2 (en) * | 2003-06-11 | 2004-12-23 | WYETH A Corporaton of the State of Delaware | Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof |
WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
MXPA06013412A (en) | 2004-05-19 | 2007-01-23 | Maxygen Inc | Interferon-alpha polypeptides and conjugates. |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
JP2008526889A (en) | 2005-01-10 | 2008-07-24 | リサーチ ディベロップメント ファウンデーション | Targeted chimeric molecules for cancer therapy |
ES2435846T3 (en) * | 2005-06-29 | 2013-12-23 | Yeda Research And Development Co. Ltd. | Interferon alpha 2 (IFN alpha 2) mutants recombinant |
US20090068637A1 (en) * | 2006-01-26 | 2009-03-12 | Ningshao Xia | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and use thereof |
EP2041175A4 (en) * | 2006-06-23 | 2011-03-16 | Augmenta Biolog Llc | Targeted immune conjugates |
WO2008065372A2 (en) * | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
AU2007345648A1 (en) | 2007-01-26 | 2008-08-07 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
-
2008
- 2008-04-05 US US12/594,747 patent/US11535673B2/en active Active
- 2008-04-05 WO PCT/US2008/004435 patent/WO2008124086A2/en active Application Filing
-
2017
- 2017-06-19 US US15/626,439 patent/US20170306030A1/en active Pending
-
2022
- 2022-01-20 US US17/579,683 patent/US20220162324A1/en active Pending
Non-Patent Citations (3)
Title |
---|
Al Qaraghuli et al. Antibody protein binding and conformational changes: identifying allosteric signaling pathways to engineer a better effector response. Nature Scientific Reports 10:13969, (2020). (Year: 2020) * |
Edwards et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. Journal of Molecular Biology 334:103-118; (2003). (Year: 2003) * |
Vajdos et al. Comprehensive functional maps of antigen-binding site of an anti-ErB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 5;320(2):415-28; (July 2002). (Year: 2002) * |
Also Published As
Publication number | Publication date |
---|---|
WO2008124086A2 (en) | 2008-10-16 |
US20220162324A1 (en) | 2022-05-26 |
WO2008124086A3 (en) | 2008-12-24 |
US20110274658A1 (en) | 2011-11-10 |
US11535673B2 (en) | 2022-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220162324A1 (en) | Chimeric activators: quantitatively designed protein therapeutics and uses thereof | |
JP6652680B2 (en) | synTac polypeptides and uses thereof | |
JP7327885B2 (en) | CLEC9A binding agents and uses thereof | |
US20230295304A1 (en) | Pd-1 and pd-l1 binding agents | |
JP2024028543A (en) | Bifunctional proteins and their production | |
US20200231674A1 (en) | Cd8 binding agents | |
KR101281208B1 (en) | Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12 | |
JP2021532170A (en) | Trispecific antagonist | |
US20200354424A1 (en) | Xcr1 binding agents and uses thereof | |
US20220119519A1 (en) | Sirp1a targeted chimeric proteins and uses thereof | |
JP2021522162A (en) | Anti-ROR antibody construct | |
JP4660092B2 (en) | Recombinant polypeptide | |
US20230279128A1 (en) | Ifngr2 binding molecules and methods of use | |
JP2022532249A (en) | Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins | |
JP2022534837A (en) | therapeutic interferon alpha 1 protein | |
JP2023536654A (en) | IL10Ra binding molecules and methods of use | |
TW202144396A (en) | Inhibitory chimeric receptor architectures | |
JP2022529891A (en) | Fibroblast-activated protein-binding substances and their use | |
JP2023510870A (en) | CD122 with altered ICD STAT signaling | |
KR20220097952A (en) | HER2/4-1BB bispecific fusion protein for the treatment of cancer | |
JP2022526194A (en) | FLT3-specific chimeric antigen receptor and its usage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CIRONI, PABLO;MIGUEZ, DAVID G.;SILVER, PAMELA A.;SIGNING DATES FROM 20100324 TO 20100408;REEL/FRAME:042809/0738 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |